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Executive Summary  
 
The challenge was brought forward in early 2005 to define the nutritional 
requirements for Exploration missions, and to define the relevant standards and 
associated operating bands related to nutrition.  This document is the result of this 
charge.  An extensive review of existing knowledge was conducted with participation 
of intramural and extramural experts, and the findings are summarized herein.  In 
short, the approach taken was to define the nutrient intake requirements, that is, the 
amount of each nutrient expected to be available in the food system.  The standards 
are defined as markers of nutritional status, with optimal (green), sub-optimal 
(yellow), and critical (red) levels for each.  For many of the nutrient requirements, it 
is not known if they are altered during space flight.  Furthermore, in many cases the 
intake of a nutrient may act as a countermeasure to one or more negative effects of 
space flight, but these potential countermeasures, too, are not well defined.  Thus, 
we have also documented herein the areas where further research is required.   
 
Accordingly, while this document is intended as a comprehensive summary of our 
knowledge to date, it is expected that this is the first edition of these requirements 
and standards.  As we learn more about space-flight nutrition, and as relationships 
between disease and nutrients are further defined in Earth-based populations, this 
document, and the approach to nutrition in the space rogram, will need to be 
updated accordingly.
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Introduction 
 
Nutrition has been critical to every phase of exploration, from the early sea voyages 
on which seafarers were plagued by scurvy to polar expeditions in which explorers 
died from under-nutrition, or in some cases nutrient toxicities.  The role of nutrition 
in space exploration will be no different, except that space explorers will lack the 
opportunity to obtain food from the local environment, making their missions even 
more challenging than the exploration of Earth.  The altered gravity environment will 
also likely alter nutrient requirements, making it even more difficult to meet these 
requirements.  It is very clear that humans on a 1000-day exploration-class mission 
will require adequate nutrition, and deficiency of any one of the required nutrients 
could be catastrophic. 
 
To serve as a tool for defining the role of nutrition in exploration is the purpose of 
this document.  The ultimate goal is to define requirements for nutrient intake and 
standards for assessing nutritional status.  To this end, we will define a set of values, 
or operating bands, that can serve as a guide for setting both required intake levels 
and nutritional status assessment standards.  Use of these operating bands will help 
NASA to maintain the health and well-being of crew members who explore beyond the 
surface of Earth.   
 
This document is based on many sources of information that were reviewed at a 
Nutrition Standards/Operating Bands workshop held March 23–24, 2005 in Houston, 
Texas.  The documents reviewed included the set of nutritional requirements defined 
in 1991 for Space Station Freedom missions, plus the updated set of requirements 
developed in 1995 (in collaboration with Russian partners) for Mir flights.  The 
activities of workshop participants included evaluation of the limited data from short-
duration Space Shuttle flights, and longer Mir and International Space Station (ISS) 
flights. The findings from the MR016L/Clinical Nutritional Assessment profile of the 
first 10 ISS missions were also reviewed, to provide background information about the 
changes seen in flights of 4 to 6 months (during which time resupply by at least one 
Progress vehicle occurred).  In many cases in this document, we have extrapolated 
from ground-based space analog studies, and in others we have only the ground-based 
nutrition literature for support, knowing nothing of the effects of space travel.  In this 
document we also highlight the areas where we are at highest risk, with no evidence 
base to support the requirements and recommendations.  For these areas, targeted 
research areas are identified as part of the requirement for exploration.  The 
supporting and detailed information have been expanded herein, but the 
recommendations are based on the panel discussion. 
 
Nutrition is a cross-cutting science, one that influences and is influenced by many 
other disciplines, and because nutrients are required for the structure and function of 
every cell and every system, the pervasiveness of nutrient requirements for the 
adaptation to space travel is no surprise.  Key areas of clinical concern for long-
duration space flight include loss of body mass (general inadequate food intake), bone 
and muscle loss, increased radiation exposure, and general depletion of body nutrient 
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stores because of inadequate food supply, inadequate food intake, increased 
metabolism, and/or irreversible loss of nutrients.  Cardiovascular and/or immune 
system changes noted during and after space flight may also be related to nutritional 
issues, but conclusive data are not yet available. 
 
The primary objectives of this document are  
? Definition of requirements related to nutrition.  This includes nutrient intake 
requirements as well as other aspects of nutrition. 
? Definition of techniques that will be used to evaluate whether the requirement 
has been met (that is, the standards that must be met). 
? For each standard, identification of the operating bands (including 
success/failure criteria for each) for potential mission impact and severe 
mission impact. 
? Identification of potential differences in operational standards for different 
mission types (for example, low Earth orbit, lunar, Mars) and durations (6, 12, 
or 36 months) 
? Identification of the effect of mission design elements (such as a traverse, 
extravehicular activity, or gravity field) on the standards 
? Identification of potential differences due to age and sex 
? Identification of areas where requirements, though defined, are not well 
understood or justified.  Specific areas are highlighted to point out where 
research is necessary to better understand the requirement and associated risk.  
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Document Organization 
 
Recommendations for nutritional status and nutrient intake for exploration must be 
based on an understanding of the known changes in nutritional status observed during 
space flight.  This document is intended to provide a complete history and rationale 
for these requirements.  Although this will make it more extensive than a typical 
requirements document, this added information will serve to justify the 
requirements, and to allow a better understanding of how we have come to the set of 
requirements described herein. 
 
A section for each nutrient provides a review of that nutrient, and a discussion of the 
requirements for the nutrient is divided into the following sub-sections: 
 
Physiological function and existing space flight knowledge 
This section includes basic background material about the nutrient and its 
function in the body.  It also includes a summary of known space flight and 
space flight analog studies. 
 
Body stores (if any) and relative time to depletion 
Background is provided for each nutrient that is stored in the body. Relative 
time to depletion may be given for a sub-optimal diet, a diet devoid of the 
nutrient, and special circumstances (such as faster depletion of vitamin C 
during stress, and depletion of vitamin D during low exposure to ultraviolet 
light). 
 
Potential implications for flight  
This section includes concerns that arise from characteristics of the unique 
flight environment (for example, potential deficiency caused by radiation 
exposure and destruction of vitamins in food, or risk that toxicity will result 
from supplementation). 
 
Targeted research needed 
Areas where lack of research limits the ability to characterize requirements are 
listed.  The extramural expert panel recommended that these areas be the 
targets of further research. 
   
Nominal requirement on Earth 
Reference material is provided for each nutrient regarding requirements for it 
on Earth, and where appropriate, requirements of sub-populations (such as 
different ages and genders). 
 
 Historical space flight requirements 
Reference material is provided for each nutrient regarding earlier defined 
space flight requirements, and the rationale for each.   
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Requirements, standards, and operating bands 
This section consists of definition of the dietary intake requirement per day 
(average) for each nutrient, techniques for monitoring fulfillment of the 
requirements, and the sets of values (operating bands) for requirements as well 
as assessment techniques that will enable human space exploration.  
Monitoring of fulfillment typically includes a need to verify actual space food 
content at production, as well as at the planned point of use (because, for 
example, storage time and environment may affect content) before 
implementing the program. Fulfillment of intake requirements will be 
monitored in part by determining dietary intake during flight.  
 
Standards are based on the results of assessment techniques or variables 
monitored, and serve to determine if requirements have been met. In general, 
fulfillment of requirements will be assessed before, during, and after flight by 
determining the levels of status indicators in biological samples. 
 
Nominal operating bands are defined as follows:  green/nominal = the nominal 
amount of intake of a nutrient needed to maintain crew health.  Yellow/sub-
optimal = the level of intake that, if maintained for prolonged periods, may 
lead to frank deficiency and disease.  Red/deficient = the level that, over a 
longer period, will lead to symptoms and/or disease.  Yellow/supra-optimal = 
the level of intake that, if maintained for prolonged periods, could lead to 
toxicity symptoms.  Red/toxic = the level that, over a longer period, will lead 
to toxicity symptoms.  These levels are illustrated below: 
 
Dietary Nutrient 
  toxic g/d red 
  supra-optimal g/d yellow 
  nominal g/d green 
  sub-optimal g/d yellow 
  deficient g/d red 
 
 
Additional sections are included at the end of the document to highlight special issues 
and concerns for exploration missions.  Examples of these are nutritional concerns for 
extravehicular activity (EVA), and drug/nutrient interactions. 
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Macronutrients 
 
Energy and Body Composition 
 
Physiological function and existing space flight knowledge 
The World Health Organization estimates of energy requirements for moderately 
active individuals (1) provide a good estimate of inflight requirements (2), and have 
thus been used as a standard for menu planning.  Although composition of the diet 
(percent of energy intake from protein, carbohydrate, and fat) is acceptable during 
flight, food and energy intake during flight are generally lower than preflight intake 
(2-7), despite data indicating that inflight and preflight energy requirements are 
similar (2) or increased (6).  Data from the Apollo program through the more recent 
flights show that crew member dietary intakes are about 70% of predicted 
requirements.  The gap between energy intake and expenditure is further widened 
with increased exercise associated with physical countermeasures. 
 
The obvious and immediate reason for concern about reduced dietary intake is the 
risk of body mass loss and dehydration.  Body mass losses of 1%–5% of preflight body 
mass have been a consistent finding in the history of space flight, and documented 
losses have occurred on short- and long-duration flights from both the U.S. and 
Russian space programs (7-10).  Indeed, all crew members on Gemini, Apollo, Skylab, 
and Apollo-Soyuz Test Project missions lost body mass (11).  In one study of 13 male 
Shuttle crew members, body mass losses ranged from 0 to 3.9 kg (2).  Body mass loss 
has also been observed to reach 10–15% of preflight body mass (12).  Although a 1% 
body mass loss can be explained by loss of body water (3), most of the observed loss 
of body mass is accounted for by muscle and adipose tissue (13, 14).  Crew members 
on the ISS have shown similar patterns of mass loss during and after flight, but some 
crew members have been able to maintain body mass (15).  Results of metabolic 
experiments on the U.S. Skylab missions showed that ingestion of the prescribed 
energy intake did not fully ensure maintenance of body mass (16); however, it is clear 
that reduced energy intake will ensure loss of body mass.  Decreased inflight energy 
intake is also associated with decreased protein synthesis (17).   
 
Insufficient dietary intake, and subsequent body mass loss, is significant not only for 
crew health, but also for medical and research studies, in which clear interpretation 
of essentially all other physiological data from malnourished subjects is impossible.  
That is to say that virtually all space flight data collected on Shuttle, Mir, and ISS 
missions are confounded by inadequate dietary intake.  Investigators who have 
studied bone and muscle, cardiovascular function, immune response, and other 
systems during space flight cannot say to what degree undernutrition affected their 
findings.  A recent study in Germany evaluating hypocaloric diets during bed rest (18) 
will help to identify these issues with greater clarity. 
 
The cause of reduced dietary intake during flight is unknown, but anecdotes provide 
many potential explanations (4, 7, 19).  A common cause of reduced dietary intake 
during the first days of a mission (20) is space motion sickness (21).  Its effects 
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typically pass after the first several days of flight, but the decreased dietary intake 
often extends well beyond the first week (4).  Anecdotal reports of appetite vary 
significantly, as indicated in a Russian study in which 40% of Mir crew members 
reported decreased appetite, 40% reported no change, and 20% reported increased 
appetite (22).  Other flight-related changes in gastrointestinal function may occur.  
Fluid shifts, in combination with reduced fluid intake, would tend to decrease 
gastrointestinal motility.  Although gastrointestinal transit time has not been 
systematically studied in flight, during 10 days of –6° head-down bed rest, mouth-to-
cecum transit time was significantly longer than during ambulatory control periods 
(23).  Russian studies of gastrointestinal function during actual and simulated space 
flight, in humans and in animal models, have been reviewed (24). 
 
The palatability of food in the space food system is occasionally identified as a cause 
of reduced food intake during flight.  From the early days of the space program, 
development of foods for space flight has proven a significant challenge (10, 25-27), 
yet the design criteria have changed little since the early programs (28).  The food 
systems used on the Space Shuttle and the Russian Mir Station are entirely shelf 
stable, and are mainly composed of rehydratable or thermostabilized food items (27).  
Although these foods are known to have lower hedonistic value (palatability) than 
fresh or frozen foods, ground-based studies have clearly shown that the Shuttle food 
system can adequately support nutritional requirements (29).  Skylab is the only U.S. 
program to date that has included frozen foods (27).  The Skylab crew members ate 
essentially 100% of their predicted (1) energy requirements (4).  Although these crew 
members were involved in metabolic studies that required complete intake of the 
prescribed diet (30), this result shows that when astronauts are required to consume 
the recommended amounts of food during space flight, they can.  Thus, hypotheses 
regarding inability to consume the requisite amount of food because of stomach 
fullness or other factors are not likely to fully explain decreased inflight dietary 
intake.  It is difficult to determine if the intakes on Skylab were related more to the 
requirement to consume the food or to the fact that the food was more palatable; 
however, it would be difficult to argue that increased palatability is not beneficial. 
 
Many anecdotal reports exist of changes in taste and aroma of food during flight 
(although many long-duration crew members indicate that this is not as significant a 
problem on long flights).  One hypothesis that supports these anecdotes is that fluid 
shifts and congestion associated with microgravity (especially in the first few days) 
alter taste and odor perception.  However, flight studies have not demonstrated 
changes in taste or olfaction (31, 32), and ground-based studies of this phenomenon 
have been equivocal.  When tongue taste perception was measured before, during, 
and after a 30-day –6° head-down bed rest period, subjects reported decreased 
appetite and lack of taste early in the bed rest phase (33, 34).  By day 13 of the bed 
rest phase, for all tastes (sweet, salt, acidic, bitter), the threshold for taste 
sensitivity had increased.  In contrast, a more recent study found no changes in odor 
and taste perception after 14 days of head-down bed rest (35), suggesting that 
multiple factors are likely involved in this process. 
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It is imperative that adequate resources be provided to support food consumption.  A 
reliable food system must include a variety of palatable foods and the means to 
process them (such as rehydration, heating, and cooling).  Time (for meal 
preparation, consumption, and clean-up) is another limited resource that often 
hinders dietary intake. 
 
Initial plans for the ISS included the use of freezers and refrigerators for food storage 
and preparation.  This would have provided a more palatable food system, which 
would serve to increase dietary intake, as well as provide added psychological 
support.  It is often difficult to balance the intangible potential increase in dietary 
intake and psychological support against a tangible dollar and power allocation, both 
of which are typically (if not always) constrained.  
 
Altered energy expenditure is a commonly proposed explanation for loss of body 
mass.  According to early hypotheses, energy expenditure during flight would be less 
than on the ground, because of the relative hypokinesia in space (19).  Lower energy 
expenditure was observed during extravehicular activity on the lunar surface 
compared with similar activities at 1 g (36).  However, studies of inflight, non-EVA 
energy expenditure of Space Shuttle crew members showed that inflight energy 
expenditure was unchanged from preflight levels (2).  More recent studies have even 
shown increased energy expenditure during flight compared to preflight levels, most 
likely as a result of increased exercise (6).  These studies involved Shuttle astronauts 
and indirect calorimetry techniques to determine total energy expenditure over 
several days.  The doubly-labeled water (water enriched with deuterium and 18O) 
technique was used to determine oxygen consumption (37).  The benefits of this 
technique are that it is non-invasive and it takes into account the energy cost of all 
activities over several days.  The drawback of the method is that information about 
the individual components of total energy expenditure (such as resting, sleep, 
exercise) is not available. 
 
Although it is assumed that less energy is expended moving the body mass around the 
cabin during flight, energy requirements for other metabolic activities (such as 
maintaining resting metabolic rate and responding to stress) may increase, to result in 
an unchanged total energy expenditure.  In ground-based studies, during bed rest 
total energy expenditure was less than before bed rest, but resting energy 
expenditure did not change (38).  Because total energy expenditure during flight is 
either unchanged (2) from preflight levels or increased (6), bed rest may not be an 
appropriate model for studies of energy metabolism during flight.  One possible 
explanation for this difference is the lack of a metabolic response to stress during bed 
rest.  Attempts have been made to improve the utility of these ground studies through 
the administration of a metabolic stressor (such as triiodothyronine or cortisol) to 
provide a better ground-based model than bed rest for the metabolic effects of space 
flight on energy and fuel metabolism (39). 
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Body stores and relative time to depletion 
Energy itself is not readily stored in the body, but the substrates for energy are.  
Energy in the form of heat is obtained by oxidizing carbohydrates, fats, proteins, and 
alcohol; it is also known as the heat of combustion.  Fat provides the most energy of 
these sources, at about 9 kcal/gram.  Carbohydrates and proteins provide about 4 
kcal/gram, and alcohol about 7 kcal/gram.  Because the body can adapt to different 
energy sources, large variations in macronutrient intake are generally well tolerated.  
 
Adipose represents the only viable long-term source of stored energy.  Carbohydrate 
stored in liver and muscle as glycogen provides a transient (hours) source of 
carbohydrate.  Protein can be broken down to release amino acids, but this is at the 
expense of the protein.  
 
Data exist from 2 studies in which subjects were semi-starved, consuming either 580 
kcal/d or 1010 kcal/d for 12 and 24 days, respectively (40).  In this study, subjects 
who consumed 580 kcal/d lost 7% of their body mass in 12 days and the subjects who 
consumed 1010 kcal/d lost 11% of their body mass in 24 days.  In another study, 
starved subjects lost 9% of their body mass after 11 days, 15% by day 18, and 18% by 
day 43 (41).  From these data, it appears that for every 500 kcal consumed per day, 
about 1% of body mass can be conserved every 12 days.  It would not be acceptable, 
however,  to use these numbers for a long-term (>21 days) prediction of body mass 
loss or conserved body mass loss because after 21 days of starvation the basal 
metabolic rate of the body decreases (40, 42).  This can be and has been accounted 
for using a mathematical model to predict body mass loss given changes in basal 
metabolic rate (42), with results estimating that survival on 1000 kcal/day could 
exceed 3 years (compared with only 6 months without accounting for decreased 
metabolic rate).   
 
It is difficult to predict the impact of sub-optimal (or lack of) energy intake in 
otherwise healthy individuals.  One issue is that the energy equivalent of the mass 
lost changes with time, as different body fuels are used at different times during 
semi-starvation (40, 42).  With partial rations available (1000 calories per day), it is 
reasonable to expect that a person could survive for more than 4 to 6 months, 
potentially longer if the metabolic rate were to decrease because of decreased 
intake.  Greater restrictions in energy availability would be expected to yield 
survivability ranging between this amount of time and the 1–2 months possible with 
no food.  These projections obviously include many assumptions, unknowns, and 
extrapolations.  Data from 10 Irish Republican Army hunger strikers, who consumed 
water ad libitum but no energy, vitamins, or minerals, indicate that an average 25-
year-old male could survive no longer than 60 days without energy (43, 44).   
 
Potential implications for flight   
On the basis of the small amount of starvation data available, it is speculated that a 
crew could survive on orbit for 40–60 days without food.  With limited rations (1000 
calories/d), a crew could survive 4 to 6 months (although physical performance 
capability might be severely degraded). 
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Deficiency of energy leads to wasting and ultimately tissue breakdown, or even death.  
An excess of energy may lead to excess body mass if metabolic rate does not increase.  
The loss of lean body mass during space flight is significant, and is associated with 
increased proteolysis and catabolism related to metabolic stress (45). In the high-
stress environment of an on-orbit contingency, this would likely be exacerbated, and 
would shorten projections of survivability from ground-based studies. 
 
Other possible effects of long-term low-calorie intake include decreased motor and 
cognitive function, both of which could impair an astronaut’s ability to perform work-
related tasks necessary for landing.  According to military survival studies, astronauts 
would be expected to experience decreased endurance early on, and the decrease in 
strength would parallel the decrease in lean body mass (46).  During total fasting, 
degradation of coordination, speed, and cognitive function would be evident within 
the first 2 weeks (46). 
 
The ketosis expected to result from starvation not only would have metabolic effects 
(including decreased appetite), but might also affect other aspects of the mission (for 
example, the life support systems may not be able to remove the ketones from the 
air).     
 
Anecdotal reports from long-duration crew members indicate that a rebound body 
mass gain occurs after flights on which on-orbit loss of body mass was significant.  We 
are attempting to obtain long-term follow-up body mass data after missions to 
evaluate these changes.  We will also test the hypothesis that metabolic rate 
decreases on orbit when dietary intake is insufficient, that is, a self-imposed “semi-
starvation” state occurs.  Compared to the nominal energy requirement of 2000–3000 
kcal per day (it varies because of individual factors), this “semi-starvation” would 
reflect the requirement for approximately 1000 kcal per day of food availability. 
 
Targeted research needed 
Further research is warranted to better understand why astronauts typically do not 
consume 100% of their recommended daily energy intake.  Decreased energy intake 
has numerous negative implications for the body, and is often associated with 
decreased intake of other nutrients. 
 
Studies of energy expenditure have been conducted only on short-duration (Shuttle) 
flights (2, 6).  Whether the same trends continue on longer flights is not known.  
Anecdotal reports exist of crew members who have lost significant amounts of body 
mass during flight and gained excessive amounts after landing.  The health 
implications of this phenomenon need to be determined, and ways to prevent both 
inflight body mass loss and postflight body mass gain need to be evaluated. 
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Nominal requirement on Earth 
The estimated energy requirement (EER) of an individual on Earth is based on total 
energy expenditure (TEE) using an activity factor of 1.25 (active) along with the 
individual’s age, body mass (kg) and height (m) in the following calculations: 
 
EER for men 19 y and older 
 EER = 622 – 9.53 x Age [y] + 1.25 x (15.9 x Wt [kg] + 539.6 x Ht [m]) 
 
EER for women 19 y and older 
 EER = 354 – 6.91 x Age [y] + 1.25 x (9.36 x Wt [kg] + 726 x Ht [m]) 
 
Historical space flight requirements 
The daily energy requirements for male and female astronauts were defined in 1991 
(47), and again in 1995 (48), and are as follows: 
 
Missions of 30–120 days: Energy consumption should be sufficient to maintain body 
mass and body composition, with continuous monitoring during space flight.  A 70-kg 
man exercising 1 to 2 hours per day is expected to require about 3,000 calories/day 
(47).  
 
Missions up to 360 days: Intake of energy should be sufficient to maintain body mass 
and composition, and the extensive activities planned for International Space Station 
crew members.  Energy requirements will be calculated for each individual by using 
the World Health Organization (1) equations: 
 Men  18–30 y: 1.7 (15.3M + 679) = calories/day required 
   30–60 y: 1.7 (11.6M + 879) = calories/day required 
 
 Women 18–30 y: 1.6 (14.7M + 496) = calories/day required 
   30–60 y: 1.6 (8.7M + 829) = calories/day required 
 
   where M = mass in kg 
 
These equations are to be used for moderate levels of activity.  The original space 
flight requirements included an additional 500 calories/d that would be supplied to 
the diet during the period when end-of-mission countermeasures (such as more 
intensive exercise) are being conducted. 
 
On the basis of results from previous space missions, it was also recommended that an 
additional 500 calories/d be supplied to crew members on days of extravehicular 
activity (EVA); the extra energy should be similar in nutrient composition to the rest 
of the diet (48). 
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Requirements, standards, and operating bands 
Req. 1. The estimated energy requirements (EER) for space missions shall be based 
on total energy expenditure (TEE), using an activity factor of 1.25 (active) 
along with the individual’s age, body mass (kg), and height (m) in the 
following calculations: 
 
EER for men 19 y and older 
 EER = 622 – 9.53 x Age [y] + 1.25 x (15.9 x Mass [kg] + 539.6 x Ht [m]) 
 
EER for women 19 y and older 
 EER = 354 – 6.91 x Age [y] + 1.25 x (9.36 x Mass [kg] + 726 x Ht [m]) 
 
Energy intake operating bands are defined as a percentage of each individual’s EER, 
as follows: 
 
Energy (% of requirement) 
  120% red 
  110% yellow 
  90-100% green 
  80-90% yellow 
  <80% red 
 
Initial verification that this requirement has been met will be done by proximate 
analysis of the energy content of space food items, and analysis of crew menus. 
  
Final verification will be completed by determining dietary intake using a food 
frequency questionnaire or other method of monitoring inflight intake.  Standards will 
be assessed before and after flight (and to the extent possible, during flight) by 
determining body composition (currently done by dual-energy X-ray absorptiometry) 
before and after flight, and by determining body mass during flight. 
 
Body Mass (% of preflight) 
  >110% red 
  105-110% yellow 
  95-105% green 
  90-95% yellow 
  <90% red 
 
Body Composition (% of preflight) 
  >110% red 
  105-110% yellow 
  95-105% green 
  90-95% yellow 
  <90% red 
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Protein 
 
Physiological function and existing space flight knowledge 
As the major structural component of all cells in the body, protein includes molecules 
that perform many essential physiological functions.  Amino acids are assembled in 
various configurations to make proteins that serve as enzymes, hormones, transport 
carriers, and other important molecules necessary for life.  The total energy 
contribution of protein to the average diet is about 15%.  The type of protein, such as 
animal or vegetable protein, incorporated into the diet may be an important factor to 
consider in determining protein requirements. 
 
Exposure to microgravity reduces muscle mass, volume, and performance, especially 
in the legs, on both long (16) and short (49) flights.  Muscle biopsy studies 
demonstrated postflight decreases in cross-sectional area only in type II (fast-twitch) 
myofibers, the muscle fiber type that responds to resistive exercise (50). 
 
Potassium and nitrogen balances became increasingly negative throughout the Skylab 
flights, but urinary creatinine did not change (30, 51) despite losses of leg volume 
(16, 52).  Disuse atrophy of muscle in space may be related to changes in whole-body 
protein turnover.  One ground-based study demonstrated that whole-body protein 
synthesis decreased about 13% during 2 weeks of bed rest, and that half of that 
decrease could be accounted for by the leg muscles (53).  This bed rest study did not 
include exercise, and body mass was maintained during the bed rest period.  In the 
same study, excretion of 4-pyridoxic acid, a vitamin B6 metabolite, increased during 
bed rest (54), suggesting that metabolically active muscle tissue was lost. 
  
Stable isotope turnover studies indicate that during short-term space flight, whole-
body protein turnover increases.  Protein synthesis increases, but protein breakdown 
increases even more (55, 56).  The increase in synthesis is hypothesized by Stein et al. 
(57), to be related to physiological stress, as indicated by increased urinary cortisol 
during flight (3, 58).  These findings are similar to those found in catabolic patients.  
Decreased prostaglandin secretion has also been implicated in the loss of muscle 
tissue during space flight, secondary to decreased muscle mechanical stress (58).   
 
On long-duration Mir flights, conversely, investigators have noted decreased rates of 
protein synthesis (6).  Protein synthesis was, however, directly correlated with energy 
intake, suggesting that the reduced protein synthesis was related to inadequate 
energy intake (6).  
 
Evaluation of plasma and urinary amino acids suggests that they do not provide a clear 
indication of muscle metabolism.  However, an increase in plasma amino acids was 
noted in cosmonauts after flight (59).  Limited Shuttle flight data indicate a tendency 
for plasma branched-chain amino acids to be increased during flight, compared to 
preflight levels (60).  Data from short-duration flights reveal little or no change in 
urinary amino acid profiles (20).  Skylab studies did reveal increases in excretion of 
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amino acid metabolites: creatinine, sarcosine, and 3-methylhistidine (61), suggesting 
that contractile proteins of skeletal muscle are degraded in weightlessness.  
 
Differences between flight and ground studies may relate to a number of variables, 
identifying potential shortcomings of the analog studies.  Dietary intake is one major 
difference between the two types of studies.  On the Spacelab Life Sciences missions, 
inflight intakes of protein and energy were about 20% less than preflight intakes, and 
crew members lost about 1 to 1.5% of their body mass (55).  Ground-based studies 
typically have prescribed and controlled dietary intakes or are designed to maintain 
body mass.  Variability in stress levels might explain some of the variability in the 
results from this type of study, both flight and ground-based.  An increase in stress 
level (as shown by increased cortisol) is typically associated with space-flight studies.  
Ground-based studies have the potential for increased stress; however, this is not an 
entirely consistent finding.  Lovejoy et al. (1999) (39) have suggested that 
administration of exogenous thyroid hormone provides a metabolic stress that 
produces a more accurate ground-based model of space flight.  Other groups have 
used exogenous cortisol as a means to increase muscle catabolism during bed rest 
(62). 
  
The exercise protocols used to date have not succeeded in maintaining muscle mass 
or strength, or bone mass, during space flight.  On Mir flights, crew members differed 
significantly with respect to inflight exercise frequency and intensity (related to 
mission requirements, personal habits, etc.).  However, losses of leg muscle volume, 
detected immediately after flight by magnetic resonance imaging, were almost 20% in 
all subjects (63).  Similar findings (wide variations in exercise, lack of difference in 
bone loss) have also been documented for bone loss (12).  Exogenous testosterone 
administration during bed rest studies has maintained muscle mass and protein 
balance, but with no effect on muscle strength (64).  Resistive exercise protocols 
have been proposed to aid in the maintenance of both muscle and bone during flight.  
Success with these protocols in flight analog studies (65) has yet to be documented in 
flight. 
 
Body stores and relative time to depletion  
Protein is a fundamental component of all cellular and biochemical systems.  It is one 
of the most critical limiting factors when the body is deprived of energy, because 
essential amino acids are not stored in the body.  A complete depletion of energy and 
protein reserves is said to be the cause of death from starvation.  It is estimated that 
when 33%–50% of total body protein is lost, death results (66).  Total body mass loss in 
excess of 40%–50% of initial body mass is not compatible with life (46, 67).  In one 
case report, individuals on a hunger strike lost 30% of their total body mass and 19% of 
total body protein before death (43, 44).  An adult whose body mass is initially normal 
can survive 60 to 70 days without consuming any food (68).  Protein and energy 
reserves are much smaller in infants, and a 1000-g infant can survive only 5 days 
without protein (69). 
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Potential implications for flight   
Maintaining a proper protein intake is critical, as both low-protein and high-protein 
diets can cause harm (and, at the extreme, death).  A low-protein diet (below the 
recommended dietary allowance) for up to 4 weeks can decrease calcium absorption 
and induce hyperparathyroidism in otherwise healthy subjects (70, 71).  The impact of 
chronic low protein intakes is not well understood; however, several studies suggest 
that low-protein diets are associated with loss of bone density (72, 73). 
 
Conversely, high-protein diets increase the risk that renal stones will form.  One 5-y 
study of 120 men found that the relative risk of stone formation on a restricted 
protein (52 g/d ) and salt (50 mEq/d) diet was half that of men on a calcium-
restricted diet (400 mg/d) (74).  The decreased risk of renal stones on a low-protein 
diet is not well understood, but several potential mechanisms have been postulated.  
It is generally well accepted that high-protein diets induce hypercalciuria, and this 
can contribute to formation of calcium oxalate or calcium phosphate stones.  One 
hypothesis to explain protein-induced hypercalciuria is related to the “acid-ash” 
hypothesis that excessive animal protein intake provides excess sulfur-containing 
amino acids that are metabolized to sulfuric acid.  Since bone is a large reservoir of 
base, bone can be broken down to provide carbonate or phosphate to neutralize fixed 
acid loads.  Furthermore, low urinary pH decreases urinary excretion of citrate, which 
is a potent inhibitor of stone formation.  In addition, dietary animal protein 
represents a rich source of purines that may raise uric acid excretion, which could 
increase risk of forming uric acid stones (75). 
 
Protein-induced hypercalciuria may also be detrimental to bone.  Some studies show 
that high-protein diets increase calcium absorption (76), but this is currently not well 
accepted.  Several studies show that animal protein increases acid load more than 
vegetable protein because of the higher sulfur content per serving of food.  Vegetable 
protein itself does not necessarily have less sulfur per gram of protein, but a larger 
mass of foods containing vegetable protein would have to be consumed to get the 
same amount of protein as from foods containing animal protein.  It can be assumed 
that foods containing vegetable protein contain less sulfur than foods containing 
animal protein.  In studies with controlled dietary intakes with varying sulfur content, 
diets consisting of animal protein yielded greater urinary calcium excretion and lower 
urinary pH than similar diets consisting of mainly vegetable protein (77).  Another 
study comparing the effects of two sources of protein (meat and soy protein), with 
and without additional supplementation with sulfur amino acids, indicated that 
dietary meat elicited a greater positive association between protein intake and 
urinary calcium, sulfur, ammonia, and titratable acids than dietary soy (78).  When 
the soy diet was supplemented with sulfur amino acids, urinary calcium and acid 
excretion increased.  Conversely, the addition of dietary potassium (either as fruit or 
K+ supplement) to both diets decreased urinary calcium and acid excretion (78).  
Other studies have shown that greater amounts of protein or higher ratios of animal 
protein to potassium are more detrimental when bone health is already compromised 
(such as during bed rest, and potentially during space flight) (79, 80).   
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Deficiency of protein leads to muscle loss, weakness, wasting, and ultimately tissue 
breakdown, or even death.  Toxicity of protein has not been well studied. 
 
Targeted research needed 
Research continues on the effects of amino acid supplementation as a means to 
mitigate muscle loss.  This needs to continue in order to refine the details (such as 
dose and timing) and assess the viability of this countermeasure. 
 
The extramural expert panel recommended that further research be done to better 
understand the effects of protein source (animal vs. vegetable, and the effect of 
sulfur amino acid content) on bone loss and renal stone risk.  Flight proposals 
reviewed through the NASA research announcement system have received comments 
supporting the concept that optimizing the protein source would provide a dietary 
countermeasure to bone loss, with no associated risk of side effects, no additional 
launch mass, and no stowage requirements.  This concept has long been advocated 
(81), but has yet to be evaluated. 
   
Nominal requirement on Earth  
The dietary recommendations for protein are provided as recommended dietary 
allowances (RDAs), and the current Earth-based daily recommendation for those in 
the age range of the astronaut population is 56 g/day for men and 46 g/day for 
women (82).  The acceptable macronutrient distribution range (AMDR) is 10%–35% of 
total energy intake (82).  
 
Historical space flight requirements 
The daily protein requirements were defined in 1991 (47), and again in 1995 (48), as 
follows: 
    Missions of 30–120 days:  10-15% of total energy intake (47)  
    Missions up to 360 days:  10-15% of total energy intake (48) 
 
Requirements, standards, and operating bands 
Req. 2. The dietary intake of protein shall be 0.8 g/kg per day and not exceed 35% 
of the total daily energy intake.  Approximately 2/3 of the total amount of 
protein shall be provided in the form of animal protein and 1/3 in the form 
of vegetable protein. 
 
Protein intake operating bands are defined as 
 
Dietary Protein (% of calories) 
  >35% red 
  30-35% yellow 
  15-30% green 
  10-15% yellow 
  <10% red 
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Initial verification that this requirement has been met will be done by proximate 
analysis of the protein content of the planned space food items, and analysis of crew 
menus. 
  
Final verification will be completed by determining dietary intake using a food 
frequency questionnaire or other method of monitoring inflight intake.  Standards will 
be assessed before and after flight (and to the extent possible, during flight) by 
determining levels of 3-methylhistidine (3-MH) (83), total protein (84) , albumin (84), 
retinol-binding protein (85) (RBP), and transthyretin (86) in biological samples.  Serum 
and urinary creatinine will also be determined; these are included in the “General 
Chemistry” section.  
3-MH (urine) 
  >520 µmol/d red 
  320 µmol/d yellow 
  64 µmol/d green 
 
Total Protein (serum) 
 <5.5 g/dL red 
 5.5 g/dL yellow 
  6.2 g/dL green 
  7.8 g/dL yellow 
  >9.0 g/dL red 
 
Albumin (serum) 
  5.2 g/dL green 
   3.7 g/dL yellow 
  <2.8 g/dL red 
 
Transthyretin (serum) 
  40 mg/dL green 
  20 mg/dL yellow 
  <15 mg/dL red 
 
RBP (serum) 
 Women Men  
  60 mg/L 67 mg/L green 
  32.8 mg/L 39 mg/L yellow 
  <25 mg/L <25 mg/L red 
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Carbohydrate 
 
Physiological function and existing space flight knowledge 
Carbohydrates play an important role in the body because they supply the primary 
source as well as a readily available source of energy.  This energy is oxidized and 
used by various organs and cells in the body, particularly the brain and red blood 
cells, as they depend solely on carbohydrate for energy.   
 
Dietary carbohydrates are classified into a number of different categories, all based 
on the number of sugar units present.  Monosaccharides are composed of only one 
sugar unit such as glucose or fructose, and disaccharides are composed of two sugar 
units, such as sucrose (glucose + fructose) or lactose (glucose + galactose).  Longer 
chains of sugar units, up to 10, are known as oligosaccharides, and polysaccharides 
contain more than 10 sugar units.  Examples of polysaccharides are starch and 
glycogen, which are the storage forms of carbohydrate for plants and animals, 
respectively. 
 
The human body stores carbohydrates as glycogen.  Glycogen synthesis is triggered in 
skeletal muscle by a rise in insulin after the consumption of carbohydrates.  Most of 
the total body glycogen is present in skeletal muscle for storage and utilization, with 
a small portion being stored in the liver for export and maintenance of blood glucose 
concentrations.  De novo synthesis of glucose from non-carbohydrate precursors can 
and does occur in the body, if needed.  This allows the liver to maintain adequate 
blood glucose concentrations.  Insulin is required for the uptake of glucose into cells, 
and various transporter systems are found in different types of tissues that utilize 
glucose.       
 
Carbohydrate should make up the most significant portion of the diet because it is the 
main energy source.  Space flight requirements for carbohydrate are thought to be 
similar to those on Earth.  However, to date, few investigations have been conducted 
on the effects of microgravity on the metabolism of dietary carbohydrate.  Some data 
show that bed rest (and theoretically space flight) results in insulin resistance (87-89). 
Efforts to maintain muscle mass (and presumably correct this) continue, but little 
research has been done to pursue this as a nutritional issue. 
 
Body stores and relative time to depletion 
About 150–500 g of carbohydrate is stored in the body as glycogen, in the liver and 
skeletal muscle (90). Glycogen stores, especially those in the liver, fluctuate greatly 
during the day in response to food intake, and these fluctuations may be involved in 
the regulation of food intake (91).  Muscle glycogen stores are used mainly by muscle, 
whereas liver glycogen stores are used to maintain, store, and export blood glucose. 
Liver stores are depleted after 12 to 18 hours of fasting (90).   
 
As long as the intake of protein and fat is adequate, the lower limit of dietary 
carbohydrate that is compatible with life is zero.  However, considerable metabolic 
adjustments (to ketosis) must be made for the body to adapt to using fat and protein 
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as fuels.  The level of carbohydrate required to provide optimal health is not as 
clearly defined.   
 
Potential implications for flight 
Sub-optimal carbohydrate intake before and during space flight may have 
consequences for the crew’s productivity and impede their ability to respond in 
emergency situations (92). 
 
Deficiency of carbohydrate leads to ketosis.  A ketotic state would likely impair 
performance of the crew, as seen in studies conducted by the military (46).  Other 
aspects of the mission would also be at risk (for example, the life support systems 
may not be able to remove the ketones from the air).  Toxicity of carbohydrate has 
not been well studied, and would likely be an issue only with regard to displacement 
of other nutrients (protein and fat). 
 
Targeted research needed 
No data are currently available to assess the impact of space flight on carbohydrate 
metabolism.  Observations from space flight as well as ground-based bed rest studies 
show subtle changes in insulin secretion, insulin resistance, and glucose intolerance 
(88, 89, 93, 94).  Even subtle changes in such important metabolic processes make it 
critically important to consider the possibilities of altered carbohydrate and insulin 
metabolism for exploration missions.   
  
Nominal requirement on Earth 
Acceptable daily intake of dietary carbohydrate should be between 55 and 75% of the 
total dietary energy (95).  A minimum intake of 140 g/d is required to maintain the 
needs of organs that require carbohydrate for energy production (96).   
 
Historical space flight requirements 
The daily carbohydrate requirement for male and female astronauts was originally 
defined (47, 48) as follows: 
   Missions of 30–120 days:  50% of total energy intake (47)  
   Missions up to 360 days:  50–55% of total energy intake (48) 
Most of the carbohydrate should be provided as complex carbohydrates, with less than 
10% of total carbohydrate provided as simple sugars. 
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Requirements, standards, and operating bands 
Req. 3. The dietary intake of carbohydrate shall comprise 50–55% of the total daily 
energy intake.  Carbohydrate intake operating bands are defined as   
 
Dietary Carbohydrate (% of calories) 
  >65% red 
  55-65% yellow 
  50-55% green 
  45-50% yellow 
  <45% red 
 
Initial verification that this requirement has been met will be done by proximate 
analysis of the carbohydrate content of the planned space food items, and analysis of 
crew menus. 
  
Final verification will be completed by determining dietary intake using a food 
frequency questionnaire or other method of monitoring inflight intake.  Standards will 
be assessed before, during, and after flight by determining levels of glucose (84) in 
whole blood. 
 
Glucose (whole blood) 
 >200 mg/dL red 
 200 mg/dL yellow 
  70-105 mg/dL green 
  70 mg/dL yellow 
  <50 mg/dL red 
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Fat 
 
Physiological function and existing space flight knowledge 
Fat is the most energy-dense of all the nutrients, and therefore is a major energy 
source for the body.  Dietary fat comes mainly in the form of triacylglycerols that 
contain a glycerol backbone with as many as three fatty acids attached.  A number of 
types of fatty acids exist, including saturated, monounsaturated, polyunsaturated, 
and trans.  Dietary fat assists in the absorption of fat-soluble vitamins, and also 
supplies the body with the two essential fatty acids (EFAs), linoleic acid and linolenic 
acid.  These EFAs are necessary for growth and development, as well as many other 
biochemical processes, including production of eicosanoids (physiologically active 
substances derived from arachidonic acid).  Lipids, in the form of phospholipids, make 
up a large proportion of the structural components of the cellular membrane bi-layer.  
Energy stored as fat is released in the process of fatty acid oxidation, and fat supplies 
more energy than any other macronutrient because of its higher content of carbon-to-
hydrogen bonds.         
 
Body stores and relative time to depletion 
Body stores of fat are located mainly in adipose tissue as triacylglycerols.  Adipose 
tissue is dispersed throughout the human body, its distribution differing slightly 
between genders.    
 
According to case studies, people following fat-free diets can exhibit symptoms of 
essential fatty acid deficiencies after only 1 month.  An infant consuming fat-free 
total parenteral nutrition (TPN) for 3 months developed skin lesions and had 
polyunsaturated fatty acid levels less than 10% of control values (97).  In another 
study, an adult consumed fat-free TPN for 7 months and developed a severe 
dermatitis by the end of the first month.  Omega-3 (n-3) fatty acids comprised 0.01% 
of the fatty acids of this person’s plasma phospholipids, which means that the patient 
was almost completely depleted of n-3 fatty acids (98). 
 
Potential implications for flight  
Deficiency of fat leads to essential fatty acid deficiency and ultimately death.  Toxic 
levels of fat lead to high cholesterol, atherosclerotic plaques, and ultimately coronary 
heart disease, or even death. 
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Targeted research needed 
The role of n-3 fatty acids in cancer prevention is currently being investigated in 
animal models of space flight radiation effects (99).  Not only do n-3 fatty acids show 
promise in alleviating cancer risk, but these fatty acids also have well documented 
cardiovascular benefits, have been used in numerous clinical trials, and show promise 
as a muscle loss countermeasure.  The abundant data showing that eicosapentaenoic 
acid (EPA) can successfully prevent muscle atrophy during other muscle-wasting 
conditions, such as cancer or sepsis, indicate the likelihood is high that EPA will have 
the same beneficial effects on muscle atrophy during space flight or ground-based 
analogs including bed rest.  Thus, further research on EPA is warranted.  This has 
been proposed and peer-approved, but not funded. 
 
Nominal requirement on Earth 
Currently no RDA or adequate intake (AI) level has been set for total fat because data 
are insufficient to determine the level of dietary fat that may put one at risk for 
inadequacy or may contribute to the prevention of chronic disease (82).  The AMDR is 
20–35% of total energy intake (82). 
 
Historical space flight requirements 
The daily total fat requirements for male and female astronauts were evaluated, and 
were determined to be 
     Missions of 30–120 days:  30–35% of total energy intake (47) 
     Missions up to 360 days:  30–35% of total energy intake (48)  
  
Requirements, standards, and operating bands 
Req. 4. The dietary intake of fat shall comprise 25–35% of the total daily energy 
intake.  Dietary intake of n-6 and n-3 fatty acids shall be 14 grams/day and 
1.1–1.6 grams/day, respectively.  Consumption of saturated fat, trans fatty 
acids, and cholesterol will be as low as possible.   
 
Dietary fat nominal operating bands are defined as 
 
Total Dietary Fat 
  >40% red 
  35–40% yellow 
  25–35% green 
  20–25% yellow 
  <20% red 
 
Initial verification that this requirement has been met will be done by proximate 
analysis of space food items for fat content, as well as individual fatty acids. The 
menu content will also be analyzed. 
  
Final verification will be completed by determining dietary intake using a food 
frequency questionnaire or other method of monitoring inflight intake.  Standards will 
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be assessed before, during (to the extent possible), and after flight by determining 
levels of cholesterol (84), cholesterol fractions (86, 100), and triglycerides (84) in 
serum samples. 
 
Cholesterol (serum) 
  125 mg/dL green 
  199 mg/dL yellow 
  >350 mg/dL red 
 
 
Triglycerides (serum) 
  35 mg/dL green 
  149 mg/dL yellow 
  >250 mg/dL red 
 
 
HDL Cholesterol (serum) 
  >60 mg/dL green 
  40 mg/dL yellow 
  <40 mg/dL red 
 
 
LDL Cholesterol (serum) 
  <129 mg/dL green 
  159 mg/dL yellow 
  >160 mg/dL red 
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Fiber 
 
Physiological function and existing space flight knowledge 
Dietary fiber consists of non-digestible food components that are typically 
carbohydrate and plant-based.  Non-starch polysaccharides, including cellulose, gums, 
pectins, mixed-linkage β-glucans, and hemicelluloses, are the major components of 
dietary fiber.  Although most dietary fibers are polysaccharides that are made up of 
10 units or more, β-linkage oligosaccharides such as inulin are also included in the 
definition of dietary fiber because of their physiological similarities.  Lignan is also 
included even though it is a non-carbohydrate component.   
 
A role for dietary fiber has been implicated in decreases in plasma cholesterol, 
modification of the glycemic response, improvements in large bowel function, and 
decreases in the bioavailability of some nutrients.  Epidemiological evidence also 
points to relationships between diets high in fiber and decreased incidence of 
cardiovascular disease and bowel cancer (101).   
 
Body stores and relative time to depletion 
By definition, fiber is not stored. 
 
Potential implications for flight 
Changes have been described in gastrointestinal function and gut transit time during 
space flight. Adequate dietary fiber will be essential to maintain gastrointestinal 
function and decrease the incidence of constipation, because mouth-to-cecum transit 
times are slower on orbit (92).  
 
Targeted research needed 
Several studies have shown that specific dietary fatty acids and types of dietary fiber 
can reduce radiation-induced cancer risk in animals (99, 102).   Further research is 
warranted to investigate the potential protective effects of fiber on radiation-induced 
cancer risk in humans exposed to high-linear energy transfer (LET) radiation during 
space flight.   
   
Nominal requirement on Earth 
Recommended intakes of dietary fiber are provided as AIs (82): 
Individuals aged 19–50 y    Individuals aged 51–70 y 
Men:  38 g/d      Men:  30 g/d 
Women:  25 g/d     Women:  21 g/d 
 
Historical space flight requirements 
The daily total fiber requirements for male and female astronauts were defined 
earlier as follows: 
   Missions of 30–120 days:  10–15 g, in soluble and insoluble forms (47) 
   Missions up to 360 days:  10–25 g, in soluble and insoluble forms (48) 
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Requirements, standards, and operating bands 
Req. 5. The dietary intake of fiber shall be 10–14 grams/1000 kcal.  The nominal 
operating bands for dietary fiber are defined as 
 
Dietary Fiber 
  21-38+ g/d green 
  20 g/d yellow 
  <20 g/d red 
 
Verification that this requirement has been met will be done by proximate analysis of 
the fiber content of the planned space food items, and analysis of crew menus. 
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Fluid, Electrolytes and Renal Stone Risk 
 
Fluid 
 
Physiological function and existing space flight knowledge 
Adequate fluid intake is necessary to maintain the body’s normal hemodynamic state 
and normal fluid osmolality, which is important for cardiovascular health and 
maintenance of fluid and electrolyte homeostasis. Water is a structural component of 
the body and the solvent for transportation of nutrients and waste. Fluid and 
electrolytes may be lost from the body by a variety of routes and for a variety of 
reasons.  Fluid and electrolytes are excreted in sweat, urine, and feces, and in 
abnormal situations excessive amounts can be lost by these routes and others.  
Significant losses may occur through the gastrointestinal tract as a result of diarrhea, 
vomiting, or gastric drainage.  Loss through the skin increases with fever, increased 
metabolism, sweating, and burns (103).   
 
Fluid and electrolyte homeostasis is significantly altered during space flight, and this 
has been extensively reviewed (3, 104-112).  The hypothesis originally proposed was 
that upon entering weightlessness, the human body would experience a headward 
shift of fluids, with subsequent diuresis and dehydration. A series of experiments was 
conducted to assess fluid and electrolyte homeostasis during space flight; the most 
comprehensive of these took place on the two Spacelab Life Sciences missions in the 
early 1990s. 
 
Within hours of the onset of weightlessness (the earliest available data point), a 
reduction in both plasma volume and extracellular fluid volume occurred, 
accompanied by the “puffy” faces typically observed early in flight (3, 113).  Initially, 
the decrement in plasma volume (~17%) was larger than the decrement in 
extracellular fluid volume (∼10%), suggesting that interstitial fluid volume (the other 
four-fifths of extracellular fluid) is conserved proportionally more than plasma volume 
(3).  Conservation of interstitial fluid volume is supported by rapid decreases in total 
circulating protein, specifically albumin (3).  This shift of protein, and associated 
oncotic pressure, from the intravascular to the extravascular space would also 
facilitate the initial changes in plasma volume (3). 
 
Following the initial adaptation, extracellular fluid volume decreased between the 
first days of flight and 8 to 12 days of flight, from the initial ∼10% below preflight 
levels to ~15% below preflight levels (3).  Plasma volume was partially restored during 
this period, from the initial ~17% below preflight levels to ∼11% below preflight levels 
(3), and it has been found to remain 10%–15% below preflight levels even for 
extended-duration flights (114). 
 
It is hypothesized that the extravascular shift of protein and fluid represents an 
adaptation to weightlessness, and that after several days, some of the extravascular 
albumin has been metabolized, with a loss of oncotic force and a resulting decreased 
extracellular fluid volume and increased plasma volume (3).  This loss of extracellular 
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protein (either intra- or extravascular), and associated decreased oncotic potential, 
probably plays a role in postflight orthostatic intolerance, which has been considered 
to result partly from reduced plasma volume at landing (115).  Furthermore, the loss 
of protein may explain why fluid loading alone does not restore circulatory volume 
(116, 117), as no additional solute load exists to maintain the fluid volume. 
 
The effect of space flight on total body water has been evaluated to assess hydration.  
Shuttle and Skylab astronauts had approximately 1% decreases in total body water 
during flight (3, 118, 119), and the percent of body mass represented by water did 
not change.  Thus, the often-proposed weightlessness-induced dehydration does not 
exist.  This has also been shown by European investigators (111, 120-122). 
 
Diuresis is also typically not observed during flight (13, 104, 105, 122-125), for a 
number of possible reasons.  Operational constraints have made it difficult to 
document urine volume accurately on the first day of space flight.  However, on the 
Spacelab Life Sciences missions, urine volume on the first 3 days of flight was 
significantly less than preflight volume, and tended to be less than preflight values 
throughout the flight (3).  Urine volumes on a week-long flight to Mir were also less 
than preflight volumes (124).  During the first week of the 59- and 84-d Skylab flights 
(30), urine volume was less than it was before flight, and for the remainder of the 
mission it was unchanged from preflight levels.  Decreased fluid intake likely accounts 
for the decreased urine volume, which was accompanied by little or no change in 
total body water.  Diuresis has been documented in bed rest studies (126), suggesting 
differences in fluid metabolism between analog studies and actual space flight.  
 
As mentioned above, the percent of body mass represented by total body water is 
relatively unchanged during flight (3).  However, on a volume basis, the change in 
extracellular fluid volume was found to be greater than the change (or lack of 
change) in total body water (3).  Thus, by difference, intracellular fluid volume 
increased during space flight.  This had been previously hypothesized from ground-
based studies (127) and observed in postflight studies of Apollo crew members (13).  
The mechanism for a space flight-induced increase in intracellular fluid volume is 
unknown.  One possible explanation is that a shift in fuel utilization results in altered 
glycogen storage, a condition known to increase cellular water content. 
 
Body stores and relative time to depletion 
Total body water makes up about 50%–70% of body mass (128). 
 
Fluid requirements increase with metabolic rate and heat stress.  Death from 
dehydration from depriving the body of all water can occur within weeks (129).    
 
Potential implications for flight  
Inadequate fluid intake increases the risk of renal stone formation and dehydration, 
and may be a consequence of reduced thirst during space flight (92). Fluid intakes 
during flight are typically less than preflight levels, and are often below the 
recommended quantities.  Although no space flight-induced dehydration occurs, care 
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must be taken to ensure adequate fluid intake and hydration status.  This is critical 
for closed flight vehicles where water is often a limiting resource.  Rationing of water 
should be avoided wherever possible. 
 
Deficiency of fluid leads to dehydration and ultimately death.  Likewise, an excess of 
fluid intake leads to water intoxication or even death. 
 
Targeted research needed 
Studies described above have documented that total body water is unchanged during 
flight, but an apparent shift of fluid from the extracellular to the intracellular 
compartment occurs.  The effect of this on cell size and cell function (such as the 
effect of a change in the density of receptors on cell membranes) has not been 
evaluated.  This might be responsible for some of the changes noted in other systems 
(such as the endocrine, cardiovascular, and immune systems). 
   
Nominal requirement on Earth 
Recommended intakes of total water (including that contained in food, beverages, 
and drinking water) are provided as AIs (130): 
    Men, 19 y and older:    3.7 L/d 
    Women, 19 y and older:   2.7 L/d 
 
Historical space flight requirements 
The daily total fluid requirements for male and female astronauts were defined 
earlier as follows: 
 
Missions of 30–120 days:  Water intake should be adequate to reduce the incidence of 
kidney stones; a tentative guideline could be 1 mL/kcal of consumed energy (47).  
 
Missions up to 360 days:  Intake of fluid shall be sufficient to reduce the incidence of 
kidney stones and prevent dehydration.  The daily fluid requirement is estimated to 
be 1.0–1.5 mL/kcal consumed (at least 2000 mL/day).  It is imperative for health of 
the crew that fluid intake be maintained (48). 
 
Requirements, standards, and operating bands 
Req. 6. The dietary intake of fluid shall be 1–1.5 mL/kcal, with a minimum intake 
of 2000 mL.  The nominal operating bands are defined as 
 
Fluid Intake 
  1-1.5 mL/kcal green 
  2 L/d yellow 
  <2 L/d red 
 
 
Initial verification that this requirement has been met will be done by proximate 
analysis of space food items for water content, as well as by analysis of the selected 
menus. 
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 Final verification will be completed by determining fluid intake using a food 
frequency questionnaire or other method of monitoring inflight intake.  Standards will 
be assessed before, during (to the extent possible), and after flight by determining 
blood protein and electrolyte levels in blood and serum samples (operating bands for 
these are described in other sections). 
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Sodium 
 
Physiological function and existing space flight knowledge  
Sodium is the major cation of extracellular fluid (103). Together with chloride, 
sodium is utilized by the body to maintain normal water distribution, osmotic 
pressure, and anion-cation balance in the extracellular fluid compartment (131).  
Electrolyte concentrations in the body are critical for proper cardiovascular function 
and are under renal and hormonal control (132). Increases in blood sodium levels can 
be caused by diabetes, renal polyuria, diarrhea, insufficient water intake, excessive 
sweating, or increased dietary sodium intake. Sodium levels decrease with edema, 
excessive water intake, vomiting, diarrhea, diuretic therapy, renal tubular damage, 
hyperaldosteronism, or lower dietary intake. 
 
Inflight sodium intakes during Skylab and Shuttle missions averaged 4 – 5 g, and were 
not dissimilar from the astronauts’ preflight intakes (133). The current food system is 
high in dietary sodium, and typical intakes on the ISS have been in excess of 4.5 g, 
even with sub-optimal food intake (15).  Although sodium homeostasis and blood 
sodium levels are maintained during real and simulated space flight (134), excessive 
intake of sodium can affect bone and renal health (135). 
 
Body stores and relative time to depletion 
For the normal adult, total body sodium averages about 60 mmol/kg body weight. 
Forty to 45% of total sodium resides in bone, with the balance found in extracellular 
and intracellular fluid. These sodium stores are classified as either exchangeable (42 
mmol/kg body weight) or non-exchangeable, the former being composed of all 
cellular and less than half of bone sodium (136). Exchangeable sodium becomes 
available by diffusion when plasma sodium levels become low, and in states of 
edema, the exchangeable sodium stores absorb sodium. 
 
Animal studies show that symptoms of a sodium deficiency occur after 3 to 4 weeks of 
dietary sodium restriction (137). During acute starvation, urinary sodium excretion 
decreases to less than 0.2 g within 10 days (138), and can be affected by the amount 
of sweat (139). Plasma sodium levels are maintained fairly well during acute 
starvation: an initial decrease is followed by a return toward normal values (140).  
Maintenance of blood sodium is also observed during semi-starvation. During the 
Minnesota Experiment, plasma sodium levels in samples taken after the 6-month semi-
starvation period were 0.6 ± 7.3% higher than baseline levels (n=4) (139). Six days of 
under-nutrition resulted in large negative balances of sodium chloride (–12.8 ± 3.6 
g/d), likely related to changes in water balance (data from (139)).   
 
Potential implications for flight  
Dietary sodium is known to affect calcium homeostasis (141, 142). High salt intakes 
are typically found during space flight, and have potential consequences for renal 
stone risk and microgravity-induced osteoporosis. Changes in plasma volume, 
extracellular fluid volume, and cardiovascular function have also been observed 
during space flight (3).   
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On Earth, excessive sodium intake has been associated with increased bone turnover 
(143).  In a review of the interaction between dietary salt, calcium, and bone, Massey 
and Whiting (144) suggest that habitual excessive salt intake contributes to bone loss 
and increases risk of renal stone formation (as reviewed in (145-147), and that the 
effects of dietary sodium are different in different subpopulations (for example, renal 
calcium stone formers are more responsive to a change in dietary salt than are non-
stone formers).  
 
Increased risk of renal stone formation during and after space flight is well 
documented (148, 149), and crew intakes of sodium are typically high even when 
energy intakes are inadequate (15).  Dietary sodium also seems to exacerbate the 
calciuric responses to musculoskeletal unloading in weightlessness. Bed rest subjects 
consuming a low-sodium (100 mmol/d) diet had no change in urinary calcium, while 
those on a high-sodium diet (190 mmol/d) had hypercalciuria (150).  The high sodium 
content of the current space food system makes it particularly important to monitor 
and restrict dietary sodium intake of astronauts to maintain their bone and renal 
health.  Thus, the research emphasis for food system development for exploration-
class missions should include a focus on low-sodium, long-shelf-life, palatable foods 
(151).   
 
Deficiency of sodium leads to hyponatremia and hypotension, or even death.  
Conversely, an excess of sodium leads to hypernatremia and hypertension, or even 
death. 
 
Targeted research needed  
The extramural expert panel recommended that further research be done to 
investigate potential effects of high sodium intake during space flight, since the space 
food system currently has very high sodium levels.  The impact of high sodium intake 
on bone, calcium, and pH is not well understood, and adjustments in sodium intake 
may serve as a viable countermeasure to bone loss.   Furthermore, the role of high-
sodium diets in potassium homeostasis is not well understood.  This may prove to be 
an area where nutrition and cardiovascular effects of space flight may interact, and 
study of the interaction may produce a dietary countermeasure. 
 
Nominal requirement on Earth 
The recommendations for sodium intake are provided as AIs (130): 
   Men and women, 19–50 y: 1.5 g/d   
   Men and women, 51–70 y: 1.3 g/d 
 
Historical space flight requirements 
The intake for male and female astronauts was defined as 1.1–3.3 g/d on missions of 
30 to 120 days in duration, and 1.5–3.5 g/d on missions up to 360 days (23, 152).  The 
food system was unable to support this requirement, and intakes were often much 
higher (intakes as high as 7–10 g Na per day have been observed). 
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Requirements, standards, and operating bands 
Req. 23. The dietary intake of sodium shall be 1500–2300 mg/day for both women 
and men.  The nominal operating bands are defined as 
 
Dietary Sodium 
  >3500 mg/d red 
  3500 mg/d yellow 
  1500-2300 mg/d green 
  500-1500 mg/d yellow 
  <500 mg/d red 
 
Initial verification that this requirement has been met will be done by proximate 
analysis of space food items for sodium content, as well as by analysis of the crew 
menus. 
  
Standards will be assessed before, during (to the extent possible), and after flight by 
determining levels of sodium in blood (84, 153, 154) samples. Determination of 
urinary sodium allows indirect assessment of the level of sodium intake (153, 154), 
although this is considered supporting data and not a standard per se.  Normal ranges 
for urinary sodium are documented in the General Chemistry section. 
 
Sodium (serum) 
 >155 mmol/L red 
 144-155 mmol/L yellow 
  135-144 mmol/L green 
  128-135 mmol/L yellow 
  <128 mmol/L red 
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Potassium 
 
Physiological function and existing space flight knowledge 
As the major intracellular cation, potassium has a significant role in several 
physiological processes (132). Potassium is critical to regulation of acid-base balance, 
energy metabolism, blood pressure, membrane transport, and fluid distribution within 
the body.  It is also involved in the transmission of nerve impulses and cardiac 
function (155). Disordered potassium metabolism because of excess or deficient 
circulating levels has negative consequences for cardiac, muscle, and neurological 
function. 
 
Body stores and relative time to depletion 
Total body potassium averages 45 mmol/kg body weight, totaling about 3150 mmol 
(1230 g) of potassium in a reference 70-kg person. Two percent of body potassium 
(~60 mmol) is distributed in the extracellular fluid, and intracellular fluid levels are 
typically maintained at 140–150 mmol/L). 
 
Potassium levels cannot be maintained at intakes under 10–20 mmol/day (156).  
Moderate depletion of potassium in humans is associated with clinically significant 
impaired active relaxation of the left ventricle (157).  In the referenced study, 
healthy adults were placed on a potassium-depletion diet for 7 days.  At the end of 7 
days, isovolumic relaxation time and deceleration time of flow through the mitral 
valve were significantly increased. 
 
Potential implications for flight  
Increased levels of urinary potassium may be related to muscle disuse atrophy and 
inadequate intake during space flight (134). 
 
Deficiency of potassium leads to hypokalemia, muscle weakness, constipation, and 
fatigue, or even death.  There is no evidence of adverse effects associated with 
toxicity of potassium from naturally occurring sources.  However, supplemental intake 
may cause hyperkalemia (and associated weakness, cardiac arrest, paralysis), 
metabolic acidosis, decreased neuromuscular functions, or even death. 
 
Targeted research needed  
The extramural expert panel recommended that the relationship between bone health 
and the protein:potassium ratio in the diet be further investigated, along with the 
role of potassium in cardiovascular health during flight.  The loss of lean body mass, 
along with high sodium intake, may result in potassium depletion. 
   
Nominal requirement on Earth 
The recommended intake for potassium is provided as AIs (130): 
    Men and women, 19–70 y:  4.7 g/d 
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Historical space flight requirements 
The intake of potassium for male and female astronauts was defined as approximately 
3500 mg/day (47, 48).  
 
Requirements, standards, and operating bands 
Req. 24. The dietary intake of potassium shall be 4.7 g/d.  The nominal operating 
bands are defined as 
 
 
 
 
 
 
 
Initial verification that this requirement has been met will be determined by 
proximate analysis of space food items for potassium content, as well as by analysis of 
the crew menus. 
  
Standards will be assessed before, during (to the extent possible), and after flight by 
determining levels of potassium in blood (84) and urine (153) samples. Determination 
of urinary potassium allows indirect assessment of the level of potassium intake (130), 
although this is considered supporting data and not a standard per se.  Normal ranges 
for urinary potassium are documented in the General Chemistry section. 
 
Potassium (serum) 
 >5.8 mmol/L red 
 5.2-5.8 mmol/L yellow 
  3.7-5.2 mmol/L green 
  3.0-3.7 mmol/L yellow 
  <3.0 mmol/L red 
 
Dietary Potassium 
  4.7 g/d  green 
  3.5-4.7 g/d yellow 
  <3.5 g/d red 
 37
Renal Stone Risk 
 
Physiological function and existing space flight knowledge 
In-flight data show that there is an increased risk for renal stones during space flight 
(148, 158, 159).  Urinary components, such as decreased citrate, decreased 
potassium, increased calcium, and increased relative supersaturation of calcium 
oxalate and brushite (148) contribute to an increased renal stone risk among 
crewmembers during flight.   
 
Ground-based clinical data show that certain dietary components have a major impact 
on renal stone-forming risk.  High sodium diets, excess animal protein in the diet, and 
excess dietary oxalate increase calcium excretion, decrease citrate excretion, 
increase urinary uric acid, and decrease the inhibitor activity against calcium oxalate 
crystallization in the urine (160, 161).   
 
Potential implications for flight  
It is imperative that renal stone risk be minimized prior to space flight, and that 
recommended fluid and dietary guidelines are followed during flight to minimize risk.  
If crewmembers have an increased risk of renal stones prior to space flight because of 
dietary habits or other factors, then exposure to microgravity and the resultant bone 
loss, hypercalciuria, increased urinary sodium and decreased urinary output, may 
further exacerbate their risk of renal stone formation (148, 149). 
 
Targeted research needed  
It is not uncommon for astronauts to consume 4-8 g sodium per day during flight (15, 
148).  A high sodium diet is associated with elevated urinary calcium and sodium 
excretion, and decreased urinary citrate (144, 147, 148, 160-162).  It is not known 
whether increased risk from high dietary sodium and protein intake have an additive 
effect with the increased risk from space flight itself, therefore further studies are 
warranted.  It is ideal if renal stone risk could be mitigated through dietary changes 
alone to minimize potential side effects from pharmacological agents, but this 
approach needs to be investigated during flight for its efficacy.     
 
Nominal requirement on Earth 
Clinical experience has demonstrated that a program of monitoring urinary 
parameters related to renal stone risk and estimating the risk for renal stone 
development can virtually lead to total control of renal stone disease (163, 164).   
Meeting DRIs for fluid intake, dietary calcium, sodium, phosphorus, magnesium, and 
protein are recommended for reducing renal stone risk (82, 130, 165). 
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Historical space flight requirements 
The renal stone risk profile has been evaluated extensively on Shuttle, Mir, and ISS 
crews (148, 149, 159), and was included as part of the nutritional assessment profile 
from the inception (166). 
 
 
Requirements, standards, and operating bands 
The renal stone risk profile shall be assessed in order to minimize risk of stone 
formation.  
 
Metabolic factors and limits are: urinary calcium shall not exceed 375 mg per day; 
urinary oxalate shall not exceed 62 mg per day; urinary uric acid shall not exceed 1000 
mg per day; urinary citrate shall be greater than 160 mg per day; and urinary pH shall 
not be greater than 8. 
 
Environmental standards and limits are: the total volume of urine shall be at least 1 
liter per day; urinary sodium shall not exceed 300 meq per day; urinary sulfate (SO4) 
shall not exceed 45 mmol per day; urinary phosphorus shall not exceed 1400 mg per 
day; urinary magnesium shall be greater than 30 mg per day. 
 
Relative supersaturation standards and limits are: urinary calcium oxalate 
supersaturation shall not exceed 3; urinary brushite supersaturation shall not exceed 3; 
sodium urate supersaturation shall not exceed 3; struvite supersaturation shall not 
exceed 750; uric acid supersaturation shall not exceed 3. 
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Fat-Soluble Vitamins 
 
Vitamin A 
 
Physiological function and existing space flight knowledge 
Vitamin A is a general term that refers to a family of fat-soluble compounds that are 
structurally similar to retinol and share its biological activity.  Among these are 
retinol, α-carotene, β-carotene, and retinyl palmitate.  Trans-retinol is the primary 
biologically active form of vitamin A.  Many carotenoids, such as β-carotene, can be 
converted to trans-retinol and thus contribute to vitamin A activity.  Collectively, 
these carotenoids are termed provitamin A carotenoids and are measured in retinol 
equivalents (REs).  Vitamin A is directly involved in vision, gene expression, 
reproduction, embryonic development, and immunity.  Vitamin A and β-carotene 
serve as biological antioxidants and have been shown in multiple studies to reduce the 
risk of cancer and coronary heart disease (167, 168).  Vitamin A also plays a role, 
albeit sometimes indirectly, in the function of almost all of the body’s organs (169).  
 
Serum levels of retinol and retinol-binding protein are significantly decreased after 
long-duration space flight (15). 
 
Body stores and relative time to depletion 
Vitamin A is stored mainly (80%) in the liver, with the remainder stored in peripheral 
organs and tissues. Total body stores range from 1.05 to 3.14 nmol (300 to 900 mg) in 
normal adults (170).   
 
Liver stores of vitamin A are severely depleted when levels are less than 20 µg (171).  
A study of vitamin A depletion in baboons found a 59% decrease in hepatic vitamin A 
after 4 months of a chronic ethanol diet (172).  After 24 to 48 months, the 
researchers found a 95% decrease in hepatic vitamin A stores, which was accompanied 
by fibrosis and cirrhosis of the liver.  Alcoholism is often associated with vitamin A 
deficiency because retinol and ethanol are competing substrates for the same 
enzymes (173). 
 
Potential implications for flight  
Oxidant stress is increased during space flight, and this could affect cardiovascular 
health and cancer risk. Vitamin A status may play a critical role in maintaining 
antioxidant health during space flight. 
 
Deficiency of vitamin A leads to xerophthalmia, loss of appetite, drying and 
keratinization of membranes, infection, or even death.   
 
Acute toxicity of vitamin A leads to nausea, vomiting, headache, blurred vision, and 
muscular incoordination.  Chronic toxicity of vitamin A leads to rapid reduction in 
bone mineral density, liver abnormalities, or even death. 
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Targeted research needed 
The extramural expert panel recommended that vitamin A content and stability in the 
space food supply be determined. 
   
Nominal requirement on Earth 
The RDA for vitamin A is 900 µg RE/d for men aged 19 and older, and 700 µg RE/d for 
women aged 19 and older (174).  Upper limits exist for vitamin A (3000 µg RE/d), and 
β-carotene supplementation is advised only in situations where there is a risk of 
vitamin A deficiency. 
 
Historical space flight requirements 
The daily vitamin A requirements for male and female astronauts were determined 
earlier, and are as follows: 
   Missions of 30 – 120 days (47): 
       Males 1000 µg RE/d   
       Females   800 µg RE/d   
   Missions up to 360 days (48):  
       Males 1000 µg RE/d   
       Females 1000 µg RE/d   
    RE = retinol equivalents; 1 RE = 1 µg retinol or 6 µg β-carotene 
 
Requirements, standards, and operating bands 
Req. 7. The dietary intake of vitamin A shall be 700–900 µg/day.  The nominal 
operating bands are defined as  
 
 Dietary Vitamin A  
 >3000 µg/d red 
 700-900 µg/d green 
 500-700 µg/d yellow 
   <500 red 
 
 
Initial verification that this requirement has been met will be determined by 
proximate analysis of space food items for vitamin A content, as well as by analysis of 
the crew menus. 
  
Final verification will be completed by determining vitamin A intake using a food 
frequency questionnaire or other method of monitoring inflight intake.  Standards will 
be assessed before, during (to the extent possible), and after flight by determining 
levels of retinol (85)and retinyl palmitate (175) in blood samples. Blood levels of 
retinyl palmitate are measured to identify any evidence of vitamin A toxicity.  
Chronic and acute vitamin A toxicities are associated with increased plasma retinyl 
esters because excess retinol in the blood is converted to this less toxic form (174). 
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Retinol 
  1.2 µg/mL green 
  0.3 µg/mL yellow 
  <0.1 µg/mL red 
 
Retinyl Palmitate 
  0-0.19 µg/mL green 
  >0.20 µg/mL red 
 
β-carotene 
  0.04-0.373 µg/mL green 
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Vitamin D 
 
Physiological function and existing space flight knowledge 
The major function of vitamin D is to maintain normal blood levels of calcium and 
phosphorus.  The liver converts vitamin D3 to 25-hydroxyvitamin D3, which is typically 
the gold standard measurement for determining vitamin D status.  25-hydroxyvitamin 
D3 is converted to 1,25-dihydroxyvitamin D3 in the kidney, and from there it is 
transported systemically to target organs.  Classic target organs include bone, 
intestine, and kidney.  Numerous other tissues are affected by vitamin D status 
because their cell nuclei contain receptors for 1,25-dihydroxyvitamin D3.  Some of 
these tissues are adipose tissue, bone marrow, brain, breast, cancer cells, cartilage, 
lung, muscle, ovary, placenta, prostate, stomach, testis, thymus, and uterus (176). 
 
The 2005 Dietary Guidelines for Healthy Americans reports that optimal serum 25-
hydroxyvitamin D may be as high as 80 nmol/L (177).  These guidelines recommend 
that people in high-risk groups (elderly and those exposed to little sunlight) have 
substantially higher intakes of vitamin D (25 µg or 1000 IU) than the general 
population, to maintain serum 25-hydroxyvitamin D values at 80 nmol/L (177).  These 
findings were based, in part, on numerous studies showing that for individuals with 
little sun exposure, dietary intake is insufficient to maintain vitamin D status and 
parathyroid hormone (PTH) suppression (178). 
 
Decreased vitamin D status is one of the most striking nutritional changes that occurs 
during space flight (15, 179).  In several different studies, crew members on the 
Russian space station Mir had serum 25-hydroxyvitamin D3 concentrations that were 
32%–36% less during and after long-duration (3- to 4-month) missions than before the 
missions (12, 179).  Ground-based studies of bed rest subjects (180) and subjects 
living in closed-chamber facilities for extended periods also support these data (181).  
Attempts to supplement with vitamin D have not been successful in correcting the 
problem.  Specific examples of this include data from individual Skylab missions 
showing that crew members on the longest mission (Skylab 4, 84 days), but not the 
shorter missions (28 and 59 days), had decreased serum 25-hydroxyvitamin D3 at 
landing despite daily vitamin D supplementation (30), and similar data from ISS crew 
members, for whom supplementation did not seem to correct the problem of vitamin 
D status (15).  Another important observation was related to the relationship between 
PTH and 25-hydroxyvitamin D3 before and after flight.  Before launch, 25-
hydroxyvitamin D3 was inversely correlated with PTH (r = –0.72, P < 0.05), but this 
relation was not evident after landing, suggesting that the body’s normal response to 
changes in vitamin D was altered (15). 
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Body stores and relative time to depletion 
7-Dehydrocholesterol is present in the skin, and can be converted to vitamin D3 by 
ultraviolet (UV) light.  Vitamin D is also present in the liver and kidney, where 
hydroxylation reactions occur to produce the active form of vitamin D.  
 
The classic indications of vitamin D deficiency are rickets and osteomalacia.  During 
space flight, vitamin D status was decreased after long missions (84 to 195 d), but not 
after shorter missions (28 to 59 d) (15, 30). 
 
Potential implications for flight  
Since the current space food system includes very few dietary sources of vitamin D, 
and vitamin D cannot be synthesized endogenously due to lack of UV light, decreased 
vitamin D status is a serious concern for exploration missions that could last up to 
1000 d.  Decreased vitamin D status could lead to fragile or brittle bones upon return 
to Earth.  Furthermore, decreased vitamin D status is related to increased risk for 
multiple diseases (182), including cancer and multiple sclerosis, probably because the 
cells in a variety of tissues contain 1,25-dihydroxyvitamin D3 nuclear receptors (183, 
184). 
 
Deficiency of vitamin D leads to osteomalacia and osteoporosis, which could lead to 
life-threatening fractures and even death.  Toxicity of vitamin D leads to 
hypercalcemia caused by hypervitaminosis D, nephrocalcinosis, arteriosclerosis, 
irreversible calcification of soft tissue, or even death. 
 
Targeted research needed 
The extramural expert panel expressed concern that vitamin D status is decreased 
during space flight, despite vitamin D supplementation.  They recommended that 
vitamin D levels be determined in the food system, and that the stability of vitamin D 
in the food system be investigated.  Furthermore, additional research is needed to 
understand whether supplementation (and what level of supplementation) can 
maintain vitamin D stores.  
   
Nominal requirement on Earth  
The AI for vitamin D recommended by the 1998 Food and Nutrition Board of the 
Institute of Medicine is 200 IU/d (5 µg/d) for adults < 51 y.  For adults > 51 y, the AI is 
400 IU/d (10 µg/d) (185). 
 
The 2005 Dietary Guidelines for Healthy Americans recommend that people in high-
risk groups (elderly and those exposed to little sunlight) have substantially higher 
intakes of vitamin D (25 µg or 1000 IU) to maintain serum 25-hydroxyvitamin D values 
at 80 nmol/L (177).  
 
Historical space flight requirements 
The space flight requirements for vitamin D were defined as 10 µg/d for men and 
women.  This was higher than the requirement for the general population, where 
about 50% of the daily requirement for vitamin D was expected to be obtained from 
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sun exposure.  This 10 µg per day was designed to augment vitamin D stores in light of 
decreased (or lack of) exposure to ultraviolet light (and thus, decreased endogenous 
production) (4, 15, 186)  
 
Requirements, standards, and operating bands 
Req. 8. The dietary intake of vitamin D shall be 25 µg per day.  The nominal 
operating bands are defined as 
 
Dietary Vitamin D 
  >50 µg/d yellow 
  25-50 µg/d green 
  10-25 µg/d yellow 
  <10 µg/d red 
 
Initial verification that this requirement has been met will be done by proximate 
analysis of space food items for vitamin D content, as well as by analysis of the crew 
menus. 
  
Final verification will be completed by determining vitamin D intake using a food 
frequency questionnaire or other method of monitoring inflight intake.  Standards will 
be assessed before, during (to the extent possible), and after flight by determining 
levels of 25-OH vitamin D (154, 187) and 1,25-(OH)2 vitamin D (154, 187) in serum 
samples. 
 
25-Hydroxy Vitamin D 
  >400 nmol/L red 
  138 nmol/L yellow 
  25-138 nmol/L green 
  12 nmol/L Yellow 
  <12 nmol/L red 
 
 
1,25-Dihydroxy Vitamin D 
  48 pmol/L green 
  100 pmol/L yellow 
  >206 pmol/L red 
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Vitamin K 
 
Physiological function and existing space flight knowledge 
Vitamin K occurs naturally in 2 forms:  phylloquinone (vitamin K1) and menaquinone 
(vitamin K2).  Menaquinones are produced by bacteria, while phylloquinone is 
synthesized in plants.  Phylloquinone represents the main source of dietary vitamin K 
in Western countries (188). 
 
The function of vitamin K was originally assumed to be strictly limited to involvement 
in blood coagulation, but an increasing amount of evidence indicates that this vitamin 
affects multiple physiological systems.  Vitamin K is a cofactor in the post-
translational synthesis of gamma-carboxyglutamic acid (GLA).  Gamma-
carboxyglutamic acid is common to all vitamin K-dependent proteins, and its role is 
related to increasing the affinity of the proteins for calcium (189).  Vitamin K-
dependent proteins include blood coagulation proteins (prothrombin; factors VII, IX, 
and X; and proteins C and S) and bone proteins (osteocalcin, matrix GLA protein, and 
protein S).  
 
The limited data available show that vitamin K status is decreased during space flight.  
Data from 11 U.S. astronauts from Expeditions 1–8 (mission durations of 128 to 195 d 
during 2000–2004) reveal that on landing day serum phylloquinone (vitamin K1) was 
42% less than it was before flight, whereas urinary GLA did not change (15).  Other 
studies show that vitamin K supplementation during space flight elevates urinary GLA 
and decreases urinary undercarboxylated osteocalcin, suggesting that vitamin K status 
is lower during space flight (190, 191).     
 
Body stores and relative time to depletion 
The main storage depot for vitamin K is the liver.  Large amounts of vitamin K are also 
present in cortical and trabecular bone (192).   
 
Vitamin K stores are very small compared to those of other fat-soluble vitamins, and 
hepatic vitamin K is rapidly depleted when dietary vitamin K is restricted (193).  One 
study found that undercarboxylated osteocalcin was elevated (a sign of vitamin K 
insufficiency) as early as the 8th day of space flight, and remained high during 21- and 
180-d missions (190). 
 
Potential implications for flight  
Decreased vitamin K status has serious implications for space flight because it is 
related to bone health. Studies on the EuroMir 95 mission demonstrated that markers 
of vitamin K status were decreased after 12.5 weeks of space flight, and vitamin K 
supplementation (10 mg/d for 6 weeks) reversed these effects (191).  These data, 
along with data from ISS crew members (15), suggest that vitamin K status during 
long-duration space flight is sub-optimal.     
 
 47
Elevated undercarboxylated osteocalcin has been associated with increased fracture 
risk in certain populations, and evidence exists that vitamin K antagonists increase 
the risk of fracturing vertebrae and ribs in a time-dependent manner (194, 195).   
 
Deficiency of vitamin K is not common in adults, as the intestinal microflora 
synthesize vitamin K.  The reliability of this source of vitamin K during flight is 
unknown, and expert panels have recommended having higher intake requirements 
because of this uncertainty.  Given the (limited) space flight data documenting the 
improvement in bone marker status with vitamin K supplementation, clearly more 
needs to be known before exploration missions are undertaken. 
 
Toxicity of vitamin K in the form of menadione leads to fatal anemia and severe 
jaundice. 
 
Targeted research needed  
The extramural expert panel expressed concern that phylloquinone levels are 
decreased after long-duration space flight, and that research from the European 
Space Agency has found evidence for increased amounts of undercarboxylated 
osteocalcin during flight.  They recommended that vitamin K levels and stability in 
the space food system be determined. 
   
Nominal requirement on Earth  
The recommended AI for vitamin K is 120 µg/d for men and 90 µg/d for women (174).  
No upper limit has been established. 
 
Historical space flight requirements 
The space flight requirement for vitamin K for males and females was determined to 
be 80 µg/d (47, 48).  
 
Requirements, standards, and operating bands 
Req. 9. The dietary intake of vitamin K shall be 90 and 120 µg per day for women 
and men, respectively.  The nominal operating bands are defined as 
 
Dietary Vitamin K 
 Women Men  
  90 µg/d 120 µg/d green 
  60 µg/d 90 µg/d yellow 
  45 µg/d 60 µg/d red 
 
Initial verification that this requirement has been met will be done by proximate 
analysis of space food items for vitamin K content, as well as by analysis of the crew 
menus. 
  
Standards will be assessed before, during (to the extent possible), and after flight by 
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determining levels of phylloquinone (154, 196, 197) and γ-carboxyglutamic acid (198-
200) in blood and urine samples. 
 
Phylloquinone (serum) 
  1.51 nmol/L green 
  0.38 nmol/L yellow 
  0.1 nmol/L red 
 
 
 
 
 
 
 
 
 
 
 
GLA (urine) 
  >6.5 µmol/mmol creat red 
 5  µmol/mmol creat yellow 
  4 µmol/mmol creat green 
 2.3 µmol/mmol creat yellow 
  <1.75 µmol/mmol creat red 
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Vitamin E 
 
Physiological function and existing space flight knowledge 
Vitamin E is a lipid-soluble, chain-breaking antioxidant found in body tissues, and is 
also the first line of defense against lipid peroxidation reactions.  Eight naturally-
occurring compounds have vitamin E activity: four tocopherol derivatives (alpha-, 
gamma-, delta-, and beta-tocopherol) and four tocotrienol derivatives (alpha-, 
gamma-, delta-, and beta-tocotrienol) (201).  The tocopherols that are most abundant 
in biological systems are alpha- and gamma-tocopherol, but small amounts of delta-
tocopherol and alpha-tocopheryl quinine are also present.  About 90% of the 
tocopherol found in human plasma is in the form of alpha-tocopherol (202).   
 
Vitamin E helps protect cell membranes in the early stages of free-radical attack 
because of its free-radical quenching activity.  Free radicals attack polyunsaturated 
fatty acids found in membrane phospholipids, causing damage to cellular membranes 
and possibly cell death.  The interception of a free radical by vitamin E produces a 
tocopheroxyl radical that can be reduced by vitamin C or another reducing agent to 
return vitamin E to its reduced state.  The extent of regeneration and recycling of 
vitamin E in human tissue has not been well established (201, 203).       
 
After crew members have spent 4 to 6 months in space, their plasma γ-tocopherol is 
50% less than preflight levels (15).  No change in α-tocopherol occurred in these 
subjects.   
 
Body stores and relative time to depletion 
Vitamin E is stored mainly in the adipose tissue and is also found in phospholipid 
membranes.  Results of studies conducted to determine vitamin E tissue levels have 
shown that tissue α-tocopherol concentrations are largely reflected by changes in 
plasma α-tocopherol concentrations.     
 
Vitamin E deficiencies in humans are rare; however, fat malabsorption syndromes, 
genetic abnormalities, and protein-energy malnutrition are specific cases when a 
vitamin E deficiency is likely to occur.  Symptoms include neurological problems 
associated with nerve degeneration in the extremities (202).  Vitamin E depletion has 
been detected when markers of lipid peroxidation were elevated.  However, the 
lowering of levels of these lipid peroxidation markers has not been shown to have any 
health benefits, and therefore they have not been used to establish α-tocopherol 
requirements.      
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Potential implications for flight  
Because oxidative stress can increase in a microgravity and high-radiation 
environment, it may be necessary to provide enough vitamin E for astronauts’ blood 
levels of the vitamin to be higher during space flight than on Earth.  The antioxidant 
properties of vitamin E may help to counteract the free-radical damage caused by 
high linear energy transfer radiation in space. Pretreatment with antioxidants may 
help decrease radiation damage during missions (204). 
   
Deficiency of vitamin E leads to neurological disorders, hemolytic anemia, 
retinopathy, and abnormal platelets and lymphocytes, or even death.  Toxicity of 
vitamin E from naturally occurring sources has not been shown to occur. 
 
Targeted research needed 
The extramural expert panel recommended that vitamin E content of space foods, 
along with the stability of vitamin E in these foods, be determined.  
 
 Nominal requirement on Earth 
The dietary reference intake for vitamin E is 15 mg/d for men and women.  No upper 
limit has been established because the highest level of daily intake is not likely to 
pose serious health risks to the majority of individuals (202).   
 
Historical space flight requirements 
The space flight requirement for vitamin E, in tocopherol equivalents (TE), for males 
and females was defined as 20 mg TE/d (47, 48).  
 
Requirements, standards, and operating bands 
Req. 10. The dietary intake of vitamin E shall be 15 mg/day.  The nominal operating 
bands are defined as 
 
Dietary Vitamin E 
  15 mg/d green 
  7.5-15 mg/d yellow 
  <7.5 mg/d red 
 
Initial verification that this requirement has been met will be done by proximate 
analysis of space food items for vitamin E content, as well as by analysis of the crew 
menus. 
  
Standards will be assessed before, during (to the extent possible), and after flight by 
determining levels of α-tocopherol (86) in serum samples.   Markers of oxidative 
status [total antioxidant capacity (205, 206), superoxide dismutase (205, 207, 208), 
glutathione peroxidase (207, 209-211) and antioxidant damage [8-hydroxy-2'-
deoxyguanosine (212-214), malondialdehyde (215), 4-hydroxynonenal (216)] will also 
be measured. 
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The health benefits of γ-tocopherol (217) are unknown (as opposed to the well-
studied α-tocopherol), but several studies suggest potential beneficial effects.  
Plasma γ-tocopherol was strongly and inversely correlated with risk of prostate cancer 
in men with the lowest quintile of γ-tocopherol (218).  Other studies show lower γ-
tocopherol concentrations in coronary heart disease patients compared with controls 
(219, 220).  The low γ-tocopherol in these studies could be a secondary effect of the 
accompanying condition; therefore, until further research is done to conclusively 
determine primary effects of low serum γ-tocopherol, a critical level of γ-tocopherol 
will not be defined. 
 
  
α-Tocopherol (serum) 
  18 µg/mL green 
  5.5 µg/mL yellow 
  <3.0 µg/mL red 
 
γ-Tocopherol (serum) 
  3.9 µg/mL green 
  0.47 µg/mL yellow 
 
Total Antioxidant Capacity 
  1.77 mmol/L green 
  1.30 mmol/L yellow 
  <1.20 mmol/L red 
 
Superoxide Dismutase 
  >1600 U/g Hgb red 
  1567 U/g Hgb yellow 
  1295 U/g Hgb green 
  1024 U/g Hgb yellow 
  <763 U/g Hgb red 
 
Glutathione Peroxidase 
  88 U/g Hgb green 
  29 U/g Hgb yellow 
  <27.5 U/g Hgb red 
 
8-OH-2’-Deoxyguanosine 
  0.17 µg/g creat green 
  5.9 µg/g creat yellow 
  >15µg/g creat red 
 52
 
Malondialdehyde 
  0 µmol/L green 
  3 µmol/L yellow 
  >5 µmol/L red 
 
4-Hydroxy-2(E)-nonenal 
  <1 nmol/L green 
  2 nmol/L yellow 
  >4 nmol/L red 
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Water-Soluble Vitamins 
 
Vitamin C 
 
Physiological function and existing space flight knowledge 
The term “vitamin C” actually refers to two different compounds, both of which have 
anti-scorbutic activity:  ascorbic acid and dehydroascorbic acid.  Vitamin C functions 
as an antioxidant because it acts as a reducing agent for most physiologically relevant 
reactive oxygen species, reactive nitrogen species, singlet oxygen, and hypochlorite.  
It serves as a cofactor for enzymes involved in the biosynthesis of collagen, carnitine, 
and neurotransmitters.  Vitamin C also provides antioxidant protection by returning α-
tocopherol to its biologically active state during lipid oxidation.  The reducing agents 
glutathione and either reduced nicotinamide adenine dinucleotide (NADH) or reduced 
nicotinamide adenine dinucleotide phosphate (NADPH) regenerate the oxidation 
products of ascorbate.   
 
It has been suggested that vitamin C requirements should be greater in persons who 
are under excessive physical or emotional stress, given the role of ascorbate in the 
biosynthesis of steroid hormones and neurotransmitters.  However, no substantial 
data show that vitamin C metabolism is altered in healthy subjects under mental or 
emotional stress (202). 
 
One concern for space flight is the possibility that vitamin C could be degraded in 
foods during extended-duration missions when space foods are exposed to large 
amounts of radiation and undergo long-term storage (up to 5 years).  The stability of 
vitamin C has been studied in food supplies, and it is generally unstable at a neutral 
or alkaline pH, or in high-oxygen environments (221).  Vitamin C is also unstable when 
exposed to light or heat (221), and in irradiated foods (222, 223).  Salem (223) found 
that gamma irradiation of fresh onion bulbs significantly reduced their vitamin C 
content.  This group also found that vitamin C content of onion bulbs had decreased 
about 50% after 6 months of storage.  The destructive effects of gamma-irradiation 
(10 kGy) on vitamin C are also evident in commercial spices such as basil, black 
pepper, cinnamon, nutmeg, oregano, parsley, rosemary, and sage (224).   Gamma-ray 
exposure of these spices for >3 months resulted in a marked increase of quinone 
radicals. 
 
Body stores and relative time to depletion 
The total body pool of vitamin C varies with intake.  Higher concentrations are found 
in the pituitary and adrenal glands, liver, spleen, heart, kidneys, lungs, pancreas, 
leukocytes, eye tissues and humors, and the brain, while lower concentrations are 
found in the saliva, muscle, and plasma.  Blood cell and tissue concentrations become 
saturated at intakes from 100 to 140 mg/day, and steady-state plasma vitamin C 
concentrations occur with intakes of 200 mg/day.  Catabolic turnover varies from 10 
to 45 mg/day and with low intakes, turnover is reduced.  Maximum body pools of 
ascorbate are ~2 grams.  
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Vitamin C deficiency most commonly presents itself as any of an array of symptoms 
commonly referred to as scurvy.  Scurvy is seen in adults within 45 to 80 days of 
stopping vitamin C intake.  Intake below the RDA can cause a deficiency once the 
body pools fall below ~300 mg of ascorbic acid.  The length of time until scurvy 
symptoms develop when intake is sub-optimal depends on the size of the individual’s 
body pool of vitamin C before intake was decreased. 
 
Potential implications for flight  
Free-radical formation is increased in space because greater amounts of radiation are 
present than on Earth.  Because of this and increases in other oxidative stressors, 
antioxidants such as vitamin C are in greater demand by the body to act as buffers 
and minimize the oxidative damage.  Studies have shown that supplementation with 
vitamin C and other antioxidants can modify human tissue radiosensitivity and protect 
DNA against damage (225, 226).  Just as important to consider, however, is the 
possibility that vitamin C could induce DNA damage.  Cai and colleagues (226) found 
that vitamin C can act as an antioxidant to prevent DNA damage caused by ionizing 
radiation, but in the presence of copper, it can also act as a reducing agent to induce 
DNA damage.   Because vitamin C can reduce redox-active metals such as iron and 
copper, this “antioxidant” can increase the pro-oxidant chemistry of these metals 
(227).  Thus, vitamin C can serve as both a pro-oxidant and an antioxidant. 
 
Vitamin C assessments from the ISS have not been completed yet, but they will be 
available soon and may raise additional questions. 
 
Deficiency of vitamin C leads to fatigue, depressed immune function, and ultimately 
scurvy (fatigue, muscle cramps, bruised and/or bleeding gums), or even death.  
Toxicity of vitamin C leads to gastrointestinal distress. 
 
Targeted research needed 
The extramural expert panel recommended that vitamin C levels and stability be 
determined in the space food supply.  The panel also suggested that vitamin C 
supplementation during exposure to oxygen or high-LET radiation be investigated 
before making recommendations for supplement use during flight. 
 
Nominal requirement on Earth 
The RDAs for vitamin C for men and women aged 19 and older are 90 mg/day and 75 
mg/day, respectively.  They are set by assuming a coefficient of variation of 10 
percent because information about the standard deviation is unavailable.  The RDA is 
defined as equal to the estimated average requirement (EAR) plus twice the 
coefficient of variation, to cover the needs of at least 98% of the population (202). 
 
Historical space flight requirements 
Because of the increased level of stress predicted for orbiting crews, the requirement 
for vitamin C was initially defined as 100 mg/day for males and females (47, 48).  
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Requirements, standards, and operating bands 
Req. 11. The dietary intake of vitamin C shall be 90 mg/day.  The nominal operating 
bands are defined as  
 
Dietary Vitamin C 
  >2000 mg/d red 
  90 mg/d green 
  30-90 mg/d yellow 
  <30 mg/d red 
 
Initial verification that this requirement has been met will be done by proximate 
analysis of space food items for vitamin C content, as well as by analysis of the crew 
menus. 
  
Standards will be assessed before, during (to the extent possible), and after flight by 
determining levels of vitamin C (228) in blood samples. 
 
Vitamin C (serum) 
  >96 µmol/L red 
 >85 µmol/L yellow 
  23-85 µmol/L green 
  <23 µmol/L yellow 
 <11 µmol/L red 
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Vitamin B12 
 
Physiological function and existing space flight knowledge 
Vitamin B12 functions as a coenzyme in two metabolic forms: adenosylcobalamin and 
methylcobalamin.  Vitamin B12 works as a cofactor for 3 different enzymatic 
reactions: 1) the conversion of homocysteine to methionine, 2) the conversion of L-
methylmalonyl-coenzyme A (CoA) to succinyl-CoA, and 3) the isomerization of L-
leucine and β-leucine.  B12 deficiency may cause the accumulation of folate in the 
serum due to the reduction in B12-dependent methyltransferase, also known as the 
methyl-folate trap (229). Vitamin B12 also functions in the synthesis of choline, which 
can be converted to the neurotransmitter acetylcholine.   
 
No data are available on vitamin B12 status during or after long-duration space flight. 
 
Body stores and relative time to depletion 
Unlike other water-soluble vitamins, vitamin B12 can be stored in the body for years.  
The vitamin is stored predominantly in the liver, but smaller amounts can also be 
found in the muscles, kidneys, bones, heart, brain, and spleen.  About 2–5 mg of 
vitamin B12 is stored (230).  The size of B12 stores remains relatively stable, partly 
because urinary and fecal excretion decrease in direct relationship to decreases in the 
body pools.   
 
The half-life of vitamin B12 is 350 to 400 days in humans (230).   
 
Potential implications for flight 
No evidence of toxicity has been found with vitamin B12 supplementation in amounts 
greater than the RDA (230).  If a person went for many years without adequate intake 
and/or supplementation, body stores could be depleted.  Other factors that could 
contribute to a vitamin B12 deficiency include a decrease in gastric acidity, the 
presence of atrophic gastritis, and bacterial overgrowth accompanied by 
malabsorption of food-bound B12 (231). 
 
Deficiency of vitamin B12 leads to pernicious anemia or even death.  However, no 
adverse effects are reported to be caused by an excess of vitamin B12. 
 
Targeted research needed 
The extramural expert panel recommended that vitamin B12 levels and stability be 
determined in the space food supply. 
 
Nominal requirement on Earth 
The required amount of vitamin B12 for both men and women aged 19 years and older 
is 2.4 µg/day (230).     
 
Historical space flight requirements 
Intake of vitamin B12 was originally defined as 2.0 µg/day for males and females (23, 
152).  
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Requirements, standards, and operating bands 
Req. 12. The dietary intake of vitamin B12 shall be 2.4 µg/day.  The nominal 
operating bands are defined as  
 
Dietary Vitamin B12 
  100 µg/d red 
  2.4 µg/d green 
  1.2-2.4 µg/d yellow 
  <1.2 µg/d red 
 
Initial verification that this requirement has been met will be done by proximate 
analysis of space food items for vitamin B12 content, as well as by analysis of the crew 
menus. 
 
The extramural expert panel concluded that if dietary sources of vitamin B12 are 
adequate, definition of a standard to ensure that vitamin B12 requirements are met is 
unnecessary.  Accordingly, no biochemical measures of vitamin B12 status are required 
for exploration missions. 
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Vitamin B6 
 
Physiological function and existing space flight knowledge 
Vitamin B6 comprises a group of three compounds and their 5′-phosphates (P): 
pyridoxal (PL) and PLP, pyridoxine (PN) and PNP, and pyridoxamine (PM) and PMP.  
These vitamers of B6 serve as coenzymes in many transamination reactions by forming 
a Schiff’s base with the ε-amino group of lysine and the carbonyl group of PLP (230, 
232).  They can also function in decarboxylation reactions, such as the formation of 
gamma-aminobutyric acid from glutamate and serotonin from 5-hydroxytryptophan, 
and they function in trans- and desulfhydration, where cysteine is synthesized from 
methionine and pyruvate is generated from cysteine, respectively.  The vitamers also 
function in cleavage reactions, racemization of D- and L-amino acids, synthesis of 
multiple compounds, glycogen catabolism (where vitamin B6 is required for the 
activity of glycogen phosphorylase), and steroid hormone action (where the vitamers 
decrease the actions of steroids) (233).  
 
According to data from astronauts on 4- to 6-month space flights, no change occurs in 
red blood cell (RBC) transaminase activation (15).  Plasma PLP has not been 
determined after long-duration space flight.  Bed rest studies have demonstrated 
reductions in body pools of vitamin B6, most likely related to loss of muscle mass (54). 
 
Body stores and relative time to depletion 
Approximately 80% of vitamin B6 is stored in muscle tissue and 10% is stored in the 
liver, with the rest being stored in the plasma pool.  Data from studies have shown 
that total body stores are about 1,000 µmol or 167 mg (230).   
 
Overall body half-lives of the vitamers of vitamin B6 are about 25 days (230, 234).  
 
Potential implications for flight  
Weightlessness has been shown to reduce the cross-sectional area of muscle fibers 
and is associated with a change from type I to type II muscle fibers (235).  Since 
vitamin B6 is stored mainly in muscle tissue, a decrease in muscle cross-sectional area 
could reduce the amount of the vitamin that is stored.  A deficiency in vitamin B6 
causes a decrease in the synthesis of serotonin and catecholamines, which has been 
shown to be associated with depression (236). 
 
Deficiency of vitamin B6 leads to dermatitis, microcytic anemia, convulsions, altered 
mental status, hyperhomocysteinemia, or even death.  Toxicity of vitamin B6 leads to 
sensory neuropathy or even death. 
 
Targeted research needed 
The extramural expert panel recommended that vitamin B6 levels and stability be 
determined in the space food supply.  The panel also recommended that plasma PLP 
be added to the list of indicators used to determine B6 status. 
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Nominal requirement on Earth 
The vitamin B6 requirement for all adults over age 19 years is 1.3 mg/day (230).  
 
Historical space flight requirements 
Intake of vitamin B6 was originally defined as 2.0 mg/day for males and females (47, 
48).  
 
Requirements, standards, and operating bands 
Req. 13. The dietary intake of vitamin B6 shall be 1.7 mg/day.  The nominal 
operating bands are defined as 
 
Dietary Vitamin B6 
 100 mg/d red 
 1.7 mg/d green 
 0.8-1.2 mg/d yellow 
 <0.8 mg/d red 
 
Initial verification that this requirement has been met will be determined by 
proximate analysis of space food items for vitamin B6 content, as well as by analysis 
of the crew menus. 
  
Standards will be assessed before, during (to the extent possible), and after flight by 
determining levels of RBC transaminase (85, 154, 237), urinary 4-pyridoxic acid (154), 
and plasma PLP (85, 153, 238).   
 
RBC Transaminase 
  >85% activation red 
  70% activation yellow 
  0% activation green 
 
4-Pyridoxic Acid (urine) 
  >5.0 µmol/d green 
  3 µmol/d yellow 
  <1 µmol/d red 
 
PLP (plasma) 
  >30 nmol/L green 
  20 nmol/L yellow 
  <20 nmol/L red 
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Thiamin 
 
Physiological function and existing space flight knowledge 
Thiamin functions as a coenzyme in the metabolism of carbohydrates and branched-
chain amino acids.  The coenzyme form of thiamin, thiamin pyrophosphate (TPP), 
functions in the decarboxylation of pyruvate and α-ketoglutarate.  Without these 
decarboxylations, synthesis of both adenosine triphosphate (ATP) and acetyl-CoA 
would be inhibited.  TPP also functions as part of a major enzyme involved in the 
hexose monophosphate shunt, the pathway by which 6-carbon sugars are converted to 
pentoses and NADPH.  Thiamin pyrophosphate is also believed to be involved in nerve 
conduction and nerve membrane function, although its role is not completely clear 
(233).  Very little is known about thiamin status during space flight. 
 
Body stores and relative time to depletion 
Approximately 30 mg of thiamin is stored in the human body (230).  About half of the 
body’s thiamin is stored in the skeletal muscle, with the rest being stored in the 
heart, liver, kidney, and brain.   
 
Thiamin in excess of tissue needs and storage capacity is excreted in the urine.  The 
biological half-life of thiamin is in the range of 9 to 18 days. 
 
Potential implications for flight  
Thiamin deficiency first became prevalent in the 19th century in rice-growing 
countries when steam-powered rice mills were becoming more efficient.  The milling 
process removed the aleurone layer that contained most of the rice’s thiamin 
content.  Beriberi, a polyneuritic paralysis that affects the lower limbs, was first 
characterized in these populations.  This historical information illustrates the 
importance of every nutrient.  A deficiency in one nutrient can be devastating.  It is 
well known that thiamin is highly susceptible to destruction by radiation (239, 240) 
and processing in foods (241).  It will be crucial to determine if thiamin can survive a 
3-year-plus mission to deep space. 
 
Deficiency of thiamin ultimately leads to beriberi (enlarged heart, muscle weakness, 
anorexia, apathy, reduction in nerve impulse transmission), or even death.  There are 
no known toxicity symptoms of excess thiamin.  
 
Targeted research needed 
The extramural expert panel recommended that thiamin levels and stability be 
determined in the space food supply, particularly since thiamin is highly susceptible 
to degradation from radiation exposure. 
   
Nominal requirement on Earth  
The thiamin RDA is 1.2 mg/day for men aged 19 and older and 1.1 mg/day for women 
(230). 
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Historical space flight requirements 
The daily thiamin intake was originally defined as 1.5 mg/day for males and females 
(47, 48).  
  
Requirements, standards, and operating bands 
Req. 14. The dietary intake of thiamin shall be 1.1 and 1.2 µmol/day for women and 
men, respectively.  The nominal operating bands are defined as 
  
Dietary Thiamin 
 Women Men  
  1.1 µmol/d 1.2 µmol/d green 
  0.8-1.0 µmol/d 0.8-1.0 µmol/d yellow 
  <0.8 µmol/d <0.8 µmol/d red 
  
Initial verification that this requirement has been met will be done by proximate 
analysis of space food items for thiamin content, as well as by analysis of the crew 
menus. 
  
Standards will be assessed before, during (to the extent possible), and after flight by 
determining levels of erythrocyte transketolase (ETK) (85)activation in blood samples. 
 
RBC Transketolase (ETK) 
  0% activation green 
  15% activation yellow 
  >25% activation red 
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Riboflavin  
 
Physiological function and existing space flight knowledge 
The most important biologically active forms of riboflavin are flavin mononucleotide 
and flavin adenine dinucleotide (FAD).  These cofactors participate in a range of 
redox reactions in numerous metabolic pathways (242).  Some of these pathways are 
niacin-dependent and independent dehydrogenations, reactions with sulfur-containing 
compounds, hydroxylations, oxidative decarboxylations, dioxygenations, and 
reduction of oxygen to hydrogen peroxide.  The cofactors also play a role in the 
formation and function of some vitamins, including folate, vitamin B12, and vitamin B6 
(242). 
 
There is no evidence that riboflavin status is altered during 4- to 6-month space 
flights (15).   
 
Body stores and relative time to depletion 
The highest concentrations of stored riboflavin are found in the liver, kidneys, and 
heart (230), and almost all riboflavin in tissues is enzyme-bound, such as FAD 
covalently bound to succinic dehydrogenase (243).  Unbound flavins are labile and are 
rapidly hydrolyzed to release free riboflavin.  Excess free riboflavin is excreted in the 
urine (242). 
 
The total body stores of riboflavin are enough to meet the demands of the body for 2 
to 6 weeks (230). 
 
Potential implications for flight  
There is no evidence that riboflavin status is altered during 4- to 6-month space 
flights (15); however, riboflavin content in the space food supply needs to be 
investigated to ensure that riboflavin will not degrade during long-duration storage.  
Riboflavin is relatively heat-stable, but it is readily degraded by light (242, 244).  It 
does not seem to be degraded by gamma-radiation of foods (240, 245). 
 
Riboflavin deficiency affects ferritin iron mobilization and iron absorption.  Other 
symptoms of riboflavin deficiency include peripheral nerve demyelination, neurologic 
abnormalities, and anemia.  Cataract incidence is higher in space travelers than the 
general population (246), and cataracts have also been described in riboflavin-
deficient animal models (242, 247).   
 
No toxicity symptoms of excess riboflavin are known. 
 
Targeted research needed 
The extramural expert panel recommended that riboflavin content and stability be 
determined in the space food supply. 
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Nominal requirement on Earth 
The RDA for riboflavin for men and women aged 19 and older is 1.3 and 1.1 mg/day, 
respectively (230).   
 
Historical space flight requirements 
The daily requirement for riboflavin was defined as 2.0 mg/day for males and females 
(47, 48).  
 
Requirements, standards, and operating bands 
Req. 15. The dietary intake of riboflavin shall be 1.3 mg/day.  The nominal operating 
bands are defined as 
 
 
 
 
 
 
 
Initial verification that this requirement has been met will be done by proximate 
analysis of space food items for riboflavin content, as well as by analysis of the crew 
menus. 
  
Standards will be assessed before, during (to the extent possible), and after flight by 
determining levels of erythrocyte glutathione reductase (EGR) (85) activation in blood 
samples. 
 
RBC Glutathione Reductase (EGR) 
  0% activation green 
  20% activation yellow 
  40% activation red 
 
 
 
 
 
 
 
 
 
Dietary Riboflavin 
  1.3 mg/d green 
  1.0 mg/d yellow 
  <0.8 mg/d red 
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Folate 
 
Physiological function and existing space flight knowledge 
Folate is the general term used to describe folic acid and other compounds that have 
activity similar to that of folic acid.  Folic acid is the form of the vitamin used in 
vitamin supplements and fortified food products, but it is rarely found to occur 
naturally in food.   
 
Folate is in its active form when folic acid and dihydrofolate are reduced by a 
cytosolic enzyme to generate tetrahydrofolate (THF).  THF accepts single-carbon 
groups from reactions in amino acid metabolism to form derivatives of THF.  These 
THF derivatives function in amino acid metabolism in the reversible reaction of serine 
synthesis from glycine, methionine synthesis from homocysteine, and histidine 
metabolism.  Folate is essential in cell division because the THF derivatives play 
important roles in purine and pyrimidine synthesis.  THF derivatives play a major role 
in the formation of thymidylate, which is a substrate needed for DNA synthesis.   
 
It is evident from previous long-duration space flight research (4 to 6 months) that 
folate status decreases significantly (15).  It is unknown whether this is related to the 
food, the stability of folate in food during flight, or alterations in absorption, 
metabolism, or excretion. 
 
Body stores and relative time to depletion 
About 50% of all folate is stored in the liver.  The average liver concentration of 
folate is about 8 µg/g (248).  Estimated total body folate stores are between 12 and 
28 mg (230).  Very little folate is excreted in the urine or feces.  Most of the absorbed 
folate is secreted by the liver into the bile, which is then reabsorbed through 
enterohepatic recirculation.  Most of the folate excreted in feces is synthesized by 
intestinal bacteria. 
 
Low folate intake will cause red blood cell folate concentrations to diminish within 4 
months.  Bone marrow cells become megaloblastic and anemia occurs after 4 to 5 
months of low folate intake (233).  As outlined in Figures 1 and 2, folate deficiency 
in humans has 4 stages (249, 250):    
 
Stage 1:  Early negative balance is accompanied by serum folate <3.5 ng/mL.  
  
Stage 2:  Serum folate continues to be low, and RBC folate decreases to below  
 160 ng/mL. 
 
Stage 3:  Defective DNA synthesis can be detected.  Deoxyuridine (dU)  
suppression tests are abnormal, and homocysteine levels are elevated. 
 
Stage 4:  Clinical folate deficiency is manifested by macroovalocytosis,  
elevated mean corpuscular volume (MCV), and large, nucleated embryonic cells  
 
  Negative Balance 
 Positive balance Normal Depletion Deficiency 
 Stage II Stage I  Stage I Stage II Stage III Stage IV 
 Excess Early positive folate balance Normal 
Early negative 
folate balance 
Folate 
depletion 
Metabolic 
damage: folate 
deficiency 
erythropoiesis 
Clinical 
damage: folate 
deficiency 
anemia 
Liver folate 
 
Plasma folate 
 
Erythron folate 
 
 
 
 
 
 
      
Serum folate >10 >10 >5 <3 <3 <3 <3 
RBC folate >400 >300 >200 >200 <160 <120 <100 
Diagnostic dU 
suppression Normal Normal Normal Normal Normal Abnormal Abnormal 
Liver folate >5 >4 >3 >3 <1.6 <1.2 <1 
Homocysteine Normal Normal Normal Normal Normal High High 
Eythrocytes Normal Normal Normal Normal Normal Normal Macroovalocytic 
MCV Normal Normal Normal Normal Normal Normal Increased 
Hemoglobin >12 >12 >12 >12 >12 >12 <12 
Plasma clearance of 
intravenous folate Normal Normal Normal Normal Normal Increased Increased 
Figure 1.  Sequence of events in developing folate deficiency.  Earliest abnormalities are boxed.  Adapted from 
Herbert 1999 (250). 
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2 4 6 8 10 12 14 16 18 20
LOW SERUM FOLATE
HYPERSEGMENTATION
HIGH URINE FIGLU
LOW RBC FOLATE
MACROOVALOCYTOSIS
MEGALOBLASTIC MARROW
ANEMIA
WEEKS
 
Figure 2.  Biochemical sequence of events in developing dietary folate deficiency in 
humans (adapted from Herbert (250)). FIGLU is formiminoglutamic acid. 
 
Potential implications for flight  
It has been suggested that folate may influence the metabolism of certain 
neurotransmitters.  Folate deficiency is associated with irritability, forgetfulness, and 
hostile or paranoid behavior (250).  Radiation exposure and inadequate dietary 
consumption can lead to inadequate intake of folate (230). 
 
Deficiency of folate leads to megaloblastic anemia or even death.  The upper limit of 
folate is set because very high doses of folate can mask a deficiency of vitamin B12. 
 
Targeted research needed 
The extramural expert panel recommended that folate levels in the space food 
system be determined.  If the diet does in fact provide 400 µg/d, then they 
recommended that further research be done to understand the stability of folate 
during radiation exposure.   
   
Nominal requirement on Earth 
The RDA for all individuals aged 14 and older is 400 µg/day of dietary folate 
equivalents (DFEs).  Using DFEs adjusts for the 50% reduction in food folate 
bioavailability compared to that of folic acid. 1 µg/d DFE = 0.6 µg of folic acid from 
fortified food or as a supplement taken with meals = 1 µg food folate = 0.5 µg of a 
supplement taken on an empty stomach.   
 
Historical space flight requirements 
Intake of folate was defined as 400 µg/day for males and females (47, 48).  
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Requirements, standards, and operating bands 
Req. 16. The dietary intake of folate shall be 400 µg/day.  The nominal operating 
bands are defined as 
 
Dietary Folate 
  1000 µg/d red 
  400 µg/d green 
  200 µg/d yellow 
  <200 µg/d red 
 
 
Initial verification that this requirement has been met will be done by proximate 
analysis of space food items for folate content, as well as by analysis of the crew 
menus. 
  
Standards will be assessed before, during (to the extent possible), and after flight by 
determining serum (154, 251) and RBC folate (86, 154) in blood samples.  
 
Folate (RBC) 
  600 ng/mL green  
  150 ng/mL yellow 
  <140 ng/mL red 
 
 
Folate (serum) 
  5.4-40 ng/mL green  
  3.4-5.3 ng/mL yellow 
  <3.3 ng/mL red 
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Niacin 
 
Physiological function and existing space flight knowledge 
The term “niacin” includes nicotinamide, nicotinic acid, and their derivatives that 
have the biological activity of nicotinamide (230).  In its coenzyme forms, 
nicotinamide adenine dinucleotide (NAD) and nicotinamide adenine dinucleotide 
phosphate (NADP), niacin has many different metabolic roles in the human body.  The 
nicotinamide moiety accepts hydride ions in numerous biological redox reactions.  
NAD functions in respiration and as a co-dehydrogenase with enzymes involved in the 
oxidation of fuel molecules.  NAD is converted to NADH, which transfers electrons 
from the Krebs cycle through the electron transport chain.  NAD also acts as a donor 
of adenine dinucleotide phosphate-ribose for the posttranslational modification of 
proteins (233). The coenzyme NADP has a role in fatty acid, cholesterol, and steroid 
syntheses, and as a co-dehydrogenase in the pentose phosphate pathway.  Conversion 
of folate to its active forms also requires NADP.   
 
Very little is known about niacin metabolism during space flight.  One concern for 
exploration missions is the stability of niacin in the food system, particularly because 
of reports showing that the niacin content of foods decreases after exposure to 6 kGy 
of radiation (252).   
 
Body stores and relative time to depletion 
Niacin is stored in the liver as NAD.  This storage NAD can be converted from 
tryptophan, nicotinic acid, or plasma nicotinamide. 
 
Limited data show that after 80 to 135 days of ingesting a low-niacin diet, subjects’ 
urinary excretion of N1-methylnicotinamide is at a level representing deficiency status 
(251).    
 
Potential implications for flight  
Niacin in the amount of 3 g/day or more has been associated with toxic effects (230).  
Flushing, gastrointestinal problems, hepatotoxicity, glucose intolerance, and ocular 
effects have all been associated with high doses of the vitamin.  However, many of 
these toxic effects have been shown to occur only after treatment over long periods 
and in amounts that far exceed the RDA. 
 
Deficiency of niacin leads to dermatitis, glossitis, growth retardation, and ultimately 
pellagra (diarrhea, dermatitis, dementia), or even death.  Likewise, toxicity from 
mega doses of niacin can cause vasodilatory effects (flushing), gastrointestinal 
distress, hepatotoxicity, glucose intolerance, and blurred vision. 
 
Targeted research needed 
The extramural expert panel recommended that niacin levels and stability be 
determined in the space food supply. 
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Nominal requirement on Earth 
The niacin requirement for men aged 19 and older is 16 mg/day of niacin equivalents 
and for women aged 19 and older the requirement is 14 mg/day of niacin equivalents 
(230).  One niacin equivalent is equal to approximately 60 mg of the amino acid 
tryptophan and can be obtained from 6 grams of high-quality protein (233).  The RDA 
for niacin can be met from the actual niacin content of the diet or by conversion of 
tryptophan in the diet. 
  
Historical space flight requirements 
Intake of niacin was defined as 20 mg NE/day for men and women (NE = niacin 
equivalent; 1 NE = 1 mg niacin or 60 mg dietary tryptophan) (47, 48).  
  
Requirements, standards, and operating bands 
Req. 17. Based on the current recommendations for Earth (230), the dietary intake 
of niacin shall be 16 mg NE/day.  The nominal operating bands are defined 
as 
 
Dietary Niacin 
  35 mg NE/d red 
  16 mg NE/d green  
  12 mg NE/d yellow 
  <12 mg NE/d red 
 
Initial verification that this requirement has been met will be done by proximate 
analysis of food items for niacin content, as well as by analysis of the crew menus. 
  
Standards will be assessed before, during (to the extent possible), and after flight by 
determining levels of NAD/NADP (85), N1-methylnicotinamide (153, 251), and 2-
pyridone (154) in blood and urine samples. 
 
Erythrocyte NAD/NADP 
  >1.5 green 
  1 yellow 
  <1 red 
 
N1-methyl Nicotinamide (urine) 
  46.7 µmol/d green  
  17.5 µmol/d yellow 
  <5.8 µmol/d red 
 
2-Pyridone (urine) 
  >4.0 mg/g creatinine green  
  2.0 mg/g creatinine yellow 
  <2.0 mg/g creatinine red 
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Biotin 
 
Physiological function and existing space flight knowledge 
Biotin is a required cofactor for pyruvate carboxylase, acetyl-CoA carboxylase 
isoforms 1 and 2, propionyl-CoA carboxylase, and β-methylcrotonyl-CoA carboxylase.  
The five biotin-dependent enzymes are involved in carbohydrate, fatty acid, and 
amino acid metabolism. 
 
No data currently exist regarding biotin intake or status during or after space flight.   
 
Body stores and relative time to depletion 
Biotin exists freely or bound to proteins.  Approximately 81% of biotin in the human 
body is free biotin in serum, and 10% is free in tissues (253). 
 
Low-biotin diets administered to 10 healthy subjects who also consumed large 
amounts of avidin (an egg-white protein that binds biotin very tightly) showed signs of 
decreased biotin status by the third day (254).  Urinary excretion of biotin and its 
metabolites decreased significantly and urinary excretion of 3-hydroxyisovaleric acid 
increased significantly after 3 d; however, these decreases were not out of the 
normal range until days 7 and 17, respectively.  Serum biotin did not decrease 
significantly, and it was suggested that serum biotin is not an early and sensitive 
indicator of marginal biotin deficiency (255).  Animal studies indicate that a biotin 
deficiency, marked by urinary biotin excretion, generally occurs about 2 to 3 weeks 
after beginning consumption of a biotin-free diet (256, 257). 
 
Potential implications for flight  
Despite the observation that frank signs of deficiency are rare, there is growing 
appreciation of genetic, physiologic, and pharmacologic conditions that marginally 
impair biotin status (258-260).  This suggests that the lack of physiologic 
manifestations of biotin deficiency may not be a reliable measure to gauge biotin 
status.  Marginal changes in biotin status have been shown to affect a range of 
metabolic factors, from carboxylase activity to the expression of non-biotin-
dependent enzymes such as glucokinase, ornithine transcarbamoylase, and 
phosphoenolpyruvate carboxykinase (261-263).   
 
Frank biotin deficiencies are associated with neurological and dermatological 
manifestations, which are likely caused by the loss of function of biotin-dependent 
enzymes.  Seizures, hearing loss, optic atrophy, dermatitis, and aciduria (associated 
with elevated blood concentrations of organic acids) are common symptoms of a frank 
biotin deficiency.   
 
There is no evidence of toxicity of biotin at high intake levels. 
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Targeted research needed 
The extramural expert panel recommended that biotin levels in the space food system 
be determined. The lack of data on biotin status, and the fact that gastrointestinal 
changes during space flight may lead to changes in microbial synthesis of biotin, 
warrant further study.  Furthermore, the interaction of biotin with some 
pharmacological agents (such as phenobarbital) included in the medical kit supplied 
to astronauts during space flight has been shown to yield biotin deficiencies in other 
populations (259). 
   
Nominal requirement on Earth 
The dietary reference intake for biotin has been based only on adequate intake (AI) 
data (251).  To date, no RDA has been reported for biotin due to lack of data and a 
general consensus that colonic bacteria synthesize biotin that contributes to the daily 
supply.  Because microbial synthesis of biotin takes place in the lower part of the 
intestine, where nutrient absorption is limited, controversy exists about how much of 
the biotin produced by colonic bacteria is available for host metabolism.  The AI for 
adults is extrapolated from the AI for healthy infants consuming breast milk, and has 
been determined to be 30 µg/d for men and women >19 years.  No upper limit has 
been set for biotin because of lack of symptoms of biotin toxicity when it is 
administered at high doses. 
 
Historical space flight requirements 
Intake of biotin was defined as 100 µg/day for males and females (47, 48).  
  
Requirements, standards, and operating bands 
Req. 18. The dietary intake of biotin shall be 30 µg/day.  The nominal operating 
bands are defined as 
 
Dietary Biotin 
  30 µg/d green 
  10 µg/d yellow 
  <10 µg/d red 
 
Initial verification that this requirement has been met will be done by proximate 
analysis of space food items for biotin content, as well as by analysis of the crew 
menus. 
  
The extramural expert panel concluded that if dietary sources of biotin are adequate, 
definition of a standard to ensure that biotin requirements are met is unnecessary.  
Accordingly, no biochemical measures of biotin status are required for exploration 
missions. 
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Pantothenic Acid  
 
Physiological function and existing space flight knowledge 
The primary function of pantothenic acid is in its role as a precursor of coenzyme A 
(CoA) and as a component of acyl carrier protein (ACP).  Pantothenic acid, in the form 
of CoA and ACP, is required for numerous lipid, carbohydrate, and protein metabolic 
reactions.  CoA is necessary for acetyl and acyl transfer reactions associated with 
catabolism, and it acts as a precursor to ACP.  ACP is a coenzyme in fatty acid 
synthase complex. 
 
No data regarding pantothenic acid intake or status during or after space flight are 
currently available.   
 
Body stores and relative time to depletion 
Free pantothenic acid is found in various parts of the body: 10–15 µmol/L in the liver, 
~100 µmol/L in the heart, 1–5 µmol/L in plasma, 50–100 µmol/L as CoA, and 10 
µmol/L as ACP.  About 70%–90% of CoA is found in the mitochondria.  Any excess 
pantothenic acid is excreted in urine.  (264) 
 
Since pantothenic acid is widely distributed in foods, deficiencies are reported only in 
cases where semisynthetic diets or antagonists to the vitamin were used.  Individuals 
became deficient after 63 days on a diet virtually devoid of the vitamin (265). 
 
Potential implications for flight  
No space flight data are available to determine effects of microgravity on pantothenic 
acid status.  It is also unknown whether conditions of long-term space flight (such as 
extended storage time and exposure to high-LET radiation) will affect the stability of 
pantothenic acid in the food supply.  The stability of pantothenic acid under these 
conditions will have to be determined in order to minimize risk for pantothenic acid 
deficiency symptoms. 
 
Deficiency of pantothenic acid leads to dermatologic manifestations and neurological, 
immunological, hematological, reproductive, and gastrointestinal symptoms.   
 
There is no conclusive evidence that adverse effects occur from high intakes of 
pantothenic acid.  
  
Targeted research needed 
The extramural expert panel recommended that pantothenic acid levels in the space 
food system be determined.  
   
Nominal requirement on Earth  
The dietary reference intake for pantothenic acid has been based only on adequate 
intake (AI) data (251).  No RDA has been reported for pantothenic acid.  The AI for 
adults is based on mean intakes and is 5 mg/d for men and women >19 years.  No 
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upper limit has been reported for pantothenic acid, but doses of the vitamin as high 
as 10–20 g/d have been well tolerated with occasional diarrhea reported (264).   
Since pantothenic acid is required in numerous metabolic reactions, deficiency of the 
vitamin can cause neurological, immunological, hematological, reproductive, and 
gastrointestinal dysfunctions.  Specific symptoms include dermatitis, growth 
retardation, numbness and burning of hands and feet, impaired antibody production, 
headache, fatigue, insomnia, increased sensitivity to insulin, and intestinal 
disturbances.  Pantothenic acid deficiency is rare because of its presence in a wide 
variety of foods of both plant and animal origin.  Deficiency of the vitamin is 
frequently associated with multi-nutrient deficiencies, making it difficult to detect 
specific symptoms of pantothenic acid deficiency. 
 
Historical space flight requirements 
Intake of pantothenic acid was defined as 5 mg/day for males and females (266).  
 
Requirements, standards, and operating bands 
Req. 19. The dietary intake of pantothenic acid shall be 30 mg/day.  The nominal 
operating bands are defined as 
 
 
 
 
 
 
Initial verification that this requirement has been met will be done by proximate 
analysis of space food items for pantothenic acid content, as well as by analysis of the 
crew menus. 
  
The panel concluded that if dietary sources of pantothenic acid are adequate, 
definition of a standard to ensure that pantothenic acid requirements are met is 
unnecessary.  Accordingly, no biochemical measures of pantothenic acid status are 
required for exploration missions. 
 
 
 
 
 
 
Dietary Pantothenic Acid 
  30 mg/d yellow 
  5 mg/d green 
  1 mg/d yellow 
  <1 mg/d red 
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Minerals 
 
Calcium 
 
Physiological function and existing space flight knowledge 
Calcium is critical for maintaining the body’s structural and mechanical functions, and 
it makes up 37%–40% of the bone mineral hydroxyapatite in the body (267). In 
addition to its obvious role in the musculoskeletal system, calcium also has a critical 
role in modulating the function of important proteins and regulation of metabolic 
processes. Calcium binding is responsible for the activation of a wide range of 
proteins, including those involved in cell motility, blood coagulation, muscle 
contraction, neural transmission, glandular secretion, and cell division (154, 268). 
Circulating calcium levels are under tight control and are maintained within a narrow 
range (269).  
 
Bone loss is one of the main health concerns of long-duration space flight (270).  It is 
estimated that the rate of bone mineral loss during space flight is about 0.5%–1% per 
month (135, 271, 272).  During the 84-d Skylab 4 mission, calcium balance was –200 
mg/d  (51, 273), but no significant calcium losses occurred during the 28-d Skylab 2 
mission (135, 274).  The Skylab studies showed that during space flight, bone mineral 
is not uniformly lost from all parts of the skeleton.  Loss of bone tissue is most 
profound in weight-bearing bones such as the os calcis.  Of the 3 men aboard the 
59-day Skylab 3 mission, 1 lost a significant amount of os calcis bone mineral (–7.4%) 
but the other 2 did not (+2.3% and +1.4 %).  Calcium excretion in the urine was 200% 
of the preflight value for the man who lost os calcis and 50% of the preflight values 
for the other 2 men (274).   
 
The ability to understand and counteract weightlessness-induced bone loss will be 
critical for crew health and safety during and after extended-duration space station 
and exploration missions (275-278).  As a result of skeletal unloading during flight 
(274, 279-283), bone mineral is lost, leading to increased urinary excretion of calcium 
(51, 274, 282).  The bone loss and an increased risk of renal-stone formation during 
and after flight (148, 149) are significant.  Inflight and ground-based analog studies 
have shown that the loss of calcium from bones varies between sites in the same 
subject, and that the nature and degree of loss over time varies between subjects 
(279, 284).  Long-term follow-up data on bone recovery are lacking (285). 
 
Negative calcium balance was observed during the Skylab (30, 51, 274, 282, 286, 287) 
and Mir (12, 179) missions.  Increased urinary and fecal calcium excretion accounted 
for most of the deficit (12, 30, 51, 148, 179, 274, 282, 287).  During the Skylab 4 
mission, calcium losses correlated roughly with mineral losses in the os calcis (288) 
and increases in the excretion of hydroxyproline. 
 
If the rate of bone calcium loss is constant throughout a flight (a reasonable 
assumption judging by collagen crosslink excretion data (12, 179, 289), then about 
250 mg of bone calcium are lost per day (12, 51, 179, 290).  The rate of postflight 
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recovery, also if assumed to be constant (reasonable according to ground-based (284) 
and flight (12, 179) data), is approximately +100 mg/d (12, 179).  By these estimates, 
on flights up to about 6 months, it will take 2 to 3 times the mission duration to 
recover the lost bone.  For longer flights, however, the usefulness of these 
assumptions comes into question as space flight data are not available.  Although 
more data clearly are required to validate this hypothesis, it nevertheless has 
significant implications as mission durations increase.  For planetary missions, the 
ability of a terrestrial partial g force (such as Mars’ 0.38 g) to reduce bone loss, or 
even begin recovery, is unknown.  Although no data on partial g responses are 
available, the general consensus among investigators is that forces less than 0.5 g are 
likely to be of little value. 
 
Bone resorption increases during space flight, as shown by the concentrations of bone 
markers (289, 291, 292) and by the results of calcium tracer kinetic studies (12, 179).  
Urinary hydroxyproline was elevated 33% after 84 days of flight (51, 61).  Urinary 
collagen crosslinks, also markers of bone resorption, were elevated >100% during 
space flight compared to preflight levels (12, 289).  Calcium tracer kinetic data 
indicated that bone resorption increased about 50% during flight (12). 
 
Bone formation either remains unchanged or decreases during space flight (12, 135, 
179).  As indicated by serum concentrations of bone-specific alkaline phosphatase and 
osteocalcin, bone formation was unchanged during Mir flights, but increased 2 to 3 
months after landing (12, 179).  Trends toward decreased levels of bone formation 
markers were noted in 2 Mir studies with 1 subject each (291, 292).  Studies, using 
calcium tracer techniques, of bone formation in 3 Mir crew members (12, 179) were 
equivocal (formation unchanged or decreased). 
 
Together, increased resorption and decreased or unchanged formation yield an overall 
negative calcium balance (12, 179).  A number of related factors likely contribute to 
the loss of bone mineral during weightlessness.  Decreased calcium absorption has 
been observed among Mir astronauts (12, 179), which likely resulted from the 
decreased concentration of circulating 1,25-dihydroxyvitamin D that was also 
observed in these crew members (12, 179).  
 
Space flight analog studies (such as bed rest) with humans have shown qualitative 
effects on bone and calcium homeostasis similar to those shown in flight studies, with 
quantitative effects generally showing reductions.  These include loss of bone mass 
(284, 293, 294), decreased calcium absorption (295), increased urinary calcium (282, 
295-302), increased risk of renal stone formation (299, 300), and decreased serum 
concentrations of parathyroid hormone (180, 297) and 1,25-dihydroxyvitamin D (180, 
295, 297, 303). 
 
Bone resorption increases during bed rest, as measured by histomorphometry (294, 
304) or biochemical markers of bone metabolism.  Hydroxyproline excretion of bed-
rest subjects (295) is elevated.  Collagen crosslink excretion during bed rest (289, 
295) is elevated about 50% above control levels, compared with the greater than 100% 
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increase during flight (12, 289).  These data suggest that bed rest, although it is an 
analog of space flight, may not result in the same magnitude of bone changes. 
 
According to histomorphometry data from bone biopsies, bone formation decreases 
during bed rest (294, 297, 304), but the concentrations of biochemical markers (180, 
293, 295) indicate that it is unchanged.  This difference likely reflects the difference 
between site-specific (biopsy) and systemic (biochemical markers) indices of bone 
formation.  After ambulation following bed rest, bone formation is generally 
increased (293, 295). 
 
Bone loss and altered calcium metabolism occur in paralyzed individuals (as reviewed 
by (305), and there are a number of similarities between these changes and those 
associated with space flight (306-309).  Although the loss of bone that occurs after 
spinal cord injury seems to stabilize after about 25 weeks (310), studies of bone 
metabolism have not been possible during space missions of this duration, and the 
limited postflight bone assessment does not allow determination of the rate of loss. 
 
Changes in the endocrine regulation of bone metabolism seem to reflect adaptation to 
the weightless environment.  Decreases in calcium absorption and plasma levels of 
parathyroid hormone and 1,25-dihydroxyvitamin D are expected physiological 
responses to increased resorption of bone that may occur as the body adapts to an 
environment in which bones bear less weight.  This evidence, and the lack of 
improvement provided by earlier dietary countermeasures, indicate that 
supplemental nutrients such as calcium and vitamin D will not correct this problem 
(311).  Adequate nutrition will, however, be a required component in the success of 
whatever countermeasures are identified and implemented (276, 312). 
 
Body stores and relative time to depletion 
Bone acts as the body’s reserve for calcium.  Total skeletal calcium is on average 
1100–1500 g, and inadequate calcium intakes have significant impact on adult bone 
(165).  About 1% of the body’s calcium stores resides in the intracellular structures, 
cell membranes, and extracellular fluids (154). 
 
Calcium depletion is not uncommon in many subgroups of the population. During 
acute starvation, urinary calcium remains constant; the largest amounts of calcium 
loss occur in feces, with much of the mineral lost apparently coming from bone (139).  
Gamble et al. (1923) (140) examined blood mineral concentrations in children during 
acute starvation and showed that calcium levels did not change after 4 days of 
fasting. Studies in dogs and cats indicate that significant changes occur only when 
more than 35% of body mass is lost (313). Blood calcium levels after chronic semi-
starvation are variable, but most studies indicate that plasma or serum calcium levels 
decrease (139). Controlled calcium balance studies during semi-starvation provide 
more variable results, with individual calcium balances ranging from positive to 
negative (139). 
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Calcium absorption may be decreased in a variety of disease states, including Crohn’s 
disease, diabetes, chronic renal failure, and malabsorption syndromes (154). Although 
the daily calcium intake requirement rises with age, many of the elderly and other 
population groups have inadequate intakes. Assessment of calcium deficiency by 
clinical laboratory analyses is difficult because circulating calcium is tightly regulated 
over a wide range of intakes (154). Imaging techniques (such as dual-energy X-ray 
absorptiometry and quantitative computed tomography) that enable determination of 
bone mineral content may provide a good indicator of long-term calcium nutritional 
status. 
 
Deficiency of calcium leads to reduced bone mass and osteoporosis.  An excess of 
calcium leads to kidney stones, hypercalcemia, and ultimately renal insufficiency or 
even death. Intakes up to 2500 mg/d are considered safe under normal conditions 
(154). 
 
Potential implications for flight 
The effect of near-weightlessness on the human skeletal system is one of the greatest 
concerns in safely extending space missions (186, 270). Adequate intake of dietary 
calcium will be critical for maintaining skeletal health. Both dietary protein (amount 
and type) and dietary sodium affect calcium metabolism. In addition, the use of 
pharmacological countermeasures may have implications for calcium homeostasis. 
Specifically, the bisphosphonates exert their effects by inhibiting osteoclast-mediated 
bone resorption, lowering serum calcium in subjects who are normocalcemic or 
hypercalcemic (314).  It is recommended that subjects receiving bisphosphonates 
have adequate vitamin D status before therapy, and that their calcium status be 
monitored (315-317).   
 
Although it is unlikely that diet is solely responsible for the bone mineral loss 
associated with space flight, even modest protective effects from a balanced diet 
would benefit crew health.  Using diet modification as a countermeasure has several 
advantages, including no additional costs and no additional time required by 
astronauts during flight.  Maintaining a diet balanced in acid and base precursors 
would involve food choices, and could be done with the help of a dietitian planning 
the menus.  The ratio of acid and base precursors in the diet could be an important 
predictor for the extent of bone loss during space flight, and could be determined 
from the menu choices before flight.  Furthermore, until inflight resources for 
research are available, a pre- and postflight investigation of the relationship between 
diet and bone metabolism could provide a basis for defining optimal nutritional 
recommendations during recovery after space flight.   
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Targeted research needed  
To determine calcium requirements for long-duration space flight, it will be necessary 
to define the mechanisms by which calcium metabolism is altered during flight.  
Critical questions, including those addressing differences in calcium absorption during 
space flight (Risk #1: Accelerated Bone Loss and Fracture Risk; Research and 
Technology Question 1h:  does the hypogravity environment change the nutritional 
requirements for optimal bone health? and Risk #16: Inadequate Nutrition; Research 
and Technology Question 16c:  what are the decrements in nutritional status due to 
long term LEO, lunar, and exploration missions?), need to be addressed.       
 
Nominal requirement on Earth 
The dietary recommendations for calcium are provided as AIs, and the current Earth-
based daily recommendation for the astronaut population is 1000 mg for men and 
women under age 50 y and 1200 mg for men and women 51 y and older (187). 
 
Historical space flight requirements 
The daily calcium requirements for male and female astronauts were defined as 
follows: 
    Missions of 30–120 days:  800–1200 mg (47) 
    Missions up to 360 days: 1000–1200 mg (48)  
 
Requirements, standards, and operating bands 
Req. 20. The dietary intake of calcium shall be 1200–2000 mg/day.  The nominal 
operating bands are defined as 
 
Dietary Calcium 
  >2500 mg/d red 
  2000-2500 mg/d yellow 
  1200-2000 mg/d green 
  1000-1200 mg/d yellow 
 <1000 mg/d red 
 
Initial verification that this requirement has been met will be done by proximate 
analysis of space food items for calcium content, as well as by analysis of the crew 
menus. 
  
Standards will be assessed before, during (to the extent possible), and after flight by 
determining levels of bone-specific alkaline phosphatase (BSAP)(318-320), intact 
parathyroid hormone (153, 321), calcium (85, 86, 100), n-telopeptide (NTX) (153), 
helical peptide (HP)(322), deoxypyridinoline (DPD) (323), osteocalcin (total (324) and 
undercarboxylated (197-199) (325-327), serum calcium (100), and ionized calcium (84, 
153) in biological samples.  Helical peptide is a new marker of bone resorption, and a 
sensitive indicator for bone resorption, but full evaluations on normal reference 
ranges (particularly for men) have yet to be published.   
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There is clear within-subject evidence that a 2-fold increase in bone marker excretion 
is associated with a high rate of bone loss (328-330).  Because the bone resorption 
markers have considerable within- and between-subject variability, and because their 
concentrations are affected by the type of urine collection (such as single void or 24-
hour pool) (331), it is important to collect appropriate sample types (e.g., 24-h pools) 
and to evaluate within-subject changes as well as changes in the group of subjects 
compared with population means.  The operating bands presented below are based on 
available normal ranges (153, 322, 323) and serve as a useful guide; however, it may 
be more important to observe changes in a given subject.  
 
Serum Intact PTH 
 >100 pg/mL red 
 100 pg/mL yellow 
 65 pg/mL green 
  10 pg/mL yellow 
  <50 pg/mL* red 
*Hypoparathyroidism is defined as intact PTH <50 pg/mL and serum calcium <8mg/dL. 
 
Urinary Calcium 
  >350 mg/d red 
  240 mg/d yellow 
  100 mg/d green 
 
Serum Calcium 
  >13.0 mg/dL red 
  10.5 mg/dL yellow 
 8.6 mg/dL green 
 6.0 mg/dL yellow 
  <6.0 mg/dL red 
 
Urinary NTX 
 Women PreMenopause Women PostMenopause Men  
  
>130 nmol/mmol 
creat* >250 nmol/mmol creat  >200 nmol/mmol creat red 
  65 nmol/mmol creat 124 nmol/mmol creat >86 nmol/mmol creat yellow  
  5 nmol/mmol creat 26 nmol/mmol creat <86 nmol/mmol creat green 
* creat = creatinine. 
 
Urinary Helical Peptide 
 Women PreMenopause Women PostMenopause/Men  
  >200 µg/mmol creat >200 µg/mmol creat red 
  200 µg/mmol creat 200 µg/mmol creat yellow  
  <50 µg/mmol creat <100 µg/mmol creat green 
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Urinary DPD 
 Women Men  
  >15 nmol/mmol creat >15 nmol/mmol creat red 
  7.4 nmol/mmol creat 5.4 nmol/mmol creat yellow 
  3 nmol/mmol creat 2.3 nmol/mmol creat green 
 
Serum Osteocalcin (total) 
  >19.8 ng/mL red 
 19.8 ng/mL yellow 
 12.8 ng/mL green 
  6.4 ng/mL yellow 
  < 5 ng/mL red 
 
Serum Osteocalcin (undercarboxylated) 
  10 % green 
  30 % yellow 
  >70% red 
 
Serum BSAP 
 Women Men  
  >46 U/L >51 U/L red 
 42.7 U/L 51 U/L yellow 
 30.6 U/L 41.3 U/L green 
  14.2 U/L 15 U/L yellow 
  <11.6 U/L <15 U/L red 
 
Whole Blood Ionized Calcium 
 >1.45 red 
 1.32-1.45 yellow 
  1.12-1.32 mmol/L green 
  1.07-1.12 mmol/L yellow 
  <1.07 mmol/L red 
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Phosphorus 
 
Physiological function and existing space flight knowledge 
Phosphorus is an important component of cell membranes and bone mineral.  It is a 
critical element of most enzymes, cellular messengers, and carbohydrate fuels.  
Osteomalacia, a defect in bone mineralization, often occurs as a result of long-term 
phosphorus deficiencies.  Inadequate intake of phosphorus can cause the release of 
calcium from bone, a reduction in chemotactic, phagocytic, and bactericidal 
properties of granulocytes, and cardiomyopathy (332). Excessive phosphorus intake 
has been shown to affect calcium absorption by increasing endogenous calcium 
excretion in the feces (333).  
 
Long-duration space flight data show that urinary phosphorus concentrations are 
about 45% less after landing than before launch (15). 
 
Body stores and relative time to depletion 
Phosphate accounts for about 60% of bone mineral (267), and most (80%) of the body’s 
extracellular phosphorus is present in the bone as hydroxyapatite (332).  
 
Human studies show that phosphorus can be depleted by daily antacid treatment with 
either magnesium-aluminum hydroxide (60 mL, 4 times per day) or aluminum 
hydroxide (30 mL, 4 times per day) (334).  Serum calcium of these subjects was 
elevated within 12 days of treatment, and by day 20 phosphorus balance was negative 
(334).   
 
Animal studies have shown that symptoms of a phosphorus deficiency occur after 11 
days on a low-phosphorus diet.  Twelve hours after growing pigs had started 
consuming an experimental low-phosphorus diet, a marked fall occurred in their 
growth rate, plasma phosphorus, plasma growth hormone, and renal 24-hydroxylase 
activity levels (335).  Additional animal studies have demonstrated that the removal 
of phosphate from the diet rapidly produces hypercalcemia, hypercalciuria, and 
hypophosphaturia.  Rats fed a low-phosphate diet showed signs of deficiency after 11 
days (336). 
 
Potential implications for flight  
Adequate phosphorus intake before and during flight will be critical for preserving 
bone quality and quantity.  In addition, calcium:phosphorus ratios greater than 1.5 
are known to decrease calcium absorption, which could impair skeletal integrity. 
Because serum phosphorus rises with increasing phosphorus intake and can result in 
calcification of the kidney if hyperphosphatemia occurs, ensuring optimal phosphorus 
intake during flight becomes very important (135). Maintaining adequate nutritional 
status during flight will be critical for preventing impaired performance on landing, 
which could limit crew capability for emergency egress. 
 
Deficiency of phosphorus leads to hypophosphatemia, which causes cellular 
dysfunction and can lead to anorexia, muscle weakness, bone pain, and ultimately 
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rickets, or even death.  Likewise, an excess of phosphorus leads to 
hyperphosphatemia, interference with calcium absorption, ectopic calcification of the 
kidney, or even death. 
 
Targeted research needed  
Nominal determinations of phosphorus content of the space food system were 
recommended by the extramural expert panel, as well as further investigation of the 
mechanism and implications of decreased phosphorus excretion after long-duration 
space flight. 
   
Nominal requirement on Earth 
The RDA for phosphorus (165) is 700 mg/d for men and women 19 years of age and 
older. 
 
Historical space flight requirements 
The daily phosphorus requirement for male and female astronauts was defined as 
800–1200 mg/d for missions of 30 to 120 days (47). There was no specific phosphorus 
recommendation for missions up to 360 days (48); however, both sets of space flight 
dietary requirements indicate that phosphorus intake should not exceed 1.5 times the 
calcium intake.  
 
Requirements, standards, and operating bands 
Req. 21. The dietary intake of phosphorus shall be 700 mg/day, and shall not exceed 
1.5 times the calcium intake.  The nominal operating bands are defined as 
 
 
 
 
 
 
 
 
Initial verification that this requirement has been met will be done by proximate 
analysis of space food items for phosphorus content, as well as by analysis of the crew 
menus. 
  
Standards will be assessed before, during (to the extent possible), and after flight by 
determining levels of phosphorus in blood (154, 187, 334) and urine (84, 86, 154) 
samples. 
 
 
Dietary Phosphorus 
  4000 mg/d red 
  700 mg/d green 
  580-700 mg/d yellow 
  <580 mg/d red 
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Phosphorus (serum) 
 1.50 mmol/L yellow 
  1.41 mmol/L green  
  0.87 mmol/L yellow 
  <0.3 mmol/L red 
Phosphorus (urine) 
  >1300 mg/d red 
 1300 mg/d yellow 
 800 mg/d green 
  600 mg/d yellow 
  <50 mg/d red 
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Magnesium 
 
Physiological function and existing space flight knowledge 
Magnesium is the fourth most abundant cation in the body and within the cell is 
second only to potassium (337). It is required as a cofactor for over 300 enzyme 
systems and serves as a substrate for phosphate transfer reactions in all cells.  
Adequate intake of magnesium is necessary to prevent hypocalcemia, resistance to 
vitamin D, and resistance to parathyroid hormone. Excessive intake has been shown to 
impair calcium absorption (338).  Several studies show that magnesium metabolism 
may be altered during long-duration space flight (15, 30, 339).  After crew members 
have spent 4 to 6 months in space, their urinary magnesium is about 45% less than it 
was before flight (15).   
 
Body stores and relative time to depletion 
More than half of the body’s magnesium is contained in bone, about 30% in muscle, 
and the remainder mostly in soft tissue (338).  
 
Few studies have addressed experimental magnesium depletion in humans. Consuming 
a diet containing 10 mg/d for 110 days led to a steady decline in plasma magnesium 
to levels 10–30% of control values, and urinary magnesium levels were negligible (< 1 
mEq/d) within 7 days (338). Abnormal neuromuscular signs occurred in 5 of 7 subjects 
after 25 to 110 days of magnesium deficiency (338).  
 
Potential implications for flight  
Adequate magnesium intake before and during flight will be critical to reduce the 
potential for altered magnesium status, and to help preserve bone quality and 
quantity.  Maintaining adequate nutritional status during flight will be critical for 
preventing impaired performance on landing, which might limit crew capability for 
emergency egress. 
 
Deficiency of magnesium leads to neuromuscular hyperexcitability, seizures, cardiac 
complications, or even death (165).  No evidence has been reported of adverse 
effects associated with toxicity from naturally occurring sources of magnesium, but 
mega doses may cause gastrointestinal distress.  
 
Targeted research needed  
Nominal determinations of magnesium content of the space food system were 
recommended by the extramural expert panel.  Significant decreases in urinary 
magnesium excretion after 4- to 6-month space flights (15) also warrants further 
investigation.   
  
Nominal requirement on Earth 
The RDA for magnesium (165) is as follows: 
   Men,      19–30 y:  400 mg/d    Men,      31–70 y:  420 mg/d 
   Women, 19–30 y: 310 mg/d    Women, 31–70 y: 320 mg/d 
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Historical space flight requirements 
The daily magnesium requirement for male and female astronauts was defined as 
follows: 
    Missions of 30–120 days (47) 
      Male: 350 mg/d   
      Female:  280 mg/d 
    Missions up to 360 days (48) 
      Male and female: 350 mg/d 
 
Requirements, standards, and operating bands 
Req. 22. The dietary intake of magnesium shall be 320 and 420 mg/day for women 
and men respectively.  The upper limit for both genders is defined as 350 
mg/d from supplements only (not from dietary sources). The nominal 
operating bands are defined as 
 
 
 
 
 
 
 
 
                        
                                  *Upper red band is for supplement intake only 
 
Initial verification that this requirement has been met will be done by proximate 
analysis of space food items for magnesium content, as well as by analysis of the crew 
menus. 
  
Standards will be assessed before, during (to the extent possible), and after flight by 
determining levels of magnesium in serum (154) and urine (85, 153, 154) samples. 
 
Magnesium (urine) 
  5 mmol/d green 
  3 mmol/d yellow 
  <2 mmol/d red 
 
Magnesium (serum) 
  1.25 mmol/L green 
  0.75 mmol/L yellow 
  <0.75 mmol/L red 
 
 
Dietary Magnesium 
 Women Men  
  350 mg/d* 350 mg/d* red  
  320 mg/d 420 mg/d green  
  231 mg/d 350 mg/d yellow 
  <230 mg/d <350 mg/d red 
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 Trace Elements 
 
Iron 
 
Physiological function and existing space flight knowledge 
Iron is an essential element involved in oxygen transport, oxidative phosphorylation in 
carbohydrate and lipid metabolism, and electron transport in cytochromes and 
cytochrome oxidase (340). Iron deficiency is the most common nutritional deficit 
worldwide, but iron toxicity is also of concern.  Iron deficiency results in reduced 
work capacity and impaired temperature regulation, behavior and intellectual 
performance, and immune function (341-343).  The toxic potential of iron derives 
from its ability to exist in two oxidative states (ferrous and ferric forms).  Iron serves 
as a catalyst in redox reactions; however, when these reactions are not properly 
modulated by antioxidants or iron-binding proteins, cellular damage can occur (344). 
 
Decreased red blood cell mass is a consistent finding after short- and long-term flights 
(114, 345-348).  This “space-flight anemia” was observed as early as Gemini missions 
of the 1960s (349).  Although the decrease in RBC mass is significant (reaching 10%–
15% below preflight levels within 10 to 14 days of flight), this appears to be an 
adaptation to space flight with no documented functional consequences. 
 
A confounding factor in the early flights (before Skylab) was the increased cabin 
partial pressure of oxygen (348).  The possibility of hyperoxia-induced RBC membrane 
peroxidation was considered (114).  This was ruled out, however, when changes in 
erythropoiesis were also observed during Skylab (114, 350) and Shuttle missions (346, 
347), where the partial pressure of oxygen was similar to that of the Earth’s 
atmosphere (4, 114). 
 
Decreased release of mature red blood cells into the circulation is associated with a 
decrease in circulating erythropoietin concentrations.  An early hypothesis for the 
cause of decreased RBC mass was that RBC synthesis was under-stimulated compared 
to synthesis on the ground (348).  However, iron turnover is unchanged during flight 
(346, 347), indicating that synthesis of hemoglobin and red blood cells is unchanged. 
 
During the first several days of space flight, hematocrit is either unchanged (351) or 
slightly elevated (345-347).  When elevation is noted, it is not as great as would be 
predicted from the decrease in plasma volume (3).  The initial decrease in red blood 
cell mass occurs at the rate of slightly greater than 1% per day, with an eventual loss 
of 10%–15% (345-347).  Although removal of mature red cells from the circulation is 
unchanged during flight (347, 352-354), the release of new red cells is halted upon 
entry into weightlessness (346, 347, 355).  Additionally, newly released red blood 
cells are selectively removed from the circulation (355).  These nascent cells are 
larger than the more mature circulating red blood cells, allowing their selective 
destruction (355).  
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The inflight changes in body fluid volumes and red blood cell mass seem to be 
adaptive and reach a new plateau after the first weeks of flight, as shown by data 
from long-duration flights (4, 16, 356, 357).  The triggering mechanism for these 
changes is unknown.  The body seems to sense a decreased requirement for blood 
volume, and adapts accordingly.  This may be related to changes in fluid (circulatory) 
dynamics and reduced gravitational strain on the circulatory system during flight. 
One consequence of the decreased RBC mass is that the iron released when the RBCs 
are destroyed is processed for storage.  This interpretation is based on findings of 
increased serum ferritin concentrations during and after both short- and long-duration 
flights.  Serum iron concentrations are normal to elevated during and after flight 
(346, 347).  The implications of excess stored iron during extended-duration space 
flights are currently unknown.  Current space food systems provide excessive amounts 
of dietary iron (about 20 mg/d (4, 358)), which have the potential to cause 
deleterious effects during extended-duration space missions.  Studies of dietary iron 
absorption have not been conducted, but could alleviate concern about iron overload 
during extended-duration space flight.  
 
Another consequence of the reduced blood volume and red cell mass occurs after 
return to gravity.  A dilutional “anemia” often occurs after flight (351), with the 
disproportionate return of plasma volume before the repletion of red blood cells.  For 
example, a 3%–5% decrease in hematocrit between R+0 and R+3 is common after both 
short- and long-duration flight (351). 
 
Bed-rest studies have not proven suitable models for the hematological changes of 
space flight.  Although red blood cell mass decreases during bed rest, erythropoietin 
is unchanged, and hematocrit increases (359), suggesting that the mechanisms that 
bring about hematological changes during bed rest are different from those that act 
during flight.  If the reduced red blood cell mass during flight is caused by the 
reduced gravitational load on the circulatory system, it is reasonable to assume that 
bed rest alone would not alleviate these forces, but would only reposition them.  In 
studies involving changes in altitude, however, the descent from high to low altitude 
induces changes similar to those observed for space flight (decreased red cell mass, 
increased iron storage) (360). 
 
Indices of iron metabolism and erythropoiesis return toward normal relatively quickly 
(days), although the replenishment of red blood cell mass may take several weeks.  
The efficient postflight recovery suggests that the inflight “anemia” represents an 
adaptation to weightlessness, probably in response to either the easier delivery of 
oxygen to tissues without the influence of gravity or to the decreased plasma volume 
and an increased concentration of RBCs in the first few days of space flight. 
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Body stores and relative time to depletion 
Body iron comprises hemoglobin iron (67% of total) and storage iron (27%).  Storage 
iron includes ferritin and hemosiderin, tissue iron (3.7%), a labile iron pool (2.2%) and 
transport iron (<1%) (340). 
 
Storage iron may be completely deleted before the development of iron-deficiency 
anemia (344).  As a result of this, tissue iron deficiency occurs before anemia. 
 
Potential implications for flight  
Pathological conditions in which involvement of iron-related radicals is suspected and 
that have specific relevance to space flight include ionizing radiation and 
inflammatory-immune injury (361).  Free-radical involvement subsequent to 
elevations in iron stores has also been linked to cardiovascular disease and cancer.  A 
correlation between coronary heart disease and iron status has been described in a 
number of recent studies (362-366).  Although the evidence supporting this thesis is 
contradictory (367, 368), an association between increased iron stores (as measured 
by serum ferritin) and increased incidence of myocardial infarction has been observed 
(363, 366).  Increased risk of all cancer types combined and colorectal cancer in 
particular was associated with high iron stores in a prospective Finnish study (369).  
The relationship between iron, lipids, and cancer has also been documented in the 
Framingham study (370).  A relationship has also been indicated between excessive 
iron stores and ascorbic acid deficiency; when reductions in ascorbic acid occur, 
vitamin A and selenium tend to exacerbate iron-induced peroxidation processes (371).  
These data suggest that the alterations in erythropoiesis and iron metabolism that 
occur in microgravity could cause significant changes affecting crew health.   
 
Deficiency of iron leads to anemia, fatigue, impaired performance, heart palpitations, 
congnitive deficits and memory loss, impaired thermoregulation, decreased immune 
function, or even death.  Toxicity of iron may lead to tissue damage or cancer.  High 
iron intakes have also been related to gastrointestinal distress. 
 
Targeted research needed 
The extramural expert panel recommended that iron metabolism be further 
investigated because of the high levels of dietary iron and the potential for iron to act 
as an oxidizing agent during space flight, complicated by increased radiation levels.  
An experiment to study this was approved for flight on the ISS but was later 
deselected because of resource constraints. 
   
Nominal requirement on Earth 
The recommended intakes for iron are provided as RDAs (174): 
Men, 19–70 y:   8 mg/d 
Women, 19–50 y:  18 mg/d 
                 50+ y:  8 mg/d 
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Historical space flight requirements 
Missions of 30–120 days: 
Because space flight has been associated with decreased erythropoiesis and increased 
serum ferritin concentrations, the use of iron supplementation should be prohibited, 
and the maximum intake held at the male RDA (10 mg/day) (47). 
 
Missions up 360 days: 
Iron intake requirements were defined to not exceed 10 mg/d for males and females.  
This is based on space-induced changes in iron storage, and is designed to prevent 
iron overload, a situation that may lead to oxidative tissue damage (48).  
 
The food system was unable to support this requirement, and intakes have often been 
much higher (intakes as high as 20–25 mg iron per day have been observed). 
 
Requirements, standards, and operating bands 
 
Req. 25. The dietary intake of iron shall be 8–10 mg/day.  The nominal operating 
bands are defined as 
Dietary Iron 
  35 mg/d red 
  15-35 mg/d yellow 
  8 mg/d green 
  5-8 mg/d yellow 
  3-5 mg/d red 
 
Initial verification that this requirement has been met will be done by proximate 
analysis of space food items for iron content, as well as by analysis of the crew 
menus. 
  
Standards will be assessed before, during (to the extent possible), and after flight by 
determining levels of hemoglobin (84), hematocrit (84), mean corpuscular volume 
(MCV) (84), iron (84, 100), ferritin (84, 153, 154), ferritin iron (153, 372), ferritin % 
saturation (153), transferrin receptors (174), and C-reactive protein (an indicator of 
inflammation, which could affect iron status indicators) (86) in blood or serum 
samples. 
 
Ferritin (serum) 
 Women Men  
 >200 ng/mL >300 ng/mL red 
 120-200 ng/mL 250-300 ng/mL yellow 
 120 ng/mL 250 ng/mL green 
 10 ng/mL 20 ng/mL yellow 
 <10 ng/mL <12 ng/mL red 
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Ferritin Iron (serum)* 
 >200 ng/mL red 
 35 ng/mL green 
 10 ng/mL yellow 
 <5.3 ng/mL red 
* For ferritin values ≥150 ng/mL 
 
Transferrin (serum) 
 318 mg/mL green 
 196 mg/mL yellow 
 <196 mg/mL red 
 
Transferrin Receptors (serum) 
 2.9 µg/mL green 
 8.3 µg/mL yellow 
 >8.5 µg/mL red 
 
Hemoglobin (whole blood) 
 Women Men  
 19.0 g/dL 20.0 g/dL red 
  14.8 g/dl 16.5 g/dL green  
  11.6 g/dL 13.3 g/dL yellow 
  9.0 g/dL 10.0 g/dL red 
 
Hematocrit (whole blood) 
 Women Men  
 57.0% 60.0% red 
 43.5% 49.1% green 
 33.5% 39.7% yellow 
 27.0% 30.0% red 
 
MCV (whole blood) 
 106 fL red 
  98 fL green  
  84 fL yellow 
  70 fL red 
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Iron (serum) 
 >250 µg/dL red 
 177-250 µg/dL yellow 
  46-177 µg/dL green  
  20-46 µg/dL yellow 
  <20 µg/dL red 
 
hs C-Reactive Protein (serum) 
  <1.0 mg/L green  
  1.0-3.0 mg/L yellow 
  >3.0 mg/L* red 
*Greater than 10 mg/L indicates inflammatory response. 
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Copper 
 
Physiological function and existing space flight knowledge 
Copper is an essential cofactor for enzymes involved in energy production, 
metabolism of oxygen and iron, maturation of the extracellular matrix and 
neuropeptides, and neuroendocrine signaling. Deficiencies in copper have implications 
for bone health, the nervous system, immune function, the cardiovascular system, 
and lipid metabolism. 
 
Body stores and relative time to depletion 
Copper is not usually stored in tissues, but liver, brain, and kidney typically contain 
the largest amounts per unit tissue mass (373). Total body copper is about 50–120 mg 
(0.79–1.9 mmol) (374).  Frank copper deficiency in humans is rare; however, copper 
deficiencies have been noted in infants fed milk formulas, infants recovering from 
malnutrition and fed cow’s milk, and patients receiving total parenteral nutrition for 
a prolonged period (174).  A copper deficiency developed in 6 patients fed an enteral 
diet containing 15 µg copper/100 kcal for 12 to 66 mo (375). 
 
Potential implications for flight  
The role of copper in maintaining normal immune function seems to be altered during 
space flight (90, 376). Additionally, the well documented (12, 51) changes in bone 
status during space flight may be exacerbated by copper deficiencies. Anemia of 
space flight is manifested as a reduction in circulating red blood cell mass with 
elevations in serum ferritin and iron concentrations (4, 347). Since copper is required 
for iron mobilization and absorption, alterations in copper status may affect iron and 
red blood cell changes during flight. Although deficiencies are rare in populations 
consuming a normal diet, no information about copper absorption and metabolism 
during space flight is available. 
 
Deficiency of copper leads to normocytic, hypochromic anemia, leucopenia, 
neutropenia, defects in connective tissue that lead to vascular and skeletal problems 
and central nervous system dysfunction, or even death (174).  Heartbeat irregularities 
have also been reported in cases of copper deficiency (377).  Deficiency symptoms, 
including macrocytic anemia, bone abnormalities, and decreased neutrophil 
production, have been reported in subjects with serum copper concentrations ranging 
from 0.9–7.2 µmol/L (375).  Toxicity of copper leads to gastrointestinal distress, liver 
damage, or even death.   
 
Targeted research needed 
Existing knowledge of copper metabolism seems adequate; other than the nominal 
determinations of copper content of the space food system, no other specific research 
is required.  
   
Nominal requirement on Earth  
The recommended intake for copper is provided as an RDA (174): 
Men and women, 19–70 y:  900 µg/d 
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Historical space flight requirements 
Intake of copper was defined as 1.5–3.0 mg/day for males and females (47, 48).  
 
Requirements, standards, and operating bands 
Req. 26. The dietary intake of copper shall be 0.5–9 mg/day.  The operating bands 
are defined as 
 
Dietary Copper 
  10 mg/d red 
  0.5-9 mg/d green 
  0.3-0.5 mg/d yellow 
  <0.3 mg/d red 
 
Initial verification that this requirement has been met will be done by proximate 
analysis of space food items for copper content, as well as by analysis of the crew 
menus. 
  
Standards will be assessed before, during (to the extent possible), and after flight by 
determining indices of copper status (86, 174) and ceruloplasmin (174) in blood 
samples. 
 
Copper (serum) 
  1.55 µg/mL green 
  0.70 µg/mL yellow 
  0.02 µg/mL red 
 
Ceruloplasmin (serum) 
  43 mg/dL green 
  22 mg/dL  yellow 
  18 mg/dL red 
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Manganese 
 
Physiological function and existing space flight knowledge 
Manganese can function as an enzyme activator and as part of metalloenzymes.  It is 
involved in the activation of enzyme-catalyzed reactions by causing conformational 
changes in the enzyme that it binds to.  Manganese can also bind directly to the 
substrate.   
 
Transferases, including kinases, hydrolases, oxido-reductases, ligases and lyases, all 
can be activated by manganese.  However, these enzymes can also be activated by 
other divalent cations in the presence of a manganese deficiency.  Activating these 
enzymes gives manganese a role in formation of components of connective tissue, 
urea formation, arginase activity, gluconeogenesis, the prevention of lipid 
peroxidation by superoxide radicals in the mitochondria, and the conversion of 
pyruvate to oxaloacetate in the tricarboxylic acid (TCA) cycle.  Studies are currently 
being conducted to look at the role that manganese may play in second-messenger 
pathways in tissues and the regulation of calcium-dependent processes (233). 
 
Body stores and relative time to depletion 
Only trace amounts of manganese are found in animal tissues.  Humans store about 10 
to 20 mg of the nutrient.  Although it is found in most organs and tissues, the highest 
concentrations are found in bone and the liver, pancreas, and kidneys (233). 
 
In one study, when adult men were fed a purified diet with only 0.11 mg manganese 
per day for 39 days, all of them developed a finely scaling rash, along with decreased 
serum cholesterol, increased serum calcium and phosphorus, and increased alkaline 
phosphatase (378).  Otherwise, signs of a manganese deficiency in humans have not 
been firmly established.   
 
Potential implications for flight  
Considering manganese’s function in preventing lipid peroxidation and the increase in 
lipid peroxidation during space flight, ensuring adequate manganese intake on long 
space flights is vital to preventing and/or minimizing oxidative stress. 
 
Manganese is one of the least toxic trace minerals when it is taken orally.  At 
excessively high intakes of manganese, absorption decreases and excretion increases 
to protect against toxicity.  Manganese and iron compete for binding sites.  At low 
iron intakes, manganese is absorbed at a greater rate than at higher iron intakes, so 
that higher iron intake inhibits manganese absorption.  Likewise, higher manganese 
intake can inhibit iron absorption. 
 
Deficiency of manganese has not been shown to cause any overt clinical symptoms 
due to the fact that other cations can perform the same role.  However, toxicity of 
manganese leads to neurotoxicity. 
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Targeted research needed 
Existing knowledge of manganese metabolism seems adequate; other than the 
nominal determinations of manganese content of the space food system, no other 
specific research is required.  
 
Nominal requirement on Earth  
The AI for manganese for men 19 and older is 2.3 mg/day and for women 19 and older 
it is 1.8 mg/day (174). 
 
Historical space flight requirements 
Intake of manganese was defined as 2–5 mg/day for males and females (47, 48).  
 
Requirements, standards, and operating bands 
Req. 27. The dietary intake of manganese shall be 1.8 and 2.3 mg/day for women 
and men respectively.  The nominal operating bands are defined as 
 
Dietary Manganese 
 Women Men  
  11 mg/d 11 mg/d red 
  1.8 mg/d 2.3 mg/d green 
  1.6 mg/d 2.1 mg/d yellow 
  <1 mg/d <1 mg/d red 
 
 
Initial verification that this requirement has been met will be done by proximate 
analysis of space food items for manganese content, as well as by analysis of the crew 
menus. 
 
The extramural expert panel concluded that if dietary sources of manganese are 
adequate, definition of a standard to ensure that manganese requirements are met is 
unnecessary.  Accordingly, no biochemical measures of manganese status are required 
for exploration missions. 
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Fluoride 
 
Physiological function and existing space flight knowledge 
Fluoride in bone exists in a rapidly exchangeable pool and a slowly exchangeable 
pool.  In the rapidly exchangeable pool, fluoride is present in the hydration shell on 
bone crystallites, where it is exchanged isoionically or heterionically with other ions 
nearby (187).  The slowly exchangeable pool is mobilized during the process of bone 
remodeling.  Fluoride has also been shown to influence the function of osteoblasts, 
enabling new bone to be made. 
 
Body stores and relative time to depletion 
Ninety-nine percent of fluoride is stored in mineralized tissues, predominantly in 
bone.     
 
Because specific signs of fluoride deficiency have not been fully elucidated for higher 
animals and humans, it is not possible to estimate a relative time to depletion. 
 
Potential implications for flight  
An increase in fluoride absorption increases the amount absorbed by the hard tissue, 
but urinary excretion also increases.  With the loss of bone mass associated with 
weightlessness, adequate fluoride is necessary to ensure that the bone apatite 
remains intact.   
 
Toxicity with fluoride supplementation is rare but can occur when fluoride 
concentrations are greater than 10 mg/day for at least 10 years (165).  The toxic side 
effects are skeletal fluorosis and osteosclerosis. 
 
Fluoride deficiency increases the development of dental caries and may reduce the 
integrity of skeletal tissue (233). Toxicity of fluoride leads to enamel and skeletal 
fluorosis.   
 
Targeted research needed 
Existing knowledge of fluoride metabolism seems adequate; other than the nominal 
determinations of fluoride content of the space food system, no other specific 
research is required. 
   
Nominal requirement on Earth 
The AI for fluoride for men 19 y and older is 4 mg/day and for women 19 and older it 
is 3 mg/day (174). 
 
Historical space flight requirements 
The original space requirement for fluoride was defined as 4.0 mg/d for males and 
females (47, 48).  
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Requirements, standards, and operating bands 
Req. 28. The dietary intake of fluoride shall be 3 and 4 mg/day for women and men 
respectively.  The nominal operating bands are defined as 
 
Dietary Fluoride 
 Women Men  
  3.0 mg/d 4.0 mg/d green  
  1.5 mg/d 2.0 mg/d yellow 
  1.0 mg/d 1.5 mg/d red 
 
Initial verification that this requirement has been met will be done by proximate 
analysis of space food items for manganese content, as well as by analysis of the crew 
menus. 
 
The extramural expert panel concluded that if dietary sources of fluoride are 
adequate, definition of a standard to ensure that fluoride requirements are met is 
unnecessary.  Accordingly, no biochemical measures of fluoride status are required 
for exploration missions. 
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Zinc 
 
Physiological function and existing space flight knowledge 
Zinc is a component of many enzymes, which depend on it for their catalytic activity.  
RNA polymerases, alcohol dehydrogenase, carbonic anhydrase, and alkaline 
phosphatase are all zinc metalloenzymes.  Its role with these metalloenzymes is to 
provide structural integrity to the enzyme by binding to amino acids, and it may 
participate directly in the reaction at the catalytic site (233). 
 
Tissue or cell growth, cell replication, bone formation, skin integrity, cell-mediated 
immunity and generalized host defense are all functions of zinc.  In tissue growth it is 
involved directly with the regulation of protein synthesis.  Zinc helps to regulate 
transcription by binding to promoter sequences of specific genes.  Cell membranes 
require zinc for protein-to-protein interactions and membrane proteins’ 
conformation.  It may also affect the activity of enzymes attached to plasma 
membranes.  Zinc stabilizes membrane structure by maintaining phospholipids and 
thiol groups in their necessary reduced state.  It also prevents oxidation of the 
membrane by occupying sites that might otherwise be occupied by pro-oxidant metals 
and protects against oxidation by its role in metallothionein.   
 
Zinc is an integral part of the hormone insulin and plays a role in carbohydrate 
metabolism.   
 
Body stores and relative time to depletion 
About 1.5 to 2.5 grams of zinc is stored in the human body (174).  It is found 
intracellularly in all organs, tissues, and body fluids, but mostly in bone, liver, 
kidneys, muscle, and skin (233).  Over 85% of zinc is found in skeletal muscle and 
bone (233, 379). 
 
Even when dietary zinc is sub-optimal, the zinc stored in muscle, brain, lung, and 
heart is not released.  Also, the apatite of bones releases zinc slowly and this does not 
greatly affect the zinc supply (174).  When zinc intake is sub-optimal or non-existent, 
plasma enzymes containing zinc and metallothionein are catabolized to provide the 
necessary zinc (174).  
 
The greatest losses of zinc occur through the intestine.  In men, the average daily loss 
of zinc from sources other than the intestine remains relatively constant at 1.27 
mg/day, even when individuals consume an inadequate amount of the nutrient.  For 
women, calculation of this value has been based on the difference in average surface 
area and menstruation, and is 1.0 mg/day (174).  
 
Because the stores of zinc in the body are small, inadequate intake can quickly lead 
to exhaustion of the zinc supply.  This may cause a need for catabolism of the zinc 
metalloenzymes, which would bring about a decrease in enzyme activity (233). 
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Zinc deficiency can cause decreased glucose tolerance by decreasing insulin response.  
Basal metabolic rate has been shown to be decreased in individuals who were 
receiving a zinc-deficient diet (380). 
 
Zinc toxicity can occur with excessive intakes.  Acute toxicity has been shown to 
produce metallic taste, nausea, vomiting, epigastric pain, abdominal cramps, and 
bloody diarrhea.  Long-term toxicity can cause copper deficiency because zinc and 
copper compete for absorption by the intestine (233). 
 
Deficiency of zinc leads to arrested growth and development and decreased immune 
function.  There is currently no evidence of adverse effects associated with toxicity 
from naturally occurring sources.  However, supplemental intake of zinc may cause 
suppression of immune response, decreased high-density lipoprotein (HDL) 
cholesterol, reduced copper status, or even death. 
 
Potential implications for flight  
Many different compounds exist in food that can complex with zinc and decrease its 
absorption.  Phytates, oxalates, polyphenols, fibers, and other nutrients including 
vitamins can all inhibit zinc absorption.  
 
The release of zinc from bones (due to demineralization) has been noted in bed rest 
studies (381, 382).  Similarly, increases in urinary zinc have been noted with 
increased muscle catabolism in cases of starvation or trauma (174).  The importance 
of this phenomenon for space flight has not been evaluated (and furthermore, the 
release of other heavy metals from bone during flight has not been evaluated). 
 
Targeted research needed 
Existing knowledge of zinc metabolism seems adequate; other than the nominal 
determinations of zinc content of the space food system, no other specific research is 
required. 
   
Nominal requirement on Earth  
The AI for zinc is 11 mg/day for men and 8 mg/day for women (174). 
 
Historical space flight requirements 
The original space flight requirement for zinc was defined as 15 mg/day for males and 
females (47, 48).  
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Requirements, standards, and operating bands 
Req. 29. The dietary intake of zinc shall be 11 mg/day.  Nominal operating bands are 
defined as 
 
Dietary Zinc 
  40 mg/d red 
  11 mg/d green 
  6-11 mg/d yellow 
  <6 mg/d red 
 
Initial verification that this requirement has been met will be done by proximate 
analysis of space food items for zinc content, as well as by analysis of the crew 
menus. 
  
Standards will be assessed before, during (to the extent possible), and after flight by 
determining levels of zinc in serum (86, 100, 154) and urine (86) samples. 
 
Zinc (serum) 
 >1.5 µg/mL red 
 1.5 µg/mL yellow 
  1.2  µg/mL green 
  0.9 µg/mL yellow 
   <0.7 µg/mL red 
 
Zinc (urine) 
  1200 µg/d green 
  200 µg/d yellow 
  <200 µg/d red 
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Selenium 
  
Physiological function and existing space flight knowledge 
Selenium has been shown to play a role in the maintenance or induction of 
cytochrome P450, pancreatic function, DNA repair, enzyme activation, immune 
system function, and detoxification of heavy metals.  Selenium also plays a role as a 
cofactor for glutathione peroxidase (GPX).  GPX plays a role in the reduction of 
organic peroxides and hydrogen peroxide.  Selenium has also been shown to be 
necessary for iodine metabolism.   
 
Selenium absorption can be enhanced by vitamins A, C, and E and reduced 
glutathione.  Selenium absorption can be reduced by chelation and precipitation of 
the mineral by heavy metals, such as mercury and phytates. 
 
Deficiency of selenium leads to decreased selenoenzyme activity, which may lead to 
biochemical changes that predispose to illness or even death.  Selenium deficiency 
has been associated with Keshan disease, which is characterized by cardiomyopathy 
and heart tissue necrosis.  It has also been shown to be associated with Kashin-Beck’s 
disease, which is characterized by osteoarthropathy of the joints and epiphyseal-plate 
cartilages of the legs and arms (233).  
 
Toxicity of selenium is called selenosis.  Nausea, vomiting, fatigue, hair and nail 
brittleness and loss, changes in nail beds, interference in sulfur metabolism and 
inhibition of protein synthesis have all been demonstrated.  
 
Long-duration space-flight data provide evidence that serum selenium is about 10% 
lower after flight than before launch (15).   
 
Body stores and relative time to depletion  
Total body selenium stores are in the amount of about 15 mg (233).  There are two 
selenium pools in the body.  One is the selenium present as selenomethionine and the 
other is the selenium present as glutathione peroxidase.   
 
In rats, symptoms of acute selenium deficiency have been shown to appear as early as 
20 days.  This was presented as a reduction in GPX activity, but no change in blood 
enzymes was seen (202). 
 
Potential implications for flight  
Little or no data are available regarding selenium during space flight.   The Clinical 
Nutritional Assessment profile has documented a significant reduction in serum 
selenium concentrations after flight.  Whether this is related to intake or metabolism 
is not known.   
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Targeted research needed 
The extramural expert panel recommended that selenium levels in the space food 
system be determined.  They also recommended that the potential role for selenium 
in protecting against oxidative stress during space flight be further investigated. 
   
Nominal requirement on Earth 
The recommended intake for selenium is provided as an RDA (202): 
Men and women, 19 y and older: 55 µg/d 
 
Historical space flight requirements 
Intake of selenium was defined as 70 µg/day for males and females (47, 48).  
 
Requirements, standards, and operating bands 
Req. 30. The dietary intake of selenium shall be 55–400 µg/day.  The nominal 
operating bands are defined as 
 
Dietary Selenium 
  400 µg/d red 
  55-400 µg/d green 
  45-55 µg/d yellow 
  <45 mg/d red 
 
Initial verification that this requirement has been met will be done by proximate 
analysis of space food items for selenium content, as well as by analysis of the crew 
menus. 
  
Standards will be assessed before, during (to the extent possible), and after flight by 
determining levels of selenium in serum (85, 150, 163).  Determination of urinary 
selenium provides supporting data (85) and not a standard per se.  Normal ranges for 
urinary selenium are documented in the General Chemistry section. 
 
Selenium (serum) 
 1000 ng/mL red 
  200 ng/mL green 
  100 ng/mL yellow 
  <65 ng/mL red 
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Iodine 
 
Physiological function and existing space flight knowledge 
The main function of iodine occurs in its ionic form, iodide.  It serves in the 
production of the thyroid hormones T3 and T4.   
 
Body stores and relative time to depletion  
About 15–20 mg iodide is stored in the human body (233).  The element tends to 
concentrate itself in the thyroid and in the salivary and gastric glands, with some 
iodide being found in the mammary glands, ovaries, placenta, and skin.  The thyroid 
gland traps the iodide and it is here that 70 to 80 percent of the total body iodide is 
stored. 
 
During a 4-week study in which rats were submitted to varying degrees of iodine 
deficiency, the most severely depleted rats showed an increase in thyroid mass after 
4 days (383). 
 
Insufficient dietary iodine has been shown to cause goiter.  This is due to over-
stimulation of the thyroid gland by TSH.  Iodine deficiency can also cause the iodine 
deficiency disorders, which include mental retardation, hypothyroidism, goiter, 
cretinism, and other growth and development abnormalities or even death. 
 
No toxic side effects have been reported when intakes in the amount of 2.0 mg/day 
have been ingested (233).  However, with prolonged intakes of greater than 18 
mg/day, the risk of goiter increases, as does the risk of thyroid cancer (174, 187).  
Other symptoms of iodine toxicity when intakes are on the order of several grams per 
day include gastrointestinal distress, thyroiditis, goiter, sensitivity reactions, thyroid 
papillary cancer, or even death (187). 
 
Potential implications for flight  
Although providing adequate amounts of dietary iodine is not a critical issue with 
regard to space flight, there is much discussion regarding the effects of the iodine 
used in the water systems on orbit (where iodine is often used as a bactericide) (384).  
 
Targeted research needed 
Existing knowledge of iodine metabolism seems adequate; other than the nominal 
determinations of iodine content of the space food system, no other specific research 
is required. 
 
Nominal requirement on Earth 
The recommended intake for iodine is provided as an RDA (174): 
Men and women, 19 y and older: 150 µg/d 
 
Historical space flight requirements 
Intake of iodine was defined as 150 µg/day for males and females (47, 48).  
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Requirements, standards, and operating bands 
Req. 31. The dietary intake of iodine shall be 150 µg/d.  Nominal operating bands are 
defined as 
 
Dietary Iodine 
  150 µg/d green 
  95-150 µg/d yellow 
  <95 µg/d red 
 
Initial verification that this requirement has been met will be done by proximate 
analysis of space food items for iodine content, as well as by analysis of the crew 
menus. 
  
Standards will be assessed before, during (to the extent possible), and after flight by 
determining levels of iodine in urine (100, 154) samples. It is also assumed that serum 
thyroid stimulating hormone and serum thyroid hormone concentrations will be 
determined in the routine clinical assessment. 
 
Iodine (urine) 
  50 µg/g creatinine  green 
  25 µg/g creatinine yellow 
  <25 µg/g creatinine red 
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Chromium 
 
Physiological function and existing space flight knowledge 
Chromium is thought to complex with nicotinic acid and amino acids to form glucose 
tolerance factor, which initiates the disulfide bridging between insulin and its 
receptor (233).  This allows the insulin hormone to be more effective and therefore 
increases cellular glucose uptake and intracellular carbohydrate and lipid metabolism.   
 
Chromium may also play a role in pancreatic insulin secretion, internalization of 
insulin through decreasing membrane fluidity, and regulation of the insulin receptor.  
It also may increase insulin sensitivity by activating insulin receptor kinase.   
 
Chromium deficiency may result in insulin resistance, which is characterized by 
hyperinsulinemia.  This has been shown to be a risk factor for coronary heart disease. 
 
Severe trauma and stress may increase the need for chromium.  Stress causes the 
release of the stress hormones, including cortisol and glucagon.  These hormones alter 
glucose metabolism and, in effect, chromium.   
 
Cr6+ is more toxic than Cr3+ when ingested orally.  Liver damage, skin ulcerations, 
dermatitis, and respiratory disease may all result from a chromium intake greater 
than 1,000 µg/day (233). 
 
Deficiency of chromium leads to impaired glucose tolerance, or even death.  Toxicity 
of chromium leads to chronic renal failure, hepatic dysfunction, rhabdomyolysis, or 
even death. 
 
Body stores and relative time to depletion  
The human body can store 4 to 6 mg of chromium.  Tissues having the greatest 
amounts of chromium are the liver, kidney, muscle, spleen, heart, pancreas, and 
bone.  It is possible that chromium is stored along with ferric iron because of its 
transport by transferrin. 
 
Several months of sub-optimal chromium intake will lead to deficiency symptoms such 
as hyperglycemia and glycosuria (385).  One study found that 9 weeks on a low-
chromium diet (5 µg/1000 kcal) was long enough to yield changes in glucose tolerance 
(386). 
 
Potential implications for flight  
Little or nothing is known about chromium in space travelers.  Chromium deficiency 
may result in insulin resistance, which has also been observed after space flight or 
bed rest (87-89).  Whether or not these are related is unknown. 
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Targeted research needed 
Existing knowledge of chromium metabolism seems adequate; other than the nominal 
determinations of chromium content of the space food system, no other specific 
research is required.   
   
Nominal requirement on Earth  
The recommended intake for chromium is provided as AI (174): 
Men, 19–50 y:   35 µg/d 
 50 y and older:  30 µg/d 
Women, 19–50 y:   25 µg/d 
    50 y and older:  20 µg/d 
 
Historical space flight requirements 
Chromium requirements were originally set at 100–200 µg/day (47, 48).  
 
Requirements, standards, and operating bands 
Req. 32. The dietary intake of chromium shall be 35 µg/day.  The nominal operating 
bands are defined as 
 
Dietary Chromium 
  35 µg/d green 
  14 µg/d  yellow 
  <14 µg/d red 
 
Initial verification that this requirement has been met will be done by proximate 
analysis of space food items for chromium content, as well as by analysis of the crew 
menus. 
  
The extramural expert panel concluded that if dietary sources of chromium are 
adequate, definition of a standard to ensure that chromium requirements are met is 
unnecessary.  Accordingly, no biochemical measures of chromium status are required 
for exploration missions. 
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General Chemistry and Supporting Analytes 
 
Several supporting factors need to be evaluated in addition to the nominal nutritional 
assessment parameters.  While all of these do not have standard “red” values, these 
are important in understanding and interpreting other findings.  One example: blood 
pH (100, 387, 388) has a direct effect on ionized calcium concentrations.  Having one 
without the other would yield uninterpretable data.  In addition, urine pH can change 
the risk for renal stone risk (389, 390). 
 
pH (urine) 
  >8 red 
 7 yellow 
 5.5 green 
  4.5 yellow 
  <4.5 red 
 
pH (blood) 
  7.35-7.45 green 
  <7.35 red 
 
Creatinine is another example of supporting measures.  Serum creatinine is a marker 
of kidney function (391), and urinary creatinine is a marker of muscle mass (86).  
Furthermore, the concentrations of many other analytes are normalized to creatinine.   
 
Creatinine (serum) 
  0.6 mg/dL green 
  1.8 mg/dL yellow 
  2.0 mg/dL red 
 
Creatinine (urine) 
 Women Men  
  700-1600 mg/d 1000-2500 mg/d green 
 
 
 
 
 
 
 
 
 
 
 
 
  108
 
 
Determination of urinary sodium (153, 154), potassium (130), and selenium (154) 
allows indirect assessment of the level of dietary intake.   
 
Sodium (urine) 
  40-220 mmol/d green 
 
Potassium (urine) 
  25-125 mmol/d green 
 
Selenium (urine) 
  0-200 µg/d green 
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Special Issues 
 
The following sections represent specific issues related to nutrition, although they are 
not related to a specific nutrient.  
 
Supplements 
 
It is generally agreed that nutrients should be provided to astronauts in standard 
foods, as opposed to supplements (4, 47, 48, 392).  This is critical, as natural foods 
provide other non-nutritive substances such as fiber and carotenoids as well as a 
sense of palatability and psychological well-being that will be important during long 
missions.  The need for more detailed information about the “psychophysiology of 
hunger and eating” was noted decades ago during the early space programs (19) but 
has yet to be studied in detail.  It is clear from astronauts’ experience on the Mir that 
when humans are in an isolated environment far from home, food becomes a very 
supportive psychological factor.  
 
The question of dietary supplements is often raised, but NASA currently does not 
recommend general nutritional supplements during flight, for several reasons.  
Experience to date indicates that crew members do not consume the recommended 
amount of energy intake, and accordingly, intake of many individual nutrients is 
therefore also inadequate.  Unfortunately, the concept of a vitamin/mineral 
supplement to remedy this is unwarranted, as the primary problem—inadequate 
dietary/energy intake—will not be resolved by a supplement.  This situation may even 
be worsened, as crew members may believe that taking the supplement reduces the 
need for adequate food consumption, and thus eat even less.  Furthermore, many 
nutrients when provided as oral supplements are not metabolized by the body as they 
are when in foods.  Changes in bioavailability and metabolism can increase the risk of 
malnutrition.  Vitamin or mineral supplements should be used only when the nutrient 
content of the nominal food system does not meet the requirements for a given 
nutrient (as is currently done with vitamin D supplementation), or when data show 
that the efficacy of single (or multiple) nutrient supplementation is advantageous. 
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Nutrient-Drug Interactions 
 
An understanding of interactions between pharmacotherapeutics and nutrients is 
necessary to implement safe and effective medical care and clinical intervention 
operations for astronauts on long-duration missions.  The most commonly and well-
studied interactions between pharmacological agents and nutrients concern their 
effects on a nutrient or drug’s absorption, distribution, biotransformation, and 
excretion.   
 
Normally, drugs must undergo biotransformation to allow excretion or activation.  To 
terminate drug activity through excretion, the compound must be made water-soluble 
by this process.  For most drugs, biotransformation yields a water-soluble compound 
that is less active than the original compound.  There are 2 phases of reactions in the 
process of biotransformation.  Phase I is an oxidation or hydrolysis reaction to expose 
a functional group on a parent compound or introduce a functional group to that 
compound.  Cytochrome P450 enzymes are involved in this process.  Humans have 12 
families of cytochrome P450 enzymes, but CYP1, CYP2, and CYP3 are the most 
commonly used forms in drug metabolism (393).  Cytochrome P450 enzymes are 
unique in their ability to use a wide range of substrates (394).  Phase II involves the 
conjugation of the parent compound to a polar group (acetate, glucuronides, sulfates, 
amino acids, glutathione).  This process inactivates most drugs.   
 
Dietary factors 
Dietary factors can influence enzyme induction or inhibition, and they are required 
for phase I and phase II biotransformations.  In phase I, three things are required: a 
sufficient energy source (because of the high energy demands of this system), a 
protein source for enzyme formation, and iron for cytochrome formation (395).  Phase 
II requires glucose, sulfur-containing amino acids, and glutathione (395).   
 
The effects of nutrients on drug metabolism have been well studied in animal models; 
however, relatively few dietary factors have been studied in humans (395, 396).  
Results from animal studies must be carefully weighed because of some differences in 
cytochrome P450 enzymes.   
 
One of the most well-documented food-drug interactions is between grapefruit juice 
and a number of medications (397, 398).  Flavonoid compounds such as naringin, 
naringenin, limonin, and obacunone, which are present in grapefruit juice, act as 
substrates for particular intestinal cytochrome P450 enzymes (CYP3A4 and CYP1A2).  
Grapefruit juice induces a sustained decrease in CYP3A4 protein expression within 4 
hours of ingestion, lasting up to 24 hours (399, 400).  The decrease in CYP3A4 results 
in decreased capability for drug metabolism, and therefore increased drug 
bioavailability.   
 
Other foods or nutrients with compounds known to affect phase I and II 
biotransformations and cytochrome P450 enzymes include protein, carbohydrate, 
lipids, certain vitamins, minerals, char-broiled foods, red wine, monosodium 
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glutamate and aspartate, and herbs such as St. John’s wort (395, 396, 401-404).  
Generally, high-protein diets increase drug metabolism, and low-protein diets 
decrease drug metabolism.   For instance, antipyrine and theophylline are 
metabolized more rapidly when subjects are on a high-protein diet (396).  Other 
macronutrients, including carbohydrate, can elicit effects on phase I and phase II 
biotransformation reactions when intakes are very high or low.  Theophylline (for 
asthma) is particularly sensitive to dietary protein:carbohydrate ratios; increasing the 
ratio can decrease effectiveness of the drug, and decreasing the ratio may lead to 
toxicity of the drug (405).  Fatty acids are metabolized by cytochrome P450 enzymes.  
Specifically, CYP2E1 is responsible for lipid peroxidation, and this enzyme is enhanced 
in the presence of highly polyunsaturated fatty acids such as fish oils.   
 
Nutrient metabolism 
Certain nutrients are metabolized by cytochrome P450 enzymes; therefore, drugs or 
other nutrients that alter the activity of these enzymes can alter nutrient 
metabolism.  Vitamin D and vitamin A are two examples of nutrients whose 
metabolism involves cytochrome P450 enzymes.   
 
Figure 3.  Diagram of vitamin D metabolism. 
 
Exposure of 7-dehydrocholesterol to sunlight converts the substrate to previtamin D3.  
Previtamin D3 undergoes an isomerization to form vitamin D3, a biologically inactive 
compound.  CYP27A is a mitochondrial mixed-function oxidase that is responsible for 
hydroxylating vitamin D3 to form 25-hydroxyvitamin D3 (Figure 3) (406).  Recently, 
CYP3A4 has been found to be a 25-hydroxylase as well (407).  CYP27B converts 25-
hydroxyvitamin D3 to 1,25 dihydroxyvitamin D3.  CYP24 is a 24-hydroxylase that 
hydroxylates the vitamin D side chain and ultimately terminates hormonal activity.  
Inhibition of CYP24 has recently been targeted in the development of novel anti-
cancer drugs.  Because 1,25-dihydroxyvitamin D3 exerts antiproliferative and 
differentiating effects on many cell types including cancer, preventing its metabolism 
by inhibiting CYP24 activity may show to be beneficial in treating cancer (408).  
Certain drugs are known to activate CYP24 activity, including rifampin, isoniazid, and 
25-hydroxylase 
CYP27A 
α-hydroxylase 
CYP27B 
1,25-dihydroxyvitamin D3 
Vitamin D3 
CYP24 
25-hydroxyvitamin D3 
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phenobarbital (409, 410).  Several studies show a relationship between the use of 
these drugs and osteomalacia (411, 412).  The discovery of the involvement of CYP3A4 
may implicate and/or explain the effects of numerous other drugs on vitamin D 
metabolism, including inducers or inhibitors of this enzyme (e.g., grapefruit juice, 
erythromycin, omeprazole, carbamazepine, dexamethasone). 
 
Vitamin A metabolism involves the actions of CYP1A2 and CYP4A4 in the conversion of 
retinol to retinoic acid (413, 414).  Inducers of CYP1A2 (cigarette smoke, cruciferous 
vegetables, broiled beef, rifampin) may affect vitamin A metabolism.   
 
Monoamine oxidase inhibitors 
First-generation monoamine oxidase (MAO) inhibitors include agents such as 
antidepressants (phenelzine, tranylcypromine, pargyline, and selegiline), 
chemotherapeutic drugs (procarbazine), antiprotozoal drugs (furazolidone), and 
analgesics (meperidine).  Monoamine oxidase is responsible for metabolizing dietary 
phenylethylamines, including tyramine, in the gastrointestinal tract and in the liver.  
Inhibitors of MAO prevent the breakdown of these compounds, and therefore the 
compounds are taken up in brain.  In the brain, tyramine displaces norepinephrine 
from storage vesicles and this results in release of a flood of norepinephrine at 
synapses.  Acute hypertension and the potential for stroke or myocardial infarction 
are the implications of this process (395).  Fermented foods and protein-rich foods 
that have begun to spoil are rich in phenylethylamines (395).  A list of foods rich in 
tyramines is included in Table 1. 
 
Tyramine-Rich Foods 
Ale Liver (beef or chicken) 
Avocados Raspberries 
Bananas Raisins 
Beans (lima beans, butter beans, bean pods) Sour cream 
Caviar Soy beans or sauce 
Cheese Tofu 
Coffee Wines (especially red) 
Figs Yeast preparations 
Fish (smoked or pickled herring) Yogurt 
Processed meat (bologna, fermented meat, 
salami, pepperoni, summer sausage)  
 
Table 1.  Foods containing a large amount of tyramine (395, 415). 
 
Antacids and proton pump inhibitors 
By altering the pH of the stomach, chronic antacid or proton pump medications can 
negatively affect the bioavailability of several nutrients, including phosphate, 
thiamin, folate, vitamin B12, vitamin C, and vitamin A (395, 416, 417).  Antacids can 
precipitate folic acid at a pH greater than 4.0, thus rendering it insoluble and not 
available for absorption (418).  A high pH also affects thiamin bioavailability because 
the vitamin is not stable at high pH (395).  Similarly, at a neutral pH, the action of 
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vitamin C on dietary nitrites is hindered because of its instability.  Normally, dietary 
nitrite is quickly reduced to nitric oxide by ascorbic acid in the acidic gastric juice, 
where it is then absorbed by the mucosa; however, at neutral pH, the nitrite does not 
react with ascorbic acid and accumulates in the stomach (417).  These changes are 
mostly observed in Helicobacter pylori-infected subjects taking proton-pump 
inhibitors (417).  Elevated nitrite concentrations in the stomach can predispose to the 
formation of potentially carcinogenic N-nitroso compounds.  
 
Vitamin B12 and vitamin A are also malabsorbed at higher pH because the acidic 
environment is essential for their release from dietary proteins.  Because large stores 
of vitamin B12 exist in the body, this is problematic mainly when a subject has been 
taking proton pump inhibitors chronically for at least 2 years (416).  This would be 
particularly harmful if vitamin B12 stores were low before initiation of therapy. 
 
Coumarin anticoagulants 
Anticoagulants such as warfarin, a coumarin-based anticoagulant, are administered to 
create a partial vitamin K deficiency to reduce risks of abnormal blood clotting (419).  
Dosing with warfarin must be closely monitored for optimal efficacy and safety.  
Generous or poor intake of vitamin K can interact with the actions of warfarin to yield 
non-therapeutic anticoagulation or life-threatening hemorrhagic complications (420, 
421).  Some foods that are rich in vitamin K are listed in Table 2.   
 
Vitamin K-Rich Foods 
Alfalfa tablets 
Broccoli 
Brussels sprouts 
Cabbage 
Cauliflower (raw) 
Green leafy vegetables (spinach, collard greens) 
Green tea 
Liver 
Soybeans 
Vegetable oils (canola, soybean) 
Watercress 
 
Table 2.  Foods containing a large amount of vitamin K (395, 422). 
 
Implications for space flight 
Currently no data are available for specific drug-nutrient interactions during space 
flight.  The main concerns for a long-duration mission include those pharmacological 
agents that are taken chronically.  Side effects will be especially harmful if 
nutritional status of all nutrients is not adequate at the beginning of a long-duration 
mission.   
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Nutritional Recommendations for Extravehicular Activity 
 
Extravehicular activity (EVA) is a unique situation from a nutritional perspective, 
because the EVA suit does not easily allow food consumption.  On early Shuttle 
missions, a 165-kcal fruit bar was custom-made to fit in the EVA suit, but it was 
typically not consumed, and is no longer included for EVA missions. As a result of the 
requirements of EVA preparation and EVA itself, crew members can go up to 8 to 10 
hours without food.  Recommendations were designed to help maximize crew 
performance and efficiency.  When reviewed in 1991, the recommendations for EVA 
crew members was that they should consume an additional 500 kcal on days of EVA 
(47).  This was designed to account for the metabolic cost of EVA (~200 kcal/hr).   
 
In 2000, another review of this situation was requested by Flight Medicine. The 
resulting recommendation was to provide food items for consumption during EVA 
preparation (as close as possible to the donning of helmets). The food items should 
contain 300–500 kcal, with about 70–100 g of carbohydrate, and a high soluble fiber 
content.  Candidate items are reviewed to ensure that in the attempt to meet the 
basic criteria, other undesirable nutrients or additives are not included, and that crew 
preferences are accounted for.  It was also recommended that crew members 
reconsider use of the in-suit food bar, or that alternatives be sought.  
 
Fluid intake during EVA is also a concern.  Crew members lose 6–8 oz fluid/h during 
an EVA.  The current EVA suit contains either a 24- or 32-ounce drink bag.  Only water 
is used (early EVAs included flavored beverages, but a problem during a lunar EVA 
resulted in a programmatic decision to only include water).  Provision of in-suit fluid 
is an important factor in suit design.  For the current suit, use of the 32-ounce drink 
bag is recommended.  The development of a larger, disposable drink bag is highly 
encouraged.  The disposable drink bag should be designed so that a flavored drink 
(such as the current Shuttle food system beverages) could be used to increase 
palatability and intake, assuming that the technical concerns can be eliminated. 
 
Although the issue of nutritional support during EVA was reviewed only briefly at the 
2005 Standards and Operating Bands meeting, no recommendations were made to 
change the 2000 guidelines.  As suits are developed for exploration mission transit and 
planetary EVAs, meeting the suggestions above would alleviate problems deemed too 
complicated given the existing suit used on Shuttle and ISS. 
 
Along with food and fluid issues associated with EVA, the hyperoxic environment also 
has the potential for causing additional damage to the body.  The prebreathe protocol 
for U.S. astronauts typically includes a 2.5-h prebreathe of >95%–100% oxygen (423) to 
reduce risk for decompression sickness. After the 2.5-h prebreathe, astronauts are 
typically exposed to hypobaric 100% oxygen for 6 to 8 h during EVA.  Studies from 
saturation dives show that oxidative damage is evident under similar conditions (424).  
Judging by the results of numerous ground-based studies with hyperoxia, the potential 
exists for nutritional countermeasures to mitigate some of oxidative damage (425-
427).   
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APPENDIX A.  Abbreviations, Acronyms, Definitions  
  
4-PA  4-pyridoxic acid 
ACP  acyl carrier protein  
AI  adequate intake 
AMDR  acceptable macronutrient distribution range 
ATP  adenosine triphosphate 
BSAP   bone-specific alkaline phosphatase 
CoA   coenzyme A  
DFE  dietary folate equivalent 
DPD  deoxypyridinoline 
DRI  dietary reference intake 
dU  deoxyuridine 
EAR  estimated average requirement 
EER  estimated energy requirement 
EFA  essential fatty acid 
EGR  erythrocyte glutathione reductase 
EPA  eicosapentaenoic acid 
ETK  erythrocyte transketolase 
EVA  extravehicular activity 
FAD  flavin adenine dinucleotide 
FIGLU  formiminoglutamic acid 
GLA  γ-carboxyglutamic acid 
GPX  glutathione peroxidase 
HDL  high-density lipoprotein  
HP  helical peptide 
ISS  International Space Station 
LDL  low-density lipoprotein 
LET  linear energy transfer 
MAO  monoamine oxidase 
MCV  mean corpuscular volume 
3-MH  3-methylhistidine 
NAD   nicotinamide adenine dinucleotide  
NADH  nicotinamide adenine dinucleotide, reduced 
NADP   nicotinamide adenine dinucleotide phosphate 
NADPH nicotinamide adenine dinucleotide phosphate, reduced 
NE  niacin equivalent 
NTX  n-telopeptide 
PL  pyridoxal 
PLP  pyridoxal 5′-phosphate 
PM  pyridoxamine 
PMP  pyridoxamine 5′-phosphate 
PN  pyridoxine 
PNP  pyridoxine 5′-phosphate 
PTH  parathyroid hormone 
RBC  red blood cell (erythrocyte) 
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RBP  retinol-binding protein 
RDA  recommended dietary allowance 
RE  retinol equivalent 
TE  tocopherol equivalent 
TEE  total energy expenditure 
THF  tetrahydrofolate 
TPN  total parenteral nutrition 
TPP  thiamin pyrophosphate 
U.S.  United States 
UV  ultraviolet 
 
 
 
Definitions 
 
Dietary Reference Intakes (DRIs): The DRIs are developed by the Institute of Medicine 
(82, 174, 187, 251) of the National Academy of Sciences. They are reference values 
used for evaluating and planning nutrient intakes for healthy individuals, and include 
the Recommended Dietary Allowances (RDAs), Adequate Intakes (AIs), Estimated 
Average Requirements (EARs), and Tolerable Upper Intake Levels (ULs). The RDA 
provides age- and gender-specific recommendations for the average daily nutrient 
requirements for nearly all (97-98%) healthy individuals. When the scientific data 
available are insufficient to determine an RDA, AIs are set, and these provide the 
minimum amount needed to maintain adequate nutritional status for nearly all 
members of a specific group. The UL is the maximum daily intake that is not likely to 
engender adverse effects.  
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APPENDIX B.  Requirements 
 
1. The estimated energy requirements (EER) for space missions shall be based on 
total energy expenditure (TEE), using an activity factor of 1.25 (active) along 
with the individual’s age, body mass (kg), and height (m) in the following 
calculations: 
 
EER for men 19 y and older 
 EER = 622 – 9.53 x Age [y] + 1.25 x (15.9 x Mass [kg] + 539.6 x Ht [m]) 
 
EER for women 19 y and older 
 EER = 354 – 6.91 x Age [y] + 1.25 x (9.36 x Mass [kg] + 726 x Ht [m]) 
 
2. The dietary intake of protein shall be 0.8 g/kg per day and not exceed 35% of 
the total daily energy intake.  Approximately 2/3 of the total amount of protein 
shall be provided in the form of animal protein and 1/3 in the form of vegetable 
protein. 
 
3. The dietary intake of carbohydrate shall comprise 50–55% of the total daily 
energy intake.   
 
4. The dietary intake of fat shall comprise 25–35% of the total daily energy intake.  
Dietary intake of n-6 and n-3 fatty acids shall be 14 grams/day and 1.1–1.6 
grams/day, respectively.  Consumption of saturated fat, trans fatty acids, and 
cholesterol will be as low as possible.   
 
5. The dietary intake of fiber shall be 10–14 grams/1000 kcal.   
 
6. The dietary intake of fluid shall be 1–1.5 mL/kcal, with a minimum intake of 
2000 mL.   
 
7. The dietary intake of vitamin A shall be 700–900 µg/day.   
 
8. The dietary intake of vitamin D shall be 25 µg per day.   
 
9. The dietary intake of vitamin K shall be 90 and 120 µg per day for women and 
men, respectively.   
 
10. The dietary intake of vitamin E shall be 15 mg/day.   
 
11. The dietary intake of vitamin C shall be 90 mg/day. 
 
12. The dietary intake of Vitamin B12 shall be 2.4 µg/day.   
 
13. The dietary intake of vitamin B6 shall be 1.7 mg/day.   
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14. The dietary intake of thiamin shall be 1.1 and 1.2 µmol/day for women and men, 
respectively.   
 
15. The dietary intake of riboflavin shall be 1.3 mg/day.   
 
16. The dietary intake of folate shall be 400 µg/day.   
 
17. Based on the current recommendations for Earth (230), the dietary intake of 
niacin shall be 16 mg NE/day.   
 
18. The dietary intake of biotin shall be 30 µg/day.   
 
19. The dietary intake of pantothenic acid shall be 30 mg/day.   
 
20. The dietary intake of calcium shall be 1200–2000 mg/day.   
 
21. The dietary intake of phosphorus shall be 700 mg/day, and shall not exceed 1.5 
times the calcium intake.   
 
22. The dietary intake of magnesium shall be 320 and 420 mg/day for women and 
men respectively.  The upper limit for both genders is defined as 350 mg/d from 
supplements only (not from dietary sources). 
 
23. The dietary intake of sodium shall be 1500–2300 mg/day for both women and 
men.   
 
24. The dietary intake of potassium shall be 4.7 g/d.   
 
25. The dietary intake of iron shall be 8–10 mg/day.   
 
26. The dietary intake of copper shall be 0.5–9 mg/day.   
 
27. The dietary intake of manganese shall be 1.8 and 2.3 mg/day for women and 
men respectively.   
 
28. The dietary intake of fluoride shall be 3 and 4 mg/day for women and men 
respectively.   
 
29. The dietary intake of zinc shall be 11 mg/day.   
 
30. The dietary intake of selenium shall be 55–400 µg/day.   
 
31. The dietary intake of iodine shall be 150 µg/d. 
 
32. The dietary intake of chromium shall be 35 µg/day.   
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